

CHIMERIC RECEPTORS TARGETING ADGRE2 AND/OR CLEC12A AND USES THEREOF

CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims priority to U.S. Provisional Patent Application Serial No. 63/179,799, filed April 26, 2021, and U.S. Provisional Patent Application Serial No. 63/287,655, filed December 9, 2021, the contents of each of which are incorporated by reference in their entirety, and to each of which priority is claimed.

SEQUENCE LISTING

The instant application contains a Sequence Listing which has been submitted electronically in ASCII format and is hereby incorporated by reference in its entirety. Said ASCII copy, created on April 21, 2022 is named 087108_0110_SL.txt and is 150,762 bytes in size.

1. INTRODUCTION

The presently disclosed subject matter provides methods and compositions for immunotherapies. It relates to chimeric receptors that target ADGRE2, and chimeric receptors that target CLEC12A, cells comprising such chimeric receptors, and methods of using such cells for treatments, e.g., for treating acute myeloid leukemia (AML).

2. BACKGROUND OF THE INVENTION

Cell-based immunotherapy is a therapy with curative potential for the treatment of cancer. T cells and other immune cells may be modified to target tumor antigens through the introduction of genetic material coding for artificial or synthetic receptors for antigen, termed Chimeric Antigen Receptors (CARs), specific to selected antigens. Targeted T cell therapy using CARs has shown recent clinical success in treating hematologic malignancies.

Relapsed and refractory acute myeloid leukemia (R/R AML) has a very poor prognosis. The only curative option is allogeneic hematopoietic stem cell transplantation, which is often associated with treatment failure and significant therapy-related toxicity and mortality. Novel therapeutic approaches are therefore direly needed for R/R AML. Over the past few years, autologous T cells genetically modified to express a chimeric antigen receptor (CAR) targeting CD19 have revolutionized the treatment and improved the outcomes of patients with R/R B-cell hematologic malignancies, leading to the approval by the FDA of three CD19 CARs (tisagenlecleucel, axicabtagene ciloleucel, and brexucabtagene autoleucel) for R/R acute lymphoblastic leukemia and/or certain B-cell non-Hodgkin lymphomas. In the case of AML, the clinical investigation of CAR T cell therapy is still in an early phase, and clinical results mainly

with CD33 and CD123 CAR T cells suggest challenges both in terms of safety and efficacy, which are due to abundant expression of CD33 and CD123 in normal hematopoiesis and phenotypic heterogeneity in AML tumor cells. Accordingly, there are needs for a novel combinatorial CAR format for R/R AML that has the potential to provide improved safety and efficacy relative to alternative CAR therapies currently under clinical investigation.

3. SUMMARY OF THE INVENTION

The presently disclosed subject matter provides chimeric receptors that target ADGRE2, and chimeric receptors that target CLEC12A, cells comprising such chimeric receptors, and methods of using such cells for treatments, e.g., for treating acute myeloid leukemia (AML).

10 In one aspect, the presently disclosed subject matter provides chimeric receptors that target ADGRE2. In certain embodiments, the ADGRE2-targeted chimeric receptor comprises an extracellular antigen-binding domain that binds to ADGRE2, a transmembrane domain, and an intracellular domain. In certain embodiments, the extracellular antigen-binding domain comprises: a) a heavy chain variable region comprising a CDR1 comprising the amino acid
15 sequence set forth in SEQ ID NO: 33 or a conservative modification thereof, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 34 or a conservative modification thereof, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 35 or a conservative modification thereof; and/or b) a light chain variable region comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 36 or a conservative modification thereof, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 37 or a conservative modification thereof, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 38 or a conservative modification thereof.

In certain embodiments, the extracellular antigen-binding domain comprises a single-chain variable fragment (scFv), a Fab, or a F(ab)₂. In certain embodiments, the extracellular
25 antigen-binding domain comprises an scFv. In certain embodiments, the scFv is a humanized scFv.

In certain embodiments, the heavy chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 33, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 34, and a CDR3 comprising the amino acid sequence set forth
30 in SEQ ID NO: 35. In certain embodiments, the light chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 36, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 37, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 38. In certain embodiments, the heavy chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 33, a CDR2 comprising the

amino acid sequence set forth in SEQ ID NO: 34, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 35; and the light chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 36, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 37, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 38.

In certain embodiments, the heavy chain variable region comprises an amino acid sequence that is at least about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98% or about 99% identical or homologous to the amino acid sequence set forth in SEQ ID NO: 39, SEQ ID NO:43, SEQ ID NO:46, SEQ ID NO:49, SEQ ID NO: 52, SEQ ID NO: 55, or SEQ ID NO: 146. In certain embodiments, the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 39, SEQ ID NO:43, SEQ ID NO:46, or SEQ ID NO:49. In certain embodiments, the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 39.

In certain embodiments, the light chain variable region comprises an amino acid sequence that is at least about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98% or about 99% identical or homologous to the amino acid sequence set forth in SEQ ID NO: 40, SEQ ID NO: 44, SEQ ID NO: 47, SEQ ID NO: 50, SEQ ID NO: 53, SEQ ID NO: 56, or SEQ ID NO: 147. In certain embodiments, the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 40, SEQ ID NO: 44, SEQ ID NO: 47, or SEQ ID NO: 50. In certain embodiments, the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 40.

In certain embodiments, the heavy chain variable region comprises an amino acid sequence that is at least about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98% or about 99% identical or homologous to the amino acid sequence set forth in SEQ ID NO: 39, SEQ ID NO:43, SEQ ID NO:46, SEQ ID NO:49, SEQ ID NO: 52, or SEQ ID NO: 55; and the light chain variable region comprises an amino acid sequence that is at least about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98% or about 99% identical or homologous to the amino acid sequence set forth in SEQ ID NO: 40, SEQ ID NO: 44, SEQ ID NO: 47, SEQ ID NO: 50, SEQ ID NO: 53, or SEQ ID NO: 56. In certain

embodiments, the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 39, SEQ ID NO:43, SEQ ID NO:46, or SEQ ID NO:49; and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 40, SEQ ID NO: 44, SEQ ID NO: 47, or SEQ ID NO: 50.

5 In certain embodiments,

a) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 39; and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 40;

b) the heavy chain variable region comprises the amino acid sequence set forth in
10 SEQ ID NO: 43; and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 44;

c) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 46; and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 47;

d) the heavy chain variable region comprises the amino acid sequence set forth in
15 SEQ ID NO: 49; and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 50;

e) the heavy chain variable region comprises the amino acid sequence set forth in
20 SEQ ID NO: 52; and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 53;

f) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 55; and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 56; or

g) the heavy chain variable region comprises the amino acid sequence set forth in SEQ
25 ID NO: 146; and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 147.

In certain embodiments,

a) the heavy chain variable region comprises the amino acid sequence set forth in
30 SEQ ID NO: 39; and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 40;

b) the heavy chain variable region comprises the amino acid sequence set forth in
SEQ ID NO: 43; and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 44;

c) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 46; and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 47; or

d) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 49; and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 50.

In certain embodiments, the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 39; and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 40.

In certain embodiments, the extracellular antigen-binding domain comprises a linker between the heavy chain variable region and the light chain variable region. In certain embodiments, the linker consists of the amino acid sequence set forth in SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, or SEQ ID NO: 149.

In certain embodiments, the heavy chain variable region and the light chain variable region are positioned from the N- to the C-terminus: V_H-V_L. In certain embodiments, the extracellular antigen-binding domain comprises or is an scFv, which comprises or consists of the amino acid sequence set forth in SEQ ID NO: 41, SEQ ID NO: 45, SEQ ID NO: 48, SEQ ID NO: 51, SEQ ID NO: 54, SEQ ID NO: 57, SEQ ID NO: 148. In certain embodiments, the extracellular antigen-binding domain comprises or is an scFv, which comprises or consists of the amino acid sequence set forth in SEQ ID NO: 41, SEQ ID NO: 45, SEQ ID NO: 48, or SEQ ID NO: 51. In certain embodiments, the extracellular antigen-binding domain comprises or is an scFv, which comprises or consists of the amino acid sequence set forth in SEQ ID NO: 41.

In certain embodiments, the extracellular antigen-binding domain binds to ADGRE2 with a dissociation constant (K_D) of less than about 10^{-8} M, less than about 10^{-9} M, less than about 10^{-10} M, less than about 10^{-11} M, less than about 10^{-12} M, or less than about 10^{-13} M. In certain embodiments, the extracellular antigen-binding domain binds to ADGRE2 with an EC₅₀ of between about 1 and about 100 nM. In certain embodiments, the EC₅₀ is between about 10 and about 95 nM. In certain embodiments, the EC₅₀ is between about 25 and about 75 nM.

In certain embodiments, the transmembrane domain comprises a CD8 polypeptide, a CD28 polypeptide, a CD3 ζ polypeptide, a CD4 polypeptide, a 4-1BB polypeptide, an OX40 polypeptide, an ICOS polypeptide, a CTLA-4 polypeptide, a PD-1 polypeptide, a LAG-3 polypeptide, a 2B4 polypeptide, or a BTLA polypeptide. In certain embodiments, the transmembrane domain comprises a CD28 polypeptide.

In certain embodiments, the intracellular domain comprises a CD3 ζ polypeptide. In certain embodiments, the CD3 ζ polypeptide is a modified CD3 ζ polypeptide. In certain embodiments, the modified CD3 ζ polypeptide comprises a native ITAM1, an ITAM2 variant consisting of two loss-of-function mutations, and an ITAM3 variant consisting of two loss-of-function mutations. In certain embodiments, the native ITAM1 consists of the amino acid sequence set forth in SEQ ID NO: 15. In certain embodiments, the ITAM2 variant consists of the amino acid sequence set forth in SEQ ID NO: 21. In certain embodiments, the ITAM3 variant consists of the amino acid sequence set forth in SEQ ID NO: 25. In certain embodiments, the modified CD3 ζ polypeptide comprises or consists of the amino acid sequence set forth in SEQ ID NO: 27.

In certain embodiments, the intracellular domain further comprises at least one co-stimulatory signaling region. In certain embodiments, the at least one co-stimulatory signaling region comprises a CD28 polypeptide, a 4-1BB polypeptide, an OX40 polypeptide, an ICOS polypeptide, a DAP-10 polypeptide, or a combination thereof. In certain embodiments, the at least one co-stimulatory signaling region comprises a CD28 polypeptide.

In certain embodiments, the ADGRE2-targeted chimeric receptor is a chimeric antigen receptor (CAR), a chimeric co-stimulating receptor (CCR), or a TCR like fusion molecule. In certain embodiments, the ADGRE2-targeted chimeric receptor is a CAR.

In one aspect, the presently disclosed subject matter provides chimeric receptors that target CLEC12A. In certain embodiments, the CLEC12A-targeted chimeric receptor comprises an extracellular antigen-binding domain that binds to CLEC12A, a transmembrane domain, and an intracellular domain. In certain embodiments, the extracellular antigen-binding domain comprises a heavy chain variable region comprising:

- i) a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 69 or a conservative modification thereof, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 70 or a conservative modification thereof, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 71 or a conservative modification thereof;
- ii) a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 81 or a conservative modification thereof, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 82 or a conservative modification thereof, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 83 or a conservative modification thereof;

- 5 iii) a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 89 or a conservative modification thereof, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 90 or a conservative modification thereof, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 91 or a conservative modification thereof;
- 10 iv) a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 89 or a conservative modification thereof, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 90 or a conservative modification thereof, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 98 or a conservative modification thereof;
- 15 v) a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 81 or a conservative modification thereof, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 103 or a conservative modification thereof, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 83 or a conservative modification thereof;
- 20 vi) a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 109 or a conservative modification thereof, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 103 or a conservative modification thereof, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 83 or a conservative modification thereof;
- 25 vii) a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 89 or a conservative modification thereof, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 90 or a conservative modification thereof, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 114 or a conservative modification thereof;
- 30 viii) a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 120 or a conservative modification thereof, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 121 or a conservative modification thereof, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 122 or a conservative modification thereof; or
- ix) a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 129 or a conservative modification thereof, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 130 or a conservative modification thereof, and a CDR3

comprising the amino acid sequence set forth in SEQ ID NO: 131 or a conservative modification thereof; and/or

a light chain variable region comprising:

- 5 i) a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 72 or a conservative modification thereof, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 73 or a conservative modification thereof, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 74 or a conservative modification thereof;
- 10 ii) a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 84 or a conservative modification thereof, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 73 or a conservative modification thereof, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 85 or a conservative modification thereof;
- 15 iii) a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 92 or a conservative modification thereof, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 93 or a conservative modification thereof, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 94 or a conservative modification thereof;
- 20 iv) a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 99 or a conservative modification thereof, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 93 or a conservative modification thereof, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 151 or a conservative modification thereof;
- 25 v) a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 104 or a conservative modification thereof, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 73 or a conservative modification thereof, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 105 or a conservative modification thereof;
- 30 vi) a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 110 or a conservative modification thereof, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 73 or a conservative modification thereof, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 85 or a conservative modification thereof;

- vii) a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 115 or a conservative modification thereof, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 93 or a conservative modification thereof, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 116 or a conservative modification thereof;
- viii) a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 123 or a conservative modification thereof, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 124 or a conservative modification thereof, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 125 or a conservative modification thereof; or
- ix) a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 132 or a conservative modification thereof, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 133 or a conservative modification thereof, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 134 or a conservative modification thereof.

In certain embodiments, the extracellular antigen-binding domain comprises a single-chain variable fragment (scFv), a Fab, or a F(ab)₂. In certain embodiments, the extracellular antigen-binding domain comprises an scFv. In certain embodiments, the scFv is a human scFv.

In certain embodiments, the heavy chain variable region comprises:

- a) a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 69, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 70, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 71;
- b) a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 81, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 82, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 83;
- c) a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 89, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 90, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 91;
- d) a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 89, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 90, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 98;
- e) a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 81, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 103, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 83;

- 5 f) a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 109, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 103, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 83;
- g) a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 89, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 90, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 114;
- 10 h) a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 120, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 121, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 122; or
- i) a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 129, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 130, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 131.

In certain embodiments, the heavy chain variable region comprises:

- 15 a) a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 69, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 70, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 71;
- b) a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 81, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 82, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 83;
- 20 c) a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 89, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 90, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 91; or
- d) a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 89, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 90, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 98.
- 25

In certain embodiments, the heavy chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 69, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 70, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 71.

- 30 In certain embodiments, the light chain variable region comprises:

- a) a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 72, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 73, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 74;

- b) a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 84, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 73, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 85;
- 5 c) a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 92, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 93, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 94;
- d) a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 99, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 93, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 151;
- 10 e) a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 104, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 73, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 105;
- f) a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 110, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 73, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 85;
- 15 g) a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 115, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 93, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 116;
- h) a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 123, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 124, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 125; or
- 20 i) a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 132, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 133, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 134.
- 25 In certain embodiments, the light chain variable region comprises:
- a) a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 72, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 73, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 74;
- b) a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 84, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 73, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 85;
- 30 c) a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 92, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 93, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 94; or

- d) a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 99, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 93, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 151.

5 In certain embodiments, the light chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 72, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 73, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 74.

In certain embodiments, the chimeric receptor comprises:

- 10 a) the heavy chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 69, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 70, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 71; and the light chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 72, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 73, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 74;
- 15 b) the heavy chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 81, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 82, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 83; and the light chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 84, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 73, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 85;
- 20 c) the heavy chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 89, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 90, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 91; and the light chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 92, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 93, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 94;
- 25 d) the heavy chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 89, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 90, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 98; and the light chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 99, a CDR2 comprising
- 30

- the amino acid sequence set forth in SEQ ID NO: 93, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 151;
- 5 e) the heavy chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 81, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 103, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 83; and the light chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 104, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 73, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 105;
- 10 f) the heavy chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 109, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 103, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 83; and the light chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 110, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 73, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 85;
- 15 g) the heavy chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 89, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 90, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 114; and the light chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 115, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 93, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 116;
- 20 h) the heavy chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 120, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 121, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 122; and the light chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 123, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 124, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 125; or
- 30 i) the heavy chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 129, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 130, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 131; and the light chain variable region comprises a CDR1

comprising the amino acid sequence set forth in SEQ ID NO: 132, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 133, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 134.

In certain embodiments,

- 5 a) the heavy chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 69, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 70, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 71; and the light chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 72, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 73, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 74;
- 10 b) the heavy chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 81, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 82, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 83; and the light chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 84, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 73, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 85;
- 15 c) the heavy chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 89, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 90, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 91; and the light chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 92, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 93, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 94; or
- 20 d) the heavy chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 89, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 90, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 98; and the light chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 99, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 93, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 151.
- 25
- 30

In certain embodiments, the heavy chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 69, a CDR2 comprising the amino acid

sequence set forth in SEQ ID NO: 70, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 71; and the light chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 72, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 73, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 74.

In certain embodiments, the heavy chain variable region comprises an amino acid sequence that is at least about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98% or about 99% identical or homologous to the amino acid sequence set forth in SEQ ID NO: 75, SEQ ID NO: 86, SEQ ID NO: 95, SEQ ID NO: 100, SEQ ID NO: 106, SEQ ID NO: 111, SEQ ID NO: 117, SEQ ID NO: 126, or SEQ ID NO: 135. In certain embodiments, the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 75, SEQ ID NO: 86, SEQ ID NO: 95, SEQ ID NO: 100, SEQ ID NO: 106, SEQ ID NO: 111, SEQ ID NO: 117, SEQ ID NO: 126, or SEQ ID NO: 135. In certain embodiments, the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 75, SEQ ID NO: 86, SEQ ID NO: 95, or SEQ ID NO: 100. In certain embodiments, the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 75.

In certain embodiments, the light chain variable region comprises an amino acid sequence that is at least about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98% or about 99% identical or homologous to the amino acid sequence set forth in SEQ ID NO: 76, SEQ ID NO: 87, SEQ ID NO: 96, SEQ ID NO: 101, SEQ ID NO: 107, SEQ ID NO: 112, SEQ ID NO: 118, SEQ ID NO: 127, or SEQ ID NO: 136. In certain embodiments, the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 76, SEQ ID NO: 87, SEQ ID NO: 96, SEQ ID NO: 101, SEQ ID NO: 107, SEQ ID NO: 112, SEQ ID NO: 118, SEQ ID NO: 127, or SEQ ID NO: 136. In certain embodiments, the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 76, SEQ ID NO: 87, SEQ ID NO: 96, or SEQ ID NO: 101. In certain embodiments, the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 76.

In certain embodiments,

- a) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 75; and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 76;
- 5 b) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 86; and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 87;
- c) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 95; and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 96;
- 10 d) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 100; and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 101;
- e) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 106; and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 107;
- 15 f) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 111; and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 112;
- g) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 117; and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 118;
- 20 h) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 126; and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 127; or
- 25 i) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 135; and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 136.

In certain embodiments, the chimeric receptor comprises:

- a) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 75; and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 76;
- 30 b) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 86; and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 87;

c) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 95; and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 96; or

5 d) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 100; and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 101.

In certain embodiments, the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 75; and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 76.

10 In certain embodiments, the extracellular antigen-binding domain comprises a linker between the heavy chain variable region and the light chain variable region. In certain embodiments, the linker consists of the amino acid sequence set forth in SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, or SEQ ID NO: 149.

In certain embodiments, the heavy chain variable region and the light chain variable
15 region are positioned from the N- to the C-terminus: V_H-V_L. In certain embodiments, the extracellular antigen-binding domain comprises or is an scFv, which comprises or consists of the amino acid sequence set forth in SEQ ID NO: 79, SEQ ID NO: 88, SEQ ID NO: 97, SEQ ID NO: 102, SEQ ID NO: 108, SEQ ID NO: 113, SEQ ID NO: 119, SEQ ID NO: 128, or SEQ ID NO: 137. In certain embodiments, the extracellular antigen-binding domain comprises or is an
20 scFv, which comprises or consists of the amino acid sequence set forth in SEQ ID NO: 79, SEQ ID NO: 88, SEQ ID NO: 97, or SEQ ID NO: 102. In certain embodiments, the extracellular antigen-binding domain comprises or is an scFv, which comprises or consists of the amino acid sequence set forth in SEQ ID NO: 79.

In certain embodiments, the extracellular antigen-binding domain comprises binds to
25 CLEC12A with a disassociation constant (K_D) of less than about 10⁻⁸ M, less than about 10⁻⁹ M, less than about 10⁻¹⁰ M, less than about 10⁻¹¹ M, less than about 10⁻¹² M, or less than about 10⁻¹³ M. In certain embodiments, the K_D is about 0.1 pM or below. In certain embodiments, the K_D is between about 0.05 pM and about 0.5 pM. In certain embodiments, the K_D is between about 0.1 nM and about 5.0 nM. In certain embodiments, the K_D is between about 0.3 nM and about
30 3.5 nM. In certain embodiments, the extracellular antigen-binding domain binds to CLEC12A with an EC₅₀ of between about 1 nM and about 100 nM.

In certain embodiments, the transmembrane domain comprises a CD8 polypeptide, a CD28 polypeptide, a CD3ζ polypeptide, a CD4 polypeptide, a 4-1BB polypeptide, an OX40 polypeptide, an ICOS polypeptide, a CTLA-4 polypeptide, a PD-1 polypeptide, a LAG-3

polypeptide, a 2B4 polypeptide, or a BTLA polypeptide. In certain embodiments, the transmembrane domain comprises a CD8 polypeptide.

In certain embodiments, the CLEC12A-targeted chimeric receptor is a chimeric antigen receptor (CAR), a chimeric co-stimulating receptor (CCR), or a TCR like fusion molecule. In certain embodiments, the CLEC12A-targeted chimeric receptor is a chimeric co-stimulating receptor (CCR).

In certain embodiments, the intracellular domain does not comprise a CD3 ζ polypeptide. In certain embodiments, the intracellular domain comprises at least one co-stimulatory signaling region. In certain embodiments, the at least one co-stimulatory signaling region comprises a CD28 polypeptide, a 4-1BB polypeptide, an OX40 polypeptide, an ICOS polypeptide, a DAP-10 polypeptide, or a combination thereof. In certain embodiments, the at least one co-stimulatory signaling region comprises a 4-1BB polypeptide.

In certain embodiments, the chimeric receptor is expressed from a vector. In certain embodiments, the vector is a viral vector. In certain embodiments, the viral vector is a retroviral vector.

The presently disclosed subject matter further provides cells comprising the chimeric receptor disclosed herein. In certain embodiments, the cell comprises an ADGRE2-targeted chimeric receptor disclosed herein. In certain embodiments, the cell comprises a CLEC12A-targeted chimeric receptor disclosed herein. In certain embodiments, the cell comprises a) an ADGRE2-targeted chimeric receptor disclosed herein, and b) a CLEC12A-targeted chimeric receptor disclosed herein. In certain embodiments, the ADGRE2-targeted chimeric receptor is a chimeric antigen receptor (CAR) and the CLEC12A-targeted chimeric receptor is a chimeric co-stimulating receptor (CCR).

In certain embodiments, the CAR comprises an extracellular antigen-binding domain that binds to ADGRE2 and comprises:

a) a heavy chain variable region comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 33 or a conservative modification thereof, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 34 or a conservative modification thereof, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 35 or a conservative modification thereof; and/or

b) a light chain variable region comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 36 or a conservative modification thereof, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 37 or a conservative modification

thereof, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 38 or a conservative modification thereof.

5 In certain embodiments, the heavy chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 33, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 34, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 35; and the light chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 36, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 37, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 38.

10 In certain embodiments,

a) the heavy chain variable region comprises an amino acid sequence that is at least about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98% or about 99% identical or homologous to the amino acid sequence set forth in SEQ ID NO: 39; and/or

15 b) the light chain variable region comprises an amino acid sequence that is at least about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98% or about 99% identical or homologous to the amino acid sequence set forth in SEQ ID NO: 40.

20 In certain embodiments, the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 39; and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 40.

In certain embodiments, the CCR comprises an extracellular antigen-binding domain that binds to CLEC12A and comprises:

25 a) a heavy chain variable region comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 69 or a conservative modification thereof, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 70 or a conservative modification thereof, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 71 or a conservative modification thereof; and/or

30 b) a light chain variable region comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 72 or a conservative modification thereof, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 73 or a conservative modification

thereof, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 74 or a conservative modification thereof.

In certain embodiments, the heavy chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 69, a CDR2 comprising the amino acid
5 sequence set forth in SEQ ID NO: 70, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 71; and the light chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 72, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 73, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 74.

10 In certain embodiments,

a) the heavy chain variable region comprises an amino acid sequence that is at least about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98% or about 99% identical or homologous to the amino acid

15 sequence set forth in SEQ ID NO: 75; and/or

b) the light chain variable region comprises an amino acid sequence that is at least about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98% or about 99% identical or homologous to the amino acid

20 sequence set forth in SEQ ID NO: 76.

In certain embodiments, the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 75; and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 76.

In certain embodiments, the cell is transduced with the ADGRE2-targeted chimeric
25 receptor and/or the CLEC12A-targeted chimeric receptor. In certain embodiments, the ADGRE2-targeted chimeric receptor and/or the CLEC12A-targeted chimeric receptor is constitutively expressed on the surface of the cell. In certain embodiments, the cell is an immunoresponsive cell. In certain embodiments, the cell is a cell of the lymphoid lineage or a cell of the myeloid lineage. In certain embodiments, the cell is selected from the group
30 consisting of a T cell, a Natural Killer (NK) cell, a stem cell from which a lymphoid cell may be differentiated, and a stem cell from which a myeloid cell may be differentiated. In certain embodiments, the cell is a T cell. In certain embodiments, the T cell is selected from the group consisting of helper T cells, cytotoxic T cells, memory T cells, regulatory T cells, tumor-infiltrating lymphocyte (TIL), Natural Killer T cells, mucosal associated invariant T cells, and $\gamma\delta$

T cells. In certain embodiments, the cell is a Natural Killer (NK) cell. In certain embodiments, the NK cell is derived from a stem cell. In certain embodiments, the stem cell is a pluripotent stem cell. In certain embodiments, the pluripotent stem cell is an embryoid stem cell or an induced pluripotent stem cell.

5 Furthermore, the presently disclosed subject matter provides nucleic acid molecules encoding the chimeric receptors disclosed herein. In certain embodiments, the nucleic acid molecule encodes an ADGRE2-targeted chimeric receptor disclosed herein. In certain embodiments, the nucleic acid molecule encodes a CLEC12A-targeted chimeric receptor disclosed herein.

10 In certain embodiments, the nucleic acid molecule further comprises a promoter that is operably linked to the chimeric receptor. In certain embodiments, the promoter is endogenous or exogenous. In certain embodiments, the exogenous promoter is selected from the group consisting of an elongation factor (EF)-1 promoter, a cytomegalovirus immediate-early promoter (CMV) promoter, a simian virus 40 early promoter (SV40) promoter, a phosphoglycerate kinase
15 (PGK) promoter, a metallothionein promoter, and Ubiquitin C promoter. In certain embodiments, the promoter is an inducible promoter. In certain embodiments, the inducible promoter is selected from the group consisting of a NFAT transcriptional response element (TRE) promoter, a CD69 promoter, a CD25 promoter, an IL-2 promoter, a 4-1BB promoter, a PD1 promoter, and a LAG3 promoter. In certain embodiments, the promoter is an endogenous
20 promoter. In certain embodiments, the endogenous promoter is selected from a TCR alpha promoter, a TCR beta promoter, and a beta 2-microglobulin promoter.

 The presently disclosed subject matter also provides a nucleic acid composition comprising a first nucleic acid molecule encoding an ADGRE2-targeted chimeric receptor disclosed herein, and a second nucleic acid molecule encoding a CLEC12A-targeted chimeric
25 receptor disclosed herein.

 The presently disclosed subject matter also provides vectors comprising the nucleic acid molecule disclosed herein or the nucleic acid composition disclosed herein. In certain embodiments, the vector is a viral vector. In certain embodiments, the vector is a retroviral vector.

30 The presently disclosed subject matter further provides cells expressing the nucleic acid molecule disclosed herein or the nucleic acid composition disclosed herein. In certain embodiments, the cell is a T cell.

 The presently disclosed subject matter provides compositions comprising the cell disclosed herein. In certain embodiments, the composition is a pharmaceutical composition

further comprising a pharmaceutically acceptable carrier. In certain embodiments, the composition comprises between about 25×10^6 and about 150×10^6 cells. In certain embodiments, the composition comprises between about 25×10^6 and about 50×10^6 cells. In certain embodiments, the composition comprises about 2.5×10^6 cells.

5 The presently disclosed subject matter further provides various methods of using the presently disclosed cells. The presently disclosed subject matter provides methods of reducing tumor burden in a subject. In certain embodiments, the method comprises administering to the subject the cells or the composition disclosed herein. In certain embodiments, the method reduces the number of tumor cells, reduces tumor size, and/or eradicates the tumor in the
10 subject.

 The presently disclosed subject matter provides methods of increasing or lengthening survival of a subject having a tumor. In certain embodiments, the methods comprise administering to the subject the cells or the composition disclosed herein.

 The presently disclosed subject matter provides methods of treating and/or preventing a
15 tumor in a subject. In certain embodiments, the methods comprise administering to the subject the cells or the composition disclosed herein.

 In certain embodiments, the tumor expresses ADGRE2 and/or CLEC12A. In certain embodiments, the tumor is cancer. In certain embodiments, the tumor is blood cancer. In certain embodiments, the tumor is selected from the group consisting of multiple myeloma, leukemia, lymphomas, and myeloid malignancies. In certain embodiments, the leukemia is selected from the group consisting of acute myeloid leukemia (AML), chronic myeloid leukemia (CML), acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute promyelocytic leukemia (APL), mixed-phenotype acute leukemia (MLL), hairy cell leukemia, and B cell prolymphocytic leukemia. In certain embodiments, the leukemia is acute myeloid leukemia
20 (AML). In certain embodiments, the AML is relapsed/refractory acute myeloid leukemia (R/R AML). In certain embodiments, the myeloid malignancies are selected from the group consisting of myelodysplastic syndromes (MDS), myeloproliferative neoplasms (MPN), myeloid/lymphoid neoplasms (e.g., myeloid/lymphoid neoplasms with eosinophilia and rearrangement of Platelet Derived Growth Factor Receptor Alpha (PDGFRA), Platelet Derived
25 Growth Factor Receptor Beta (PDGFRB), or Fibroblast Growth Factor Receptor 1 (FGFR1), or with PCM1-JAK2), acute myeloid leukemia (AML), blastic plasmacytoid dendritic cell neoplasm, B-lymphoblastic leukemia/lymphoma, and T-lymphoblastic leukemia/lymphoma. In certain embodiments, the myeloid malignancies comprise myelodysplastic syndromes (MDS). In certain embodiments, the subject is a human subject.
30

Furthermore, the presently disclosed subject matter provides methods for producing cells comprising the chimeric receptors disclosed herein. In certain embodiments, the method comprises introducing into the cell a nucleic acid molecule that encodes the chimeric receptor disclosed herein.

5 Furthermore, the presently disclosed subject matter provides methods for producing a cell comprising an ADGRE2-targeted chimeric receptor disclosed herein, and a CLEC12A-targeted chimeric receptor disclosed herein. In certain embodiments, the method comprises introducing into the cell a nucleic acid molecule that encodes the ADGRE2-targeted chimeric receptor and a nucleic acid molecule that encodes the CLEC12A-targeted chimeric receptor
10 disclosed herein.

4. BRIEF DESCRIPTION OF THE FIGURES

The following Detailed Description, given by way of example, but not intended to limit the invention to specific embodiments described, may be understood in conjunction with the accompanying drawings.

15 Figures 1A and 1B illustrate target antigen expression profiles of ADGRE2, CD33, and CD123 evaluated via flow cytometry of fresh AML patient samples (peripheral blood or bone marrow); n=16 r/r adult AML patients with the morphological disease. Target expression was compared between bulk AML cells (CD45_{dim}/SSC_{low} gate) and leukemic stem cells [LSC; Lin-CD34+CD38-(CD45RA+) within bulk AML cell gate]. Gates for target-positivity were set
20 based on the same-sample negative control population (T or B cells). Figure 1A shows the percentage of target-positive AML cells within the bulk or LSC population of an individual patient sample represented by each dot. In the majority of evaluated AML patients >90% of AML cells were positive for ADGRE2, both for bulk and LSC. Figure 1B shows the percentage of evaluated AML patient population with >70% target-positive AML cells. All evaluated AML
25 patients had >70% ADGRE2-positive AML cells, both for bulk and LSC.

Figure 2 illustrates a schematic of CAR, CCR, and CAR+CCR.

Figure 3 depicts the rationale for ADCLEC.syn1 approach for improved anti-leukemic efficacy compared to CD33 and CD123-CAR. ADGRE2-CAR alone provides some anti-leukemic activity but may be limited due to ADGRE2-low escape mechanisms. CLEC12A-CCR
30 alone does not mediate any cell lysis. ADCLEC.syn1 combines a low-affinity ADGRE2-CAR with a high-affinity CLEC12A-CCR, thereby increasing AML-directed avidity and reducing the risk of ADGRE2-low AML escape. In addition, CLEC12A-CCR-dependent trans-co-stimulation via 4-1BB further enhances T cell functionality. In comparison, single-targeting CD33-CAR or

CD123-CAR approaches could be limited in efficacy due to antigen-low escape and phenotypic heterogeneity (*see* target profiles in Figure 1).

Figures 4A-4C illustrate protein expression profiles of ADGRE2, CLEC12A (CD371), CD33, and CD123 in normal hematopoiesis and non-hematopoietic tissues, showing largely non-overlapping expression profile of ADGRE2 and CLEC12A. Figures 4A and 4B show flow cytometric co-expression profiles of ADGRE2/CLEC12A vs CD33/CD123 on representative adult normal donor bone marrow cell populations (gating: monocytes – CD45_{hi}/SSC_{med}/CD14+, granulocytes – CD45_{dim}/SSC_{hi}, HSC – CD45_{dim}/SSC_{low}/CD34+/CD38-/CD45RA-/CD90+, T cells – CD45_{hi}/SSC_{low}/CD3+, B cells – CD45_{hi}/SSC_{low}/CD19+). Figure 4C shows a heatmap depicting the summary of immunohistochemistry co-staining for ADGRE2 and CLEC12A in formalin-fixed paraffin-embedded normal human tissues. Staining intensity refers to cellular positivity, excluding fluids with a high probability for unspecific staining. ADGRE2/CLEC12A had expected co-expression on myeloid cells in immune-related tissues (mostly monocytic lineage), but no or restricted overlapping expression was found in other evaluated tissues.

Figure 5 depicts the rationale for ADCLEC.syn1 approach for improved safety profile compared to CD33- and CD123-CAR. ADGRE2-CAR with optimized affinity and fine-tuned CD3ζ-signaling strength alone spares cells with low or very-low levels of ADGRE2 (HSC or granulocytes, respectively). High-affinity CLEC12A-CCR alone does not mediate any cell lysis. ADCLEC.syn1 combines a low-affinity ADGRE2-CAR with a high-affinity CLEC12A-CCR. Normal hematopoietic cells have a largely non-overlapping expression profile of ADGRE2 and CLEC12A, and CLEC12A is negative on HSC. Therefore, the addition of a CLEC12A-CCR does not increase the risk of HSC toxicity.

Figure 6 illustrates the ADGRE2 scFv binder selection scheme.

Figures 7A-7C illustrate *in vitro* 18h CAR cytotoxicity assay in the context of different ADGRE2 target expression levels. A favorable profile for leading humanized ADGRE2 scFvs, with maximum cytotoxicity at high ADGRE2 levels and minimal cytotoxicity at very-low ADGRE2 levels was observed. Different humanized ADGRE2 scFv candidates and the original 2A1 scFv were tested in SFG-retroviral 28z1XX CAR vector backbone; for each ADGRE2 scFv, 2 signal peptides were studied, one containing our established CD8α signal peptide and the other containing an alternative IgHV1-4 signal peptide. Shown in colored lines are 6 scFvs with cytotoxicity features. The remaining scFv candidates (not included in the legend) are shown in grey. CAR T cells were cocultured for 18h with MOLM13 AML cell lines expressing different levels of ADGRE2: high (WT, Figure 7A), low (clone 1E8, Figure 7B), and very-low (clone

9D6, Figure 7C). Cytotoxicity was measured based on the Luciferase signal released from MOLM13 cells.

Figure 8 illustrates *in vivo* antitumor CAR efficacy of six (6) humanized ADGRE2 scFvs in the context of different ADGRE2 target expression levels. *In vivo* antitumor CAR efficacy model showing a favorable profile for leading humanized ADGRE2 scFvs, with potent efficacy at high ADGRE2 levels, reduced cytotoxicity at low ADGRE2 levels, and absent cytotoxicity at very-low ADGRE2 levels. Six different humanized ADGRE2 scFv candidates and the original 2A1 scFv were tested in the SFG-based retroviral 28z1XX CAR backbone. *In vivo* MOLM13 AML cell line xenograft experiment with 6-8 week-old NSG mice. On day -5, mice were injected via tail-vein with the indicated MOLM13 cell line clone (dose: 1E6 cells per mouse). On day -1, AML engraftment was confirmed via ffLuc-based *in vivo* bioluminescence imaging. On day 0, mice were injected via tail-vein with CAR T cells (dose: 3E5 CAR-positive cells per mouse). Subsequently, the AML burden was quantified via bioluminescence imaging and is represented via total flux (p/s).

Figure 9 illustrates CLEC12A scFv binder selection scheme.

Figures 10A and 10B illustrate *in vitro* CAR cytotoxicity of CLEC12A scFvs in TRAC CAR-28z1XX format in the context of AML cell lines U937 and MOLM13. *In vitro* 18h CAR cytotoxicity assay showing a favorable profile for leading CLEC12A scFvs, with potent efficacy at high and low CLEC12A levels. Different CLEC12A scFv candidates were tested in TRAC-AAV 28z1XX CAR backbone. Shown in colored lines are the nine (9) scFv with the highest efficacy in the context of different CLEC12A levels. Figure 10A shows cytotoxicity with CLEC12A-high cell line U937. Figure 10B shows cytotoxicity with CLEC12A-low cell line MOLM13. The remaining scFv candidates are shown in grey. T cells were cocultured for 18h with AML cell lines. Cytotoxicity was measured based on Luciferase signal from AML cell lines.

Figure 11 illustrates *in vivo* antitumor CAR efficacy model showing high efficacy for leading CLEC12A scFvs. Nine (9) different CLEC12A scFv candidates were tested in the TRAC-AAV 28z1XX CAR backbone. *In vivo* U937 AML cell line xenograft experiment with 6-8 week-old NSG mice. On day -4, mice were injected via tail-vein with the indicated U937 cell line clone (dose: 1E6 cells per mouse). On day -1, AML engraftment was confirmed via ffLuc-based *in vivo* bioluminescence imaging. On day 0, mice were injected via tail-vein with CAR T cells (dose: 4E5 CAR-positive cells per mouse). Subsequently, the AML burden was quantified via bioluminescence imaging and is represented via total flux (p/s).

Figures 12A-12C illustrate *in vitro* and *in vivo* CAR efficacy assays validating the ADCLEC.syn1 concept (as outlined as a schematic in Figure 3). Figure 12A shows *in vitro* 18h CAR cytotoxicity assay. ADCLEC.syn1-transduced T cells were cocultured with EL4 murine lymphoma cell line expressing no target (ADGRE2-/CLEC12A-) or overexpressing either CAR target alone (ADGRE2+/CLEC12A-), CCR target alone (ADGRE2-/CLEC12A+), or both CAR and CCR target (ADGRE2+/CLEC12A+). CD19-targeting 1928z1XX CAR construct was used as a negative control. % Cytotoxicity indicates target-specific killing efficacy at a given effector:target (E:T) ratio. Figures 12B and 12C show *in vivo* MOLM13 AML cell line xenograft experiment with 6-8 week-old NSG mice. On day -5, mice were injected via tail-vein with the indicated MOLM13 cell line clone (dose: 1×10^6 cells per mouse). On day -1, AML engraftment was confirmed via ffLuc-based *in vivo* bioluminescence imaging. On day 0, mice were injected via tail-vein with CAR T cells (dose: 5×10^5 CAR-positive cells per mouse). Subsequently, the AML burden was quantified via bioluminescence imaging and is represented via total flux (p/s).

Figure 13 illustrates a pSFG-ADCLEC.syn1 restriction map (8940 bp).

Figure 14 illustrates the gammaretroviral vector design for ADCLEC.syn1 bicistronic construct including ADGRE2ADGRE2-A-CAR and CLEC12ACLEC12A-A-CCR. Abbreviations: LTR = long terminal repeat, SD = splice donor site, SA = splice acceptor site, SP = signal peptide, scFv = single-chain variable fragment, H = hinge, TM = transmembrane, C = costimulatory domain, S = stimulatory domain.

Figure 15 illustrates a representative ADCLEC.syn1 CAR T cell manufacturing plan.

Figure 16 illustrates an algorithm to guide treatment course following D30 disease assessment.

Figures 17A and 17B illustrate solubilized membrane protein (SMP) assays.

Figures 18A and 18B illustrate combinatorial gating strategies. Figure 18A shows previously described combinatorial CAR gating strategies. Figure 18B shows the “IF-BETTER” gating strategy.

Figures 19A and 19B illustrate *in vitro* CAR efficacy assays validating the “IF-BETTER” gating strategy in the context of ADGRE2/CLEC12A co-targeting via ADCLEC.syn1. Figure 19A shows cytotoxicity induced by ADCLEC.syn1-transduced T cells and cocultured with EL4 murine lymphoma cell line expressing no target (ADGRE2-/CLEC12A-) or overexpressing either CAR target alone (ADGRE2+/CLEC12A-), CCR target alone (ADGRE2-/CLEC12A+), or both CAR and CCR target (ADGRE2+/CLEC12A+). 1928z1XX CAR was used as a negative control. Figure 19B shows cytotoxicity induced by untransduced,

ADGRE2-CAR-, CLEC12A-CCR-, or ADCLEC.syn1-transduced T cells cocultured with MOLM13 target cells that were modified to express different ADGRE2 levels (i.e., ADGRE2-high(WT), ADGRE2-low, and ADGRE2-very-low).

Figure 20 illustrates *in vivo* validation of the “IF-BETTER” gating strategy using ADCLEC.syn1 T cells. Tumor growth and survival were determined in NSG AML xenograft models receiving an injection of untransduced, ADGRE2-CAR-, ADGRE2-CAR +CLEC12A-CAR-, CLEC12A-CCR-, or ADCLEC.syn1-transduced T cells.

Figure 21 illustrates *in vivo* stress test of ADCLEC.syn1 via T cell dose-titration and AML re-challenge. Tumor growth and survival were determined in NSG AML xenograft models receiving an injection of ADCLEC.syn1-transduced T cells at different doses.

5. DETAILED DESCRIPTION OF THE INVENTION

The presently disclosed subject matter provides chimeric receptors that target ADGRE2, and chimeric receptors that target CLEC12A. The presently disclosed subject matter further provides cells comprising the presently disclosed ADGRE2-targeted chimeric receptor, cells comprising the presently disclosed CLEC12A-targeted chimeric receptor, and cells comprising the presently disclosed ADGRE2-targeted chimeric receptor, and the presently disclosed CLEC12A-targeted chimeric receptor. The cells can be immunoresponsive cells, *e.g.*, genetically modified immunoresponsive cells (*e.g.*, T cells or NK cells). The presently disclosed subject matter also provides methods of using such cells for treatments, *e.g.*, for treating and/or preventing a tumor associated with ADGRE2 and/or CLEC12A (*e.g.*, AML).

Non-limiting embodiments of the presently disclosed subject matter are described by the present specification and Examples.

For purposes of clarity of disclosure and not by way of limitation, the detailed description is divided into the following subsections:

- 25 5.1. Definitions;
- 5.2. Chimeric Receptors;
- 5.3. Extracellular antigen-binding domains of ADGRE2-Targeted Chimeric Receptors;
- 5.4. Exemplified ADGRE2-Targeted Chimeric Receptors;
- 30 5.5. Extracellular antigen-binding domains of CLEC12A-Targeted Chimeric Receptors;
- 5.6. Exemplified CLEC12A-Targeted Chimeric Receptors;
- 5.7. Cells;
- 5.8. Nucleic Acid Molecules, Vector and Genetic Modifications;

5.9. Formulations and Administration; and

5.10. Methods of Treatment.

5.1. Definitions

Unless defined otherwise, all technical and scientific terms used herein have the meaning
5 commonly understood by a person skilled in the art to which the presently disclosed subject
matter belongs. The following references provide one of skill with a general definition of many
of the terms used in the presently disclosed subject matter: Singleton et al., Dictionary of
Microbiology and Molecular Biology (2nd ed. 1994); The Cambridge Dictionary of Science and
Technology (Walker ed., 1988); The Glossary of Genetics, 5th Ed., R. Rieger et al. (eds.),
10 Springer Verlag (1991); and Hale & Marham, The Harper Collins Dictionary of Biology (1991).
As used herein, the following terms have the meanings ascribed to them below, unless specified
otherwise.

As used herein, the term “about” or “approximately” means within an acceptable error
range for the particular value as determined by one of ordinary skill in the art, which will depend
15 in part on how the value is measured or determined, *i.e.*, the limitations of the measurement
system. For example, “about” can mean within 3 or more than 3 standard deviations, per the
practice in the art. Alternatively, “about” can mean a range of up to 20%, preferably up to 10%,
more preferably up to 5%, and more preferably still up to 1% of a given value. Alternatively,
particularly with respect to biological systems or processes, the term can mean within an order
20 of magnitude, preferably within 5-fold, and more preferably within 2-fold, of a value.

By “immunoresponsive cell” is meant a cell that functions in an immune response or a
progenitor, or progeny thereof. In certain embodiments, the immunoresponsive cell is a cell of
lymphoid lineage. Non-limiting examples of cells of lymphoid lineage include T cells, Natural
Killer (NK) cells, B cells, and stem cells from which lymphoid cells may be differentiated. In
25 certain embodiments, the immunoresponsive cell is a cell of myeloid lineage.

By “activates an immunoresponsive cell” is meant induction of signal transduction or
changes in protein expression in the cell resulting in initiation of an immune response. For
example, when CD3 Chains cluster in response to ligand binding and immunoreceptor tyrosine-
based inhibition motifs (ITAMs) a signal transduction cascade is produced. In certain
30 embodiments, when an endogenous TCR or an exogenous CAR binds to an antigen, a formation
of an immunological synapse occurs that includes clustering of many molecules near the bound
receptor (*e.g.* CD4 or CD8, CD3 $\gamma/\delta/\epsilon/\zeta$, etc.). This clustering of membrane bound signaling
molecules allows for ITAM motifs contained within the CD3 chains to become phosphorylated.
This phosphorylation in turn initiates a T cell activation pathway ultimately activating

transcription factors, such as NF- κ B and AP-1. These transcription factors induce global gene expression of the T cell to increase IL-2 production for proliferation and expression of master regulator T cell proteins in order to initiate a T cell mediated immune response.

By “stimulates an immunoresponsive cell” is meant a signal that results in a robust and sustained immune response. In various embodiments, this occurs after immune cell (*e.g.*, T-cell) activation or concomitantly mediated through receptors including, but not limited to, CD28, CD137 (4-1BB), OX40, CD40 and ICOS. Receiving multiple stimulatory signals can be important to mount a robust and long-term T cell mediated immune response. T cells can quickly become inhibited and unresponsive to antigen. While the effects of these co-stimulatory signals may vary, they generally result in increased gene expression in order to generate long lived, proliferative, and anti-apoptotic T cells that robustly respond to antigen for complete and sustained eradication.

As used herein, the term “antibody” means not only intact antibody molecules, but also fragments of antibody molecules that retain immunogen-binding ability. Such fragments are also well known in the art and are regularly employed both *in vitro* and *in vivo*. Accordingly, as used herein, the term “antibody” means not only intact immunoglobulin molecules but also the well-known active fragments F(ab')₂, and Fab. F(ab')₂, and Fab fragments that lack the Fe fragment of intact antibody, clear more rapidly from the circulation, and may have less non-specific tissue binding of an intact antibody (Wahl et al., *Nucl Med* (1983);24:316-325). As used herein, include whole native antibodies, bispecific antibodies; chimeric antibodies; Fab, Fab', single chain V region fragments (scFv), fusion polypeptides, and unconventional antibodies. In certain embodiments, an antibody is a glycoprotein comprising at least two heavy (H) chains and two light (L) chains inter-connected by disulfide bonds. Each heavy chain is comprised of a heavy chain variable region (abbreviated herein as V_H) and a heavy chain constant (C_H) region. The heavy chain constant region is comprised of three domains, CH1, CH2 and CH3. Each light chain is comprised of a light chain variable region (abbreviated herein as V_L) and a light chain constant C_L region. The light chain constant region is comprised of one domain, C_L. The V_H and V_L regions can be further sub-divided into regions of hypervariability, termed complementarity determining regions (CDR), interspersed with regions that are more conserved, termed framework regions (FR). Each V_H and V_L is composed of three CDRs and four FRs arranged from amino-terminus to carboxy-terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. The variable regions of the heavy and light chains contain a binding domain that interacts with an antigen. The constant regions of the antibodies may mediate the

binding of the immunoglobulin to host tissues or factors, including various cells of the immune system (*e.g.*, effector cells) and the first component (C1q) of the classical complement system.

As used herein, “CDRs” are defined as the complementarity determining region amino acid sequences of an antibody which are the hypervariable regions of immunoglobulin heavy and light chains. *See, e.g.*, Kabat et al., Sequences of Proteins of Immunological Interest, 4th U.S. Department of Health and Human Services, National Institutes of Health (1987), or IMGT numbering system (Lefranc, *The Immunologist* (1999);7:132-136; Lefranc *et al.*, *Dev. Comp. Immunol.* (2003);27:55-77). Generally, antibodies comprise three heavy chain and three light chain CDRs or CDR regions in the variable region. CDRs provide the majority of contact residues for the binding of the antibody to the antigen or epitope. In certain embodiments, the CDRs regions are delineated using the IMGT numbering system. In certain embodiments, the CDR regions are delineated using the IMGT numbering system accessible at http://www.imgt.org/IMGT_vquest/input.

As used herein, the term “single-chain variable fragment” or “scFv” is a fusion protein of the variable regions of the heavy (V_H) and light chains (V_L) of an immunoglobulin (*e.g.*, mouse or human) covalently linked to form a $V_H::V_L$ heterodimer. The heavy (V_H) and light chains (V_L) are either joined directly or joined by a peptide-encoding linker (*e.g.*, 10, 15, 20, 25 amino acids), which connects the N-terminus of the V_H with the C-terminus of the V_L , or the C-terminus of the V_H with the N-terminus of the V_L . The linker is usually rich in glycine for flexibility, as well as serine or threonine for solubility. The linker can link the heavy chain variable region and the light chain variable region of the extracellular antigen-binding domain. Non-limiting examples of linkers are disclosed in Shen et al., *Anal. Chem.* 80(6):1910-1917 (2008) and WO 2014/087010, the contents of which are hereby incorporated by reference in their entireties. In certain embodiments, the linker is a G4S linker.

In certain embodiments, the linker comprises or consists of the amino acid sequence set forth in SEQ ID NO: 1, which is provided below:

GGGGSGGGSGGGSGGGGS [SEQ ID NO: 1]

In certain embodiments, the linker comprise or consists of the amino acid sequence set forth in SEQ ID NO: 2, which is provided below:

GGGGSGGGSGGGGS [SEQ ID NO: 2]

In certain embodiments, the linker comprises or consists of the amino acid sequence set forth in SEQ ID NO: 3, which is provided below:

GGGGSGGGSGGGSGGGSGGGGS [SEQ ID NO: 3]

GGGGSGGGGSGGGGSGGGGSGGGSGGGGS [SEQ ID NO: 4]

GGGGS [SEQ ID NO: 5]

GGGGS GGGGS [SEQ ID NO: 6]

ASTGGGGSGGGGSGGGGS [SEQ ID NO: 149]

The term “chimeric antigen receptor” or “CAR” as used herein refers to a molecule comprising an extracellular antigen-binding domain that is fused to an intracellular signaling domain that is capable of activating or stimulating an immunoresponsive cell. In certain embodiments, the CAR also comprises a transmembrane domain. In certain embodiments, the extracellular antigen-binding domain of a CAR comprises an scFv. The scFv can be derived from fusing the variable heavy and light regions of an antibody. Alternatively or additionally, the scFv may be derived from Fab’s (instead of from an antibody, *e.g.*, obtained from Fab

libraries). In certain embodiments, the scFv is fused to the transmembrane domain and then to the intracellular signaling domain.

The term “chimeric co-stimulating receptor” or “CCR” refers to a chimeric receptor that binds to an antigen and provides co-stimulatory signals, but does not alone provide an activation signal. CCR is described in Krause, et al., *J. Exp. Med.* (1998);188(4):619-626, and
5 US20020018783, the contents of which are incorporated by reference in their entireties. CCRs mimic co-stimulatory signals, but unlike, CARs, do not alone provide an activation signal, e.g., CCRs lack a CD3ζ polypeptide.

By “substantially identical” or “substantially homologous” is meant a polypeptide or
10 nucleic acid molecule exhibiting at least about 50% homologous or identical to a reference amino acid sequence (for example, any of the amino acid sequences described herein) or a reference nucleic acid sequence (for example, any of the nucleic acid sequences described herein). In certain embodiments, such a sequence is at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%,
15 at least about 95%, at least about 99%, or at least about 100% homologous or identical to the sequence of the amino acid or nucleic acid used for comparison.

Sequence identity can be measured by using sequence analysis software (for example, Sequence Analysis Software Package of the Genetics Computer Group, University of Wisconsin Biotechnology Center, 1710 University Avenue, Madison, Wis. 53705, BLAST, BESTFIT,
20 GAP, or PILEUP/PRETTYBOX programs). Such software matches identical or similar sequences by assigning degrees of homology to various substitutions, deletions, and/or other modifications. Conservative substitutions typically include substitutions within the following groups: glycine, alanine; valine, isoleucine, leucine; aspartic acid, glutamic acid, asparagine, glutamine; serine, threonine; lysine, arginine; and phenylalanine, tyrosine. In an exemplary
25 approach to determining the degree of identity, a BLAST program may be used, with a probability score between e-3 and e-100 indicating a closely related sequence.

As used herein, the percent homology between two amino acid sequences is equivalent to the percent identity between the two sequences. The percent identity between the two sequences is a function of the number of identical positions shared by the sequences (*i.e.*, %
30 $\text{homology} = \frac{\# \text{ of identical positions}}{\text{total } \# \text{ of positions}} \times 100$), taking into account the number of gaps, and the length of each gap, which need to be introduced for optimal alignment of the two sequences. The comparison of sequences and determination of percent identity between two sequences can be accomplished using a mathematical algorithm.

The percent homology between two amino acid sequences can be determined using the algorithm of E. Meyers and W. Miller (*Comput. Appl. Biosci.*, 4:11-17 (1988)) which has been incorporated into the ALIGN program (version 2.0), using a PAM120 weight residue table, a gap length penalty of 12 and a gap penalty of 4. In addition, the percent homology between two amino acid sequences can be determined using the Needleman and Wunsch (*J. Mol. Biol.* 48:444-453 (1970)) algorithm which has been incorporated into the GAP program in the GCG software package (available at www.gcg.com), using either a Blossum 62 matrix or a PAM250 matrix, and a gap weight of 16, 14, 12, 10, 8, 6, or 4 and a length weight of 1, 2, 3, 4, 5, or 6.

Additionally or alternatively, the amino acids sequences of the presently disclosed subject matter can further be used as a “query sequence” to perform a search against public databases to, for example, identify related sequences. Such searches can be performed using the XBLAST program (version 2.0) of Altschul, et al. (1990) *J. Mol. Biol.* 215:403-10. BLAST protein searches can be performed with the XBLAST program, score = 50, wordlength = 3 to obtain amino acid sequences homologous to the specified sequences (*e.g.*, heavy and light chain variable region sequences of scFv m903, m904, m905, m906, and m900) disclosed herein. To obtain gapped alignments for comparison purposes, Gapped BLAST can be utilized as described in Altschul et al., (1997) *Nucleic Acids Res.* 25(17):3389-3402. When utilizing BLAST and Gapped BLAST programs, the default parameters of the respective programs (*e.g.*, XBLAST and NBLAST) can be used. An “effective amount” is an amount sufficient to affect a beneficial or desired clinical result upon treatment. An effective amount can be administered to a subject in one or more doses. In certain embodiments, an effective amount can be an amount that is sufficient to palliate, ameliorate, stabilize, reverse or slow the progression of the disease, or otherwise reduce the pathological consequences of the disease. The effective amount can be determined by a physician on a case-by-case basis and is within the skill of one in the art. Several factors are typically taken into account when determining an appropriate dosage to achieve an effective amount. These factors include age, sex and weight of the subject, the condition being treated, the severity of the condition and the form and effective concentration of the cells administered.

As used herein, the term “endogenous” refers to a nucleic acid molecule or polypeptide that is normally expressed in a cell or tissue.

As used herein, the term “exogenous” refers to a nucleic acid molecule or polypeptide that is not endogenously present in a cell. The term “exogenous” would therefore encompass any recombinant nucleic acid molecule or polypeptide expressed in a cell, such as foreign, heterologous, and over-expressed nucleic acid molecules and polypeptides. By “exogenous”

nucleic acid is meant a nucleic acid not present in a native wild-type cell; for example, an exogenous nucleic acid may vary from an endogenous counterpart by sequence, by position/location, or both. For clarity, an exogenous nucleic acid may have the same or different sequence relative to its native endogenous counterpart; it may be introduced by genetic
5 engineering into the cell itself or a progenitor thereof, and may optionally be linked to alternative control sequences, such as a non-native promoter or secretory sequence.

By a “heterologous nucleic acid molecule or polypeptide” is meant a nucleic acid molecule (*e.g.*, a cDNA, DNA or RNA molecule) or polypeptide that is not normally present in a cell or sample obtained from a cell. This nucleic acid may be from another organism, or it may
10 be, for example, an mRNA molecule that is not normally expressed in a cell or sample.

By “modulate” is meant positively or negatively alter. Exemplary modulations include a about 1%, about 2%, about 5%, about 10%, about 25%, about 50%, about 75%, or about 100% change.

By “increase” is meant to alter positively by at least about 5%. An alteration may be by
15 about 5%, about 10%, about 25%, about 30%, about 50%, about 75%, about 100% or more.

By “reduce” is meant to alter negatively by at least about 5%. An alteration may be by about 5%, about 10%, about 25%, about 30%, about 50%, about 75%, or even by about 100%.

The terms “isolated,” “purified,” or “biologically pure” refer to material that is free to varying degrees from components which normally accompany it as found in its native state.
20 “Isolate” denotes a degree of separation from original source or surroundings. “Purify” denotes a degree of separation that is higher than isolation. A “purified” or “biologically pure” protein is sufficiently free of other materials such that any impurities do not materially affect the biological properties of the protein or cause other adverse consequences. That is, a nucleic acid or peptide is purified if it is substantially free of cellular material, viral material, or culture
25 medium when produced by recombinant DNA techniques, or chemical precursors or other chemicals when chemically synthesized. Purity and homogeneity are typically determined using analytical chemistry techniques, for example, polyacrylamide gel electrophoresis or high-performance liquid chromatography. The term “purified” can denote that a nucleic acid or protein gives rise to essentially one band in an electrophoretic gel. For a protein that can be
30 subjected to modifications, for example, phosphorylation or glycosylation, different modifications may give rise to different isolated proteins, which can be separately purified.

By “isolated cell” is meant a cell that is separated from the molecular and/or cellular components that naturally accompany the cell.

The term “antigen-binding domain” as used herein refers to a domain capable of specifically binding a particular antigenic determinant or set of antigenic determinants present on a cell.

By “receptor” is meant a polypeptide, or portion thereof, present on a cell membrane that
5 selectively binds one or more ligand.

By “signal sequence” or “leader sequence” is meant a peptide sequence (*e.g.*, 5, 10, 15, 20, 25 or 30 amino acids) present at the N-terminus of newly synthesized proteins that directs their entry to the secretory pathway

The terms “comprises”, “comprising”, and are intended to have the broad meaning
10 ascribed to them in U.S. Patent Law and can mean “includes”, “including” and the like.

As used herein, “treatment” refers to clinical intervention in an attempt to alter the disease course of the individual or cell being treated, and can be performed either for prophylaxis or during the course of clinical pathology. Therapeutic effects of treatment include, without limitation, preventing occurrence or recurrence of disease, alleviation of symptoms,
15 diminishment of any direct or indirect pathological consequences of the disease, preventing metastases, decreasing the rate of disease progression, amelioration or palliation of the disease state, and remission or improved prognosis. By preventing progression of a disease or disorder, a treatment can prevent deterioration due to a disorder in an affected or diagnosed subject or a subject suspected of having the disorder, but also a treatment may prevent the onset of the
20 disorder or a symptom of the disorder in a subject at risk for the disorder or suspected of having the disorder.

An “individual” or “subject” herein is a vertebrate, such as a human or non-human animal, for example, a mammal. Mammals include, but are not limited to, humans, primates, farm animals, sport animals, rodents and pets. Non-limiting examples of non-human animal
25 subjects include rodents such as mice, rats, hamsters, and guinea pigs; rabbits; dogs; cats; sheep; pigs; goats; cattle; horses; and non-human primates such as apes and monkeys.

As used herein, the term “a conservative sequence modification” refers to an amino acid modification that does not significantly affect or alter the binding characteristics of the presently disclosed chimeric receptors comprising the amino acid sequence. Conservative modifications
30 can include amino acid substitutions, additions and deletions. Modifications can be introduced into the extracellular antigen-binding domain of the presently disclosed chimeric receptors by standard techniques known in the art, such as site-directed mutagenesis and PCR-mediated mutagenesis. Amino acids can be classified into groups according to their physicochemical properties such as charge and polarity. Conservative amino acid substitutions are ones in which

the amino acid residue is replaced with an amino acid within the same group. For example, amino acids can be classified by charge: positively-charged amino acids include lysine, arginine, histidine, negatively-charged amino acids include aspartic acid, glutamic acid, neutral charge amino acids include alanine, asparagine, cysteine, glutamine, glycine, isoleucine, leucine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, and valine. In addition, amino acids can be classified by polarity: polar amino acids include arginine (basic polar), asparagine, aspartic acid (acidic polar), glutamic acid (acidic polar), glutamine, histidine (basic polar), lysine (basic polar), serine, threonine, and tyrosine; non-polar amino acids include alanine, cysteine, glycine, isoleucine, leucine, methionine, phenylalanine, proline, tryptophan, and valine. Thus, one or more amino acid residues within a CDR region can be replaced with other amino acid residues from the same group and the altered antibody can be tested for retained function (*i.e.*, the functions set forth in (c) through (l) above) using the functional assays described herein. In certain embodiments, no more than one, no more than two, no more than three, no more than four, no more than five residues within a specified sequence or a CDR region are altered.

Other aspects of the presently disclosed subject matter are described in the following disclosure and are within the ambit of the presently disclosed subject matter.

5.2. *Chimeric Receptors*

In certain embodiments, the presently disclosed chimeric receptor comprises an extracellular antigen-binding domain that binds to ADGRE2 or CLEC12A. The extracellular antigen-binding domain can be an antigen-binding fragment of an antibody, an antigen-binding fragment of a heavy chain variable region (V_H) of an antibody, an antigen-binding fragment of a light chain variable region (V_L) of an antibody, a single chain variable fragment (scFv), a Fab, or $F(ab)_2$. In certain embodiments, the extracellular antigen-binding fragment is a single chain variable fragment (scFv). In certain embodiments, the scFv is a human scFv. In certain embodiments, the scFv is a humanized scFv. In certain embodiments, the scFv is a murine scFv. In certain embodiments, the Fab is crosslinked.

In certain embodiments, the presently disclosed chimeric receptor is a chimeric antigen receptor (CAR). In certain embodiments, the presently disclosed chimeric receptor is a chimeric co-stimulating receptor (CCR). In certain embodiments, the chimeric receptor is a TCR like fusion molecule.

5.2.1. *Chimeric Antigen Receptor (CAR)*

In certain embodiments, the chimeric receptor is a CAR. CARs are engineered receptors, which graft or confer a specificity of interest onto an immune effector cell. CARs can

be used to graft the specificity of a monoclonal antibody onto a T cell; with transfer of their coding sequence facilitated by retroviral vectors.

There are three generations of CARs. “First generation” CARs are typically composed of an extracellular antigen-binding domain (*e.g.*, an scFv), which is fused to a transmembrane domain, which is fused to cytoplasmic/intracellular signaling domain. “First generation” CARs can provide *de novo* antigen recognition and cause activation of both CD4⁺ and CD8⁺ T cells through their CD3ζ chain signaling domain in a single fusion molecule, independent of HLA-mediated antigen presentation. “Second generation” CARs add intracellular signaling domains from various co-stimulatory molecules (*e.g.*, CD28, 4-1BB, ICOS, OX40) to the cytoplasmic tail of the CAR to provide additional signals to the T cell. “Second generation” CARs comprise those that provide both co-stimulation (*e.g.*, CD28 or 4-1BB) and activation (CD3ζ). “Third generation” CARs comprise those that provide multiple co-stimulation (*e.g.*, CD28 and 4-1BB) and activation (CD3ζ). In certain embodiments, the chimeric receptor is a second generation CAR. In certain embodiments, the chimeric receptor is a CAR that comprises an intracellular domain of a co-stimulatory molecule or a fragment thereof.

5.2.1.1. Extracellular Antigen-Binding Domain of a CAR

In certain embodiments, the extracellular antigen-binding domain is a single chain variable fragment (scFv). In certain embodiments, the scFv is a human scFv. In certain embodiments, the scFv is a humanized scFv. In certain embodiments, the scFv is a murine scFv. In certain embodiments, the scFv is identified by screening scFv phage library with an antigen-Fc fusion protein.

In certain embodiments, the extracellular antigen-binding domain is a Fab. In certain embodiments, the Fab is crosslinked. In certain embodiments, the extracellular antigen-binding domain is a F(ab)₂. Any of the foregoing molecules may be comprised in a fusion protein with a heterologous sequence to form the extracellular antigen-binding domain.

Binding of the extracellular antigen-binding domain of a chimeric receptor, *e.g.*, a CAR, can be confirmed by, for example, enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA), FACS analysis, bioassay (*e.g.*, growth inhibition), or Western Blot assay. Each of these assays generally detect the presence of protein-antibody complexes of particular interest by employing a labeled reagent (*e.g.*, an antibody, or an scFv) specific for the complex of interest. For example, the scFv can be radioactively labeled and used in a radioimmunoassay (RIA) (see, for example, Weintraub, B., Principles of Radioimmunoassay, Seventh Training Course on Radioligand Assay Techniques, The Endocrine Society, March, 1986, which is incorporated by reference herein). The radioactive isotope can be detected by

such means as the use of a γ counter or a scintillation counter or by autoradiography. In certain embodiments, the extracellular antigen-binding domain of the CAR is labeled with a fluorescent marker. Non-limiting examples of fluorescent markers include green fluorescent protein (GFP), blue fluorescent protein (*e.g.*, EBFP, EBFP2, Azurite, and mKalamal), cyan fluorescent protein (5 *e.g.*, ECFP, Cerulean, and CyPet), and yellow fluorescent protein (*e.g.*, YFP, Citrine, Venus, and YPet).

5.2.1.2. Transmembrane Domain of a CAR

In certain embodiments, the transmembrane domain of the CAR comprises a hydrophobic alpha helix that spans at least a portion of the membrane. Different transmembrane domains result in different receptor stability. After antigen recognition, receptors cluster and a signal are transmitted to the cell. In accordance with the presently disclosed subject matter, the transmembrane domain of the CAR can comprise a native or modified transmembrane domain of CD8 or a fragment thereof, a native or modified transmembrane domain of CD28 or a fragment thereof, a native or modified transmembrane domain of CD3 ζ or a fragment thereof, a native or modified transmembrane domain of CD4 or a fragment thereof, a native or modified transmembrane domain of 4-1BB or a fragment thereof, a native or modified transmembrane domain of OX40 or a fragment thereof, a native or modified transmembrane domain of ICOS or a fragment thereof, a native or modified transmembrane domain of CD84 or a fragment thereof, a native or modified transmembrane domain of CD166 or a fragment thereof, a native or modified transmembrane domain of CD8a or a fragment thereof, a native or modified transmembrane domain of CD8b or a fragment thereof, a native or modified transmembrane domain of ICAM-1 or a fragment thereof, a native or modified transmembrane domain of CTLA-4 or a fragment thereof, a native or modified transmembrane domain of CD27 or a fragment thereof, a native or modified transmembrane domain of CD40 or a fragment thereof, 25 NKGD2 or a fragment thereof, or a combination thereof.

In certain embodiments, the transmembrane domain of the CAR comprises a CD8 polypeptide (*e.g.*, a transmembrane domain of CD8 or a fragment thereof).

In certain embodiments, the transmembrane domain of the CAR comprises a CD8 polypeptide (*e.g.*, a transmembrane domain of CD8 or a fragment thereof). In certain 30 embodiments, the transmembrane domain of the CAR comprises a CD8 polypeptide (*e.g.*, a transmembrane domain of human CD8 or a fragment thereof). In certain embodiments, the CD8 polypeptide comprises or consists of an amino acid sequence that is at least about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, about 99% or about 100% homologous or identical to the amino acid sequence having a NCBI Reference No: NP_001139345.1 (SEQ ID

NO: 7) or a fragment thereof, and/or may optionally comprise up to one or up to two or up to three conservative amino acid substitutions. In certain embodiments, the CD8 polypeptide comprises or consists of an amino acid sequence that is a consecutive portion of SEQ ID NO: 7, which is at least about 20, or at least about 30, or at least about 40, or at least about 50, at least about 60, at least about 70, and up to about 235 amino acids in length. In certain embodiments, the CD8 polypeptide comprises or consists of amino acids 1 to 235, 1 to 50, 50 to 100, 100 to 150, 150 to 200, 137 to 207, or 200 to 235 of SEQ ID NO: 7. In certain embodiments, the transmembrane domain of the CAR comprises a CD8 polypeptide comprising or consisting of amino acids 137 to 207 of SEQ ID NO: 7. SEQ ID NO: 7 is provided below.

10 MALPVTALLLPLALLLHAARPSQFRVSPLDRTWNLGETVELKCQVLLSNPTSGCSWLFQPRGAAASPTFLLYLSQNK
PKAAEGLDTQRFSGKRLGDTFVLTLSDFRRENEGYFCSALSNSIMYFSHFVPVFLPAKPTTTPAPRPPTPAPTIAS
QPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCNHRNRRRVCKCPRFVVKSGDKPSLS
ARYV [SEQ ID NO: 7]

15 An exemplary nucleotide sequence encoding amino acids 137 to 207 of SEQ ID NO: 7 is set forth in SEQ ID NO: 8, which is provided below.

Cccaccacgacgcgcagcgccgcgaccaccaaccccgccgcccacgatcgcgctcgagccctgtccctgcgcccaga
ggcgtgcccggccagcggcgggggcgagtgacacagagggggctggacttcgcctgtgatatctacatctggggcg
ccctggcgggacttggtgggtccttctcctgtcactggttatcaccctttactgcaac [SEQ ID NO: 8]

20 In certain embodiments, the transmembrane domain of the CAR comprises a CD8 polypeptide (*e.g.*, a transmembrane domain of mouse CD8 or a fragment thereof). In certain embodiments, the CD8 polypeptide comprises or consists of an amino acid sequence that is at least about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, about 99% or about 100% homologous or identical to the amino acid sequence having a NCBI Reference No: AAA92533.1 (SEQ ID NO: 9) or a fragment thereof, and/or may optionally comprise up to one or up to two or up to three conservative amino acid substitutions. In certain embodiments, the CD8 polypeptide comprises or consists of an amino acid sequence that is a consecutive portion of SEQ ID NO: 9, which is at least about 20, or at least about 30, or at least about 40, or at least about 50, or at least about 60, or at least about 70, or at least about 100, or at least about 200, and up to about 247 amino acids in length. In certain embodiments, the CD8 polypeptide
30 comprises or consists of amino acids 1 to 247, 1 to 50, 50 to 100, 100 to 150, 150 to 200, 151 to 219, or 200 to 247 of SEQ ID NO: 9. In certain embodiments, the transmembrane domain of the CAR comprises a CD8 polypeptide comprising or consisting of amino acids 151 to 219 of SEQ ID NO: 9. SEQ ID NO: 9 is provided below.

1 MASPLTRFLS LLLLLMGESI ILGSGEAKPQ APELRIFPKK MDAELGQKVD LVCEVLGSVS
35 61 QGCSWLFQNS SSKLPQPTFV VYMASSHNKI TWDEKLNSSK LFSAVRDTNN KYVLTNLNFKS

In certain embodiments, the transmembrane domain of a presently disclosed CAR
5 comprises a CD28 polypeptide (*e.g.*, a transmembrane domain of CD28 or a fragment thereof).

20 1 MLRLLLALNL FPSIQVTGNK ILVKQSPMLV AYDNAVNLSK KYSYNLFSRE FRASLHKGLD
61 SAVEVCVVYG NYSQQLQVYS KTGFNCDGKL GNESVTFYLQ NLYVNQTDIY FCKIEVMYPP
121 PYLDNEKSNG TIIHVKGKHL CPSPLFPGPS KPFWVLVVVG GVLACYSLLV TVAFIIFWVR
181 SKRSRLHSD YMMNTPRRPG PTRKHYQPYA PPRDFAAYRS [SEQ ID NO: 10]

ttttgggtgctggtggtggttggaggagtcctggcttgctatagcttgctagtaacagtggcctttattattttctg
ggtg [SEQ ID NO: 11]

40

of SEQ ID NO: 12, which is at least about 20, or at least about 30, or at least about 40, or at least about 50, and up to about 218 amino acids in length. In certain embodiments, the CD28 polypeptide comprises or consists of amino acids 1 to 220, 1 to 50, 50 to 100, 100 to 150, 150 to 200, 151 to 177, or 200 to 218 of SEQ ID NO: 12. In certain embodiments, the transmembrane domain of the CAR comprises a CD28 polypeptide comprising or consisting of amino acids 151 to 177 of SEQ ID NO: 12. SEQ ID NO: 12 is provided below:

```

1 MTLRLLFLAL NFFSVQVTEN KILVKQSPLL VVDSNEVSLS CRYSYNLLAK EFRASLYKGV
61 NSDVEVCVGN GNFTYQPQFR SNAEFNCDGD FNETVTFRL WNLHVNHTDI YFCKIEFMYP
121 PPYLDNERSN GTIIHIKEKH LCHTQSSPKL FWALVVVAGV LFCYGLLVTV ALCVIWTNSR
181 RNRLQSDYM NMTPRRPGLT RKPYPYAPA RDFAAYRP [SEQ ID NO: 12]

```

In certain embodiments, the CAR further comprises a spacer region that links the extracellular antigen-binding domain to the transmembrane domain. The spacer region can be flexible enough to allow the antigen binding domain to orient in different directions to facilitate antigen recognition while preserving the activating activity of the CAR.

In certain embodiments, the hinge/spacer region of the CAR comprises a native or modified hinge region of CD8 or a fragment thereof, a native or modified hinge region of CD28 or a fragment thereof, a native or modified hinge region of CD3 ζ or a fragment thereof, a native or modified hinge region of CD40 or a fragment thereof, a native or modified hinge region of 4-1BB or a fragment thereof, a native or modified hinge region of OX40 or a fragment thereof, a native or modified hinge region of CD84 or a fragment thereof, a native or modified hinge region of CD166 or a fragment thereof, a native or modified hinge region of CD8a or a fragment thereof, a native or modified hinge region of CD8b or a fragment thereof, a native or modified hinge region of ICOS or a fragment thereof, a native or modified hinge region of ICAM-1 or a fragment thereof, a native or modified hinge region of CTLA-4 or a fragment thereof, a native or modified hinge region of CD27 or a fragment thereof, a native or modified hinge region of CD40 or a fragment thereof, a native or modified hinge region of NKGD2 or a fragment thereof, a synthetic polypeptide (not based on a protein associated with the immune response), or a combination thereof. The hinge/spacer region can be the hinge region from IgG1, or the CH₂CH₃ region of immunoglobulin and portions of CD3, a portion of a CD28 polypeptide (*e.g.*, a portion of SEQ ID NO: 10 or 12), a portion of a CD8 polypeptide (*e.g.*, a portion of SEQ ID NO: 7 or 9), a variation of any of the foregoing which is at least about 80%, at least about 85%, at least about 90%, at least about 95%, or at least about 100% homologous or identical thereto, or a synthetic spacer sequence.

In certain embodiments, the hinge/spacer region of the CAR comprises a CD28 polypeptide. In certain embodiments, the hinge/spacer region of the CAR comprises a CD28 polypeptide comprising or consisting of amino acids 114 to 152 of SEQ ID NO: 10.

An exemplary nucleotide sequence encoding amino acid 114 to 152 of SEQ ID NO: 10 is set forth in SEQ ID NO: 13, which is provided below.

```
attgaagttatgtatcctcctccttagacaatgagaagagcaatggaaccattatccatgtgaaagggaaaca
cctttgtccaagtccttatctcccgaccttctaagccc [SEQ ID NO: 13]
```

5.2.1.3. Intracellular Signaling Domain of a CAR

In certain embodiments, the CAR comprises an intracellular signaling domain. In certain embodiments, the intracellular signaling domain of the CAR comprises a CD3 ζ polypeptide. CD3 ζ can activate or stimulate a cell (*e.g.*, a cell of the lymphoid lineage, *e.g.*, a T cell). Wild type ("native") CD3 ζ comprises three functional immunoreceptor tyrosine-based activation motifs (ITAMs), three functional basic-rich stretch (BRS) regions (BRS1, BRS2 and BRS3). CD3 ζ transmits an activation signal to the cell (*e.g.*, a cell of the lymphoid lineage, *e.g.*, a T cell) after antigen is bound. The intracellular signaling domain of the CD3 ζ -chain is the primary transmitter of signals from endogenous TCRs.

In certain embodiments, the intracellular signaling domain of the CAR comprises a native CD3 ζ . In certain embodiments, the native CD3 ζ polypeptide comprises or consists of an amino acid sequence that is at least about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, about 99% or about 100% homologous or identical to the amino acid sequence having a NCBI Reference No: NP_932170 (SEQ ID NO: 14) or a fragment thereof, and/or may optionally comprise up to one or up to two or up to three conservative amino acid substitutions. In certain embodiments, the native CD3 ζ polypeptide comprises or consists of an amino acid sequence that is a consecutive portion of SEQ ID NO: 14, which is at least about 20, or at least about 30, or at least about 40, or at least about 50, at least about 100, at least about 110, and up to about 164 amino acids in length. In certain embodiments, the native CD3 ζ polypeptide comprises or consists of amino acids 1 to 164, 1 to 50, 50 to 100, 52 to 164, 100 to 150, or 150 to 164 of SEQ ID NO: 14. In certain embodiments, the intracellular signaling domain of the CAR comprises a CD3 ζ polypeptide comprising or consisting of amino acids 52 to 164 of SEQ ID NO: 14. SEQ ID NO: 14 is provided below:

```
1 MKWKALFTAA ILQAQLPITE AQSFGLDPK LCYLLDGILF IYGVILTALF LRVKFSRSAD
61 APAYQQGQNO LYNELNLGRR EYDVLDKRR GRDPEMGGKP QRRKNPQEGY YNELQDKMA
121 EAYSEIGMKG ERRRGKGHDG LYQGLSTATK DTYDALHMQA LPPR [SEQ ID NO: 14]
```

In certain embodiments, the intracellular signaling domain of the CAR comprises a modified CD3 ζ polypeptide. In certain embodiments, the modified CD3 ζ polypeptide comprises

one, two or three ITAMs. In certain embodiments, the modified CD3 ζ polypeptide comprises a native ITAM1. In certain embodiments, the native ITAM1 comprises or consists of the amino acid sequence set forth in SEQ ID NO: 15.

QNQLYNELNLGRREEYDVLDKR [SEQ ID NO: 15]

- 5 An exemplary nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 15 is set forth in SEQ ID NO: 16, which is provided below.

Cagaaccagctctataacgagctcaatctaggacgaagagaggagtacgatgttttggacaagaga [SEQ ID NO: 16]

- In certain embodiments, the modified CD3 ζ polypeptide comprises an ITAM1 variant comprising one or more loss-of-function mutations. In certain embodiments, the ITAM1 variant comprises or consists of two loss-of-function mutations. In certain embodiments, each of the one or more (*e.g.*, two) loss of function mutations comprises a mutation of a tyrosine residue in ITAM1. In certain embodiments, the ITAM1 variant consists of two loss-of-function mutations. In certain embodiments, the ITAM1 variant comprises or consists of the amino acid sequence set forth in SEQ ID NO: 17, which is provided below.

QNQLFNELNLGRREEFDVLDKR [SEQ ID NO: 17]

- An exemplary nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 17 is set forth in SEQ ID NO: 18, which is provided below.

20 CAGAACCAGCTCTTTAACGAGCTCAATCTAGGACGAAGAGAGAGTTCGATGTTTTGGACAAGAGA [SEQ ID NO: 18]

In certain embodiments, the modified CD3 ζ polypeptide comprises a native ITAM2. In certain embodiments, the native ITAM2 comprises or consists of the amino acid sequence set forth in SEQ ID NO: 19, which is provided below.

QEGLYNELQKDKMAEAYSEIGMK [SEQ ID NO: 19]

- 25 An exemplary nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 19 is set forth in SEQ ID NO: 20, which is provided below.

CAGGAAGGCCTGTACAATGAACTGCAGAAAGATAAGATGGCGGAGGCCTACAGTGAGATTGGGATGAAA [SEQ ID NO: 20]

- In certain embodiments, the modified CD3 ζ polypeptide comprises an ITAM2 variant. In certain embodiments, the ITAM2 variant comprises or consists of one or more loss-of-function mutations. In certain embodiments, the ITAM2 variant comprises or consists of two loss-of-function mutations. In certain embodiments, each of the one or more (*e.g.*, two) the loss of function mutations comprises a mutation of a tyrosine residue in ITAM2. In certain embodiments, the ITAM2 variant consists of two loss-of-function mutations. In certain embodiments, the ITAM2 variant comprises or consists of the amino acid sequence set forth in SEQ ID NO: 21, which is provided below.

QEGLFNELQKDKMAEAFSEIGMK [SEQ ID NO: 21]

An exemplary nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 21 is set forth in SEQ ID NO: 22, which is provided below.

Caggaaggcctgttcaatgaactgcagaaagataagatggcggaggccttcagtgagattgggatgaaa [SEQ ID NO: 22]

In certain embodiments, the modified CD3 ζ polypeptide comprises a native ITAM3. In certain embodiments, the native ITAM3 comprises or consists of the amino acid sequence set forth in SEQ ID NO: 23, which is provided below.

HDGLYQGLSTATKDTYDALHMQ [SEQ ID NO: 23]

An exemplary nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 23 is set forth in SEQ ID NO: 24, which is provided below.

CACGATGGCCTTTACCAGGGTCTCAGTACAGCCACCAAGGACACCTACGACGCCCTTCACATGCAG [SEQ ID NO: 24]

In certain embodiments, the modified CD3 ζ polypeptide comprises an ITAM3 variant.

In certain embodiments, the ITAM3 variant comprises or consists of two loss-of-function mutations. In certain embodiments, each of the one or more (*e.g.*, two) the loss of function mutations comprises a mutation of a tyrosine residue in ITAM3. In certain embodiments, the ITAM3 variant comprises or consists of two loss-of-function mutations. In certain embodiments, the ITAM3 variant comprises or consists of the amino acid sequence set forth in SEQ ID NO: 25, which is provided below.

HDGLFQGLSTATKDTFDALHMQ [SEQ ID NO: 25]

An exemplary nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 25 is set forth in SEQ ID NO: 26, which is provided below.

Cacgatggcctttttccaggggtctcagtagcagccaccaaggacaccttcgacgcccttcacatgcag [SEQ ID NO: 26]

Various modified CD3 ζ polypeptides and CARs comprising modified CD3 ζ polypeptides are disclosed in International Patent Application Publication No. WO2019/133969, which is incorporated by reference hereby in its entirety.

In certain embodiments, the intracellular signaling domain of the CAR comprises a modified CD3 ζ polypeptide comprising a native ITAM1, an ITAM2 variant comprising or consisting of one or more (*e.g.*, two) loss-of-function mutations, and an ITAM3 variant comprising or consisting of one or more (*e.g.*, two) loss-of-function mutations. In certain embodiments, the intracellular signaling domain of the CAR comprises a modified CD3 ζ polypeptide comprising a native ITAM1, an ITAM2 variant consisting of two loss-of-function

mutations, and an ITAM3 variant consisting of two loss-of-function mutations. In certain embodiments, the intracellular signaling domain of the CAR comprises a modified CD3 ζ polypeptide comprising a native ITAM1 consisting of the amino acid sequence set forth in SEQ ID NO: 15, an ITAM2 variant consisting of the amino acid sequence set forth in SEQ ID NO: 21, and an ITAM3 variant consisting of the amino acid sequence set forth in SEQ ID NO: 25. In certain embodiments, the modified CD3 ζ polypeptide is designated as “1XX”. In certain embodiments, the modified CD3 ζ polypeptide comprises or consists of the amino acid sequence set forth in SEQ ID NO: 27. SEQ ID NO: 27 is provided below.

RVKFSRSADA PAYQQGQNQL YNELNLGRRE EYDVLDKRRG RDPGEMGGKPR RKNPQEGLEFN ELQKDKMAEA
 10 FSEIGMKGER RRGKGHGDLF QGLSTATKDT FDLHMQALP PR [SEQ ID NO: 27]

In certain embodiments, the intracellular signaling domain of the CAR comprises a modified CD3 ζ polypeptide comprising or consisting of an amino acid sequence that is at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99%, at least about 100% identical to SEQ ID NO: 27 or a fragment thereof, and/or may optionally comprise up to one or up to two or up to three conservative amino acid substitutions.

An exemplary nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 27 is set forth in SEQ ID NO: 28, which is provided below.

agagtgaagttcagcaggagcgcagacgccccgcgtaccagcagggccagaaccagctctataacgagctcaatct
 20 aggacgaagagaggagtacgatgttttgacaagagacgtggccgggaccctgagatggggggaaagccgagaagga
 agaaccctcaggaaggcctgttcaatgaactgcagaaagataagatggcggaggccttcagtgcagattgggatgaaa
 ggcgagcgccggaggggcaaggggcacgatggccttttccagggtctcagtacagccaccaaggacaccttcgacgc
 ccttcacatgcaggccctgccccctcgc [SEQ ID NO: 28]

In certain embodiments, the CAR is a second-generation CAR. In certain embodiments, the intracellular signaling domain of the CAR further comprises at least a co-stimulatory signaling region. In certain embodiments, the co-stimulatory signaling region comprises an intracellular domain of at least one co-stimulatory molecule or a fragment thereof.

As used herein, a “co-stimulatory molecule” refers to a cell surface molecule other than antigen receptor or its ligand that can provide an efficient response of lymphocytes to an antigen. In certain embodiments, a co-stimulatory molecule can provide optimal lymphocyte activation. Non-limiting examples of co-stimulatory molecules include CD28, 4-1BB, OX40, ICOS, DAP-10, CD27, CD40, and NKGD2. The co-stimulatory molecule can bind to a co-stimulatory ligand, which is a protein expressed on cell surface that upon binding to its receptor produces a co-stimulatory response, *i.e.*, an intracellular response that effects the stimulation provided when an chimeric receptor (*e.g.*, a chimeric antigen receptor (CAR)) binds to its target

antigen. As one example, a 4-1BB ligand (*i.e.*, 4-1BBL) may bind to 4-1BB for providing an intracellular signal that in combination with a CAR signal induces an effector cell function of the CAR⁺ T cell.

In certain embodiments, the intracellular signaling domain of the CAR comprises a co-stimulatory signaling region that comprises a CD28 polypeptide, *e.g.*, an intracellular domain of CD28 or a fragment thereof. In certain embodiments, the CD28 polypeptide comprises or consists of an amino acid sequence that is at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99%, at least about 100% homologous or identical to the amino acid sequence set forth in SEQ ID NO: 10 or a fragment thereof, and/or may optionally comprise up to one or up to two or up to three conservative amino acid substitutions. In certain embodiments, the CD28 polypeptide comprises or consists of an amino acid sequence that is a consecutive portion of SEQ ID NO: 10, which is at least about 20, or at least about 30, or at least about 40, or at least about 50, and up to about 220 amino acids in length. In certain embodiments, the CD28 polypeptide comprises or consists of amino acids 1 to 220, 1 to 50, 50 to 100, 100 to 150, 114 to 220, 150 to 200, 180 to 220, or 200 to 220 of SEQ ID NO: 10. In certain embodiments, the intracellular signaling domain of the CAR comprises a co-stimulatory signaling region that comprises a CD28 polypeptide comprising or consisting of amino acids 180 to 220 of SEQ ID NO: 10.

An exemplary nucleic acid sequence encoding amino acids 180 to 220 of SEQ ID NO: 10 is set forth in SEQ ID NO: 29, which is provided below.

Aggagtaagaggagcaggctcctgcacagtgcactacatgaacatgactccccgccgccccggccccaccgcaagca
ttaccagccctatgccccaccacgcgacttcgcagcctatcgctcc [SEQ ID NO: 29]

In certain embodiments, the CD28 polypeptide comprises or consists of an amino acid sequence that is at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99%, at least about 100% homologous or identical to the amino acid sequence set forth in SEQ ID NO: 12 or a fragment thereof, and/or may optionally comprise up to one or up to two or up to three conservative amino acid substitutions. In certain embodiments, the CD28 polypeptide comprises or consists of an amino acid sequence that is a consecutive portion of SEQ ID NO: 12, which is at least about 20, or at least about 30, or at least about 40, or at least about 50, and up to 218 amino acids in length. In certain embodiments, the CD28 polypeptide comprises or consists of amino acids 1 to 218, 1 to 50, 50 to 100, 100 to 150, 150 to 218, 178 to 218, or 200 to 218 of SEQ ID NO: 12. In certain embodiments, the co-stimulatory signaling region of a

presently disclosed CAR comprises a CD28 polypeptide that comprises or consists of the amino acids 178 to 218 of SEQ ID NO: 12.

In certain embodiments, the intracellular signaling domain of the CAR comprises a co-stimulatory signaling region that comprises a 4-1BB polypeptide, *e.g.*, an intracellular domain of 4-1BB or a fragment thereof (*e.g.*, an intracellular domain of human 4-1BB or a fragment thereof). The 4-1BB polypeptide can comprise or consists of an amino acid sequence that is at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99%, at least about 100% homologous or identical to the amino acid sequence having a NCBI Ref. No.: NP_001552 (SEQ ID NO: 30) or a fragment thereof, and/or may optionally comprise up to one or up to two or up to three conservative amino acid substitutions. In certain embodiments, the 4-1BB polypeptide comprises or consists of an amino acid sequence that is a consecutive portion of SEQ ID NO: 30, which is at least about 20, or at least about 30, or at least about 40, or at least about 50, or at least about 100, or at least about 150, or at least about 150, and up to about 255 amino acids in length. In certain embodiments, the 4-1BB polypeptide comprises or consists of amino acids 1 to 255, 1 to 50, 50 to 100, 100 to 150, 150 to 200, 200 to 255, or 214 to 255 of SEQ ID NO: 30. In certain embodiments, the intracellular signaling domain of the CAR comprises a co-stimulatory signaling region that comprises a 4-1BB polypeptide comprising or consisting of amino acids 214 to 255 of SEQ ID NO: 30. SEQ ID NO: 30 is provided below.

1 MGNSCYNIVA TLLLVLNFER TRSLQDPCSN CPAGTFCDNN RNQICSPCPP NSFSSAGGQR
61 TCDICRQCKG VFRTRKECSS TSNAECDCTP GFHCLGAGCS MCEQDCKQGQ ELTKKGCKDC
121 CFGTFNDQKR GICRPWTNCS LDGKSVLVNG TKERDVVCGP SPADLSPGAS SVTPPAPARE
181 PGHSPQIISF FLALTSTALL FLLFFLTLLRF SVVKRGRKKL LYIFKQPFMR PVQTTQEEDG
241 CSCRFPPEEEE GGCEL [SEQ ID NO: 30]

25 An exemplary nucleic acid sequence encoding amino acids 214 to 255 of SEQ ID NO: 30 is set forth in SEQ ID NO: 31, which is provided below.

aaacggggcagaaagaagctcctgtatatattcaacaaccatttatgagaccagtacaaactactcaagaggaaga
tggctgtagctgccgatttccagaagaagaaggaggatgtgaactg [SEQ ID NO: 31]

30 In certain embodiments, the intracellular signaling domain of the CAR comprises a co-stimulatory signaling region that comprises intracellular domains of two or more co-stimulatory molecules or portions thereof, *e.g.*, an intracellular domain of CD28 or a fragment thereof and an intracellular domain of 4-1BB or a fragment thereof, or an intracellular domain of CD28 or a fragment thereof and an intracellular domain of OX40 or a fragment thereof.

5.2.2. Chimeric Co-Stimulatory Receptor (CCR)

In certain embodiments, the chimeric receptor is a CCR. The presently disclosed CCR binds to an antigen (e.g., ADGRE2 or CLEC12A) and provides co-stimulatory signals, but does not alone provide an activation signal. In certain embodiments, the CCR does not comprise a CD3 ζ polypeptide. CCRs provide co-stimulation, e.g., a CD28-like signal, in the absence of the natural co-stimulatory ligand on the antigen-presenting cell. A combinatorial antigen recognition, i.e., use of a CCR in combination with a CAR, can augment T-cell reactivity against the dual-antigen expressing T cells, thereby improving selective tumor targeting. Kloss et al., describe a strategy that integrates combinatorial antigen recognition, split signaling, and, critically, balanced strength of T-cell activation and co-stimulation to generate T cells that eliminate target cells that express a combination of antigens while sparing cells that express each antigen individually (Kloss et al., *Nature Biotechnology* (2013);31(1):71-75, the content of which is incorporated by reference in its entirety). With this approach, T-cell activation requires CAR-mediated recognition of one antigen, whereas co-stimulation is independently mediated by a CCR specific for a second antigen. To achieve tumor selectivity, the combinatorial antigen recognition approach diminishes the efficiency of T-cell activation to a level where it is ineffective without rescue provided by simultaneous CCR recognition of the second antigen.

In certain embodiments, the CCR comprises an extracellular antigen-binding domain that binds to an antigen (e.g., ADGRE2 or CLEC12A), a transmembrane domain, and a co-stimulatory signaling region that comprises an intracellular domain of at least one co-stimulatory molecule or a fragment thereof. In certain embodiments, the CCR does not alone deliver an activation signal to an immunoresponsive cell. Non-limiting examples of co-stimulatory molecules include CD28, 4-1BB, OX40, ICOS, DAP-10, CD27, CD40, and NKGD2. In certain embodiments, the co-stimulatory signaling region of the CCR comprises an intracellular domain of a co-stimulatory signaling molecule or a fragment thereof. In certain embodiments, the one co-stimulatory signaling molecule is CD28. In certain embodiments, the one co-stimulatory signaling molecule is 4-1BB. In certain embodiments, the co-stimulatory signaling region of the CCR comprises an intracellular domain of a first co-stimulatory signaling molecule or a fragment thereof and an intracellular domain of a second co-stimulatory signaling molecule or a fragment thereof. In certain embodiments, the first and second co-stimulatory signaling molecules are CD28 and 4-1BB.

Similar to a CAR, the extracellular antigen-binding domain of the CCR can be an scFv, a Fab, a F(ab)₂, or a fusion protein with a heterologous sequence to form the extracellular antigen-binding domain of the CCR.

5.2.3. TCR like Fusion Molecules

In certain embodiments, the chimeric receptor is a TCR like fusion molecule. Non-limiting examples of TCR fusion molecules include HLA-Independent TCR-based Chimeric Antigen Receptor (also known as “HIT-CAR”, e.g., those disclosed in International Patent Application No. PCT/US19/017525, which is incorporated by reference in its entirety), T cell receptor fusion constructs (TRuCs) (e.g., those disclosed in Baeuerle et al., “Synthetic TRuC receptors engaging the complete T cell receptor for potent anti-tumor response,” *Nature Communications* volume 10, Article number: 2087 (2019), which is incorporated by reference in its entirety), synthetic T cell receptor and antigen receptor (STAR) (e.g., those disclosed in Liu et al. *Science Translational Medicine* (2021);13(586):eabb5191, which is incorporated by reference in its entirety), antibody-T-cell receptor (AbTCR) (e.g., those disclosed in Xu et al. *Cell Discovery* (2018) 4:62, which is incorporated by reference in its entirety), and T cell antigen coupler (TAC) (e.g., those disclosed in Helsen et al. *Nature Communications* (2018);9:3049, which is incorporated by reference in its entirety).

In certain embodiments, the TCR like fusion molecule comprises an antigen binding chain that comprises an extracellular antigen-binding domain and a constant domain, wherein the TCR like fusion molecule binds to an antigen in an HLA-independent manner. In certain embodiments, the constant domain comprises a T cell receptor constant region selected from the group consisting of a native or modified TRAC polypeptide, a native or modified TRBC polypeptide, a native or modified TRDC polypeptide, a native or modified TRGC polypeptide and any variants or functional fragments thereof. In certain embodiments, the constant domain comprises a native or modified TRAC polypeptide. In certain embodiments, the constant domain comprises a native or modified TRBC polypeptide. In certain embodiments, the constant domain is capable of forming a homodimer or a heterodimer with another constant domain. In certain embodiments, the antigen binding chain is capable of associating with a CD3 ζ polypeptide. In certain embodiments, the antigen binding chain, upon binding to an antigen (e.g., ADGRE2 or CLEC12A), is capable of activating the CD3 ζ polypeptide associated to the antigen binding chain. In certain embodiments, the activation of the CD3 ζ polypeptide is capable of activating an immunoresponsive cell. In certain embodiments, the TCR like fusion molecule is capable of integrating with a CD3 complex and providing HLA-independent antigen recognition. In certain embodiments, the TCR like fusion molecule replaces an endogenous TCR in a CD3/TCR complex. In certain embodiments, the extracellular antigen-binding domain of the TCR like fusion molecule is capable of dimerizing with another extracellular antigen-binding domain. In certain embodiments, the extracellular antigen-binding domain of the TCR

like fusion molecule comprises a ligand for a cell-surface receptor, a receptor for a cell surface ligand, an antigen binding portion of an antibody or a fragment thereof or an antigen binding portion of a TCR. In certain embodiments, the extracellular antigen-binding domain of the TCR like fusion molecule comprises one or two immunoglobulin variable region(s). In certain

5 embodiments, the extracellular antigen-binding domain of the TCR like fusion molecule comprises a heavy chain variable region (V_H) of an antibody. In certain embodiments, the extracellular antigen-binding domain of the TCR like fusion molecule comprises a light chain variable region (V_L) of an antibody. In certain embodiments, the extracellular antigen-binding domain of the TCR like fusion molecule is capable of dimerizing with another extracellular

10 antigen-binding domain. In certain embodiments, the extracellular antigen-binding domain of the TCR like fusion molecule comprises a V_H of an antibody, wherein the V_H is capable of dimerizing with another extracellular antigen-binding domain comprising a V_L of the antibody and form a fragment variable (F_v). In certain embodiments, the extracellular antigen-binding domain of the TCR like fusion molecule comprises a V_L of an antibody, wherein the V_L is

15 capable of dimerizing with another extracellular antigen-binding domain comprising a V_H of the antibody and form a fragment variable (F_v).

5.3. *Extracellular Antigen-binding Domain of ADGRE2-Targeted Chimeric Receptors*

In certain embodiments, the presently disclosed chimeric receptor targets ADGRE2. In certain embodiments, the presently disclosed chimeric receptor comprises an extracellular

20 antigen-binding domain that binds to ADGRE2.

Adhesion G Protein-Coupled Receptor E2 (ADGRE2), also known as EMR2, CD312, VBU or CD97, is a member of the adhesion GPCR family. It is expressed by monocytes/macrophages, dendritic cells and all types of granulocytes. ADGRE2 is a cell surface receptor that binds to the chondroitin sulfate moiety of glycosaminoglycan chains and

25 promotes cell attachment. It promotes granulocyte chemotaxis, degranulation and adhesion. In macrophages, ADGRE2 promotes the release of inflammatory cytokines, including IL8 and TNF. Signals probably through G-proteins.

In certain embodiments, the presently disclosed chimeric receptor targets human ADGRE2. In certain embodiments, the presently disclosed chimeric receptor comprises an

30 extracellular antigen-binding domain that binds to human ADGRE2. In certain embodiments, the human ADGRE2 comprises or consists of the amino acid sequence with a Uniprot Reference No: Q9UHX3-1 (SEQ ID NO: 32), or a fragment thereof. SEQ ID NO: 32 is provided below:

MGGRVFLVFL AFCVWLTLPG AETQDSRGCA RWCPQDSSCV NATACRCNPG
FSSFSEIITT PMETCDDINE CATLSKVSCG KFSDCWNTG SYDCVCSPGY

EPVSGAKTFK NESENTCQDV DECQQNPRLC KSYGTCVNTL GSYTCQCLPG
 FKLKPEDPKL CTDVNECTSG QNPCHSSTHC LNNVGSYQCR CRPGWQPIPG
 SPNGPNNTVC EDVDECSSGQ HQCDSSSTVCF NTVGSYSCRC RPGWKPRHGI
 PNNQKDTVCE DMTFSTWTPP PGVHSQTLRS FFDKVQDLGR DYKPGLANNT
 5 IQSILQALDE LLEAPGDLET LPRLQQHCVA SHLLDGLQDV LRGLSKNLSN
 GLLNFSYPAG TELSLEVQKQ VDRSVTLRQN QAVMQLDWNQ AQKSGDPGPS
 VVGLVSIPGM GKLLAEAPLV LEPEKQMLLH ETHQGLLQDG SPILLSDVIS
 AFLSNNDTQN LSSPVTFTFS HRSVIPRQKV LCVFEWHGQN GCGHWATTGC
 STIGTRDTST ICRCTHLSSF AVLMAHYDVQ EEDPVLTVIT YMGLSVSLLC
 10 LLLAALTFLF CKAIQNTSTS LHLQLSLCLF LAHLLFLVAI DQTGHKVLCS
 IIAGTLHYLY LATLTWMLLE ALYLFLTARN LTVVNYSSIN RFMKKLMFPV
 GYGVPVAVTVA ISAASRPHLY GTPSRCWLQP EKGFIWGFLG PVCAIFSVNL
 VLFLVTLWIL KNRLSSLNSE VSTLRNTRML AFKATAQLFI LGCTWCLGIL
 QVGPAARVMA YLFTIINSLQ GVFIFLVYCL LSQQVREQYG KWSKGIRKLK
 15 TESEMHTLSS SAKADTSKPS TVN [SEQ ID NO: 32]

Human ADGRE2 comprises an EGF-like 1 domain, an EGF-like 2 domain, an EGF-like 3 domain, an EGF-like 4 domain, an EGF-like 5 domain, and a GPS domain. In certain embodiments, the EGF-like 1 domain comprises or consists of amino acids 25 to 66 of SEQ ID NO: 32. In certain embodiments, the EGF-like 2 domain comprises or consists of amino acids 67 to 118 of SEQ ID NO: 32. In certain embodiments, the EGF-like 3 domain comprises or consists of amino acids 119 to 162 of SEQ ID NO: 32. In certain embodiments, the EGF-like 4 domain comprises or consists of amino acids 163 to 211 of SEQ ID NO: 32. In certain embodiments, the EGF-like 5 domain comprises or consists of amino acids 212 to 260 of SEQ ID NO: 32. In certain embodiments, the GPS domain comprises or consists of amino acids 479 to 529 of SEQ ID NO: 32.

In certain embodiments, the presently disclosed chimeric receptor targets an ADGRE2 polypeptide comprising or consisting of an amino acid sequence that is at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99%, at least about 100% identical to the amino acid sequence set forth in SEQ ID NO: 32 or a fragment thereof.

In certain embodiments, the extracellular antigen-binding domain of a presently disclosed ADGRE2-targeted chimeric receptor binds to the stalk region of ADGRE2. In certain embodiments, the extracellular antigen-binding domain of a presently disclosed ADGRE2-targeted chimeric receptor binds to the GPS domain of ADGRE2. In certain embodiments, the extracellular antigen-binding domain of a presently disclosed ADGRE2-targeted chimeric receptor binds to the EGF-like 5 domain of ADGRE2.

In certain embodiments, the ADGRE2-targeted chimeric receptor is a chimeric antigen receptor (CAR). In certain embodiments, the ADGRE2-targeted CAR has the structure disclosed in Section 5.2.1. In certain embodiments, the ADGRE2-targeted CAR comprises an extracellular antigen-binding domain that binds to ADGRE2, a transmembrane domain, and an intracellular signaling domain.

In certain embodiments, the ADGRE2-targeted chimeric receptor is a Chimeric Co-Stimulatory Receptor (CCR). In certain embodiments, the ADGRE2-targeted CCR has the structure disclosed in Section 5.2.2. In certain embodiments, the ADGRE2-targeted CCR comprises an extracellular antigen-binding domain that binds to ADGRE2, a transmembrane domain, and an intracellular signaling domain that does not provide an activation signal to an immunoresponsive cell, e.g., the intracellular signaling domain does not comprise a CD3 ζ polypeptide.

In certain embodiments, the ADGRE2-targeted chimeric receptor is a TCR like Fusion Molecules. In certain embodiments, the ADGRE2-targeted TCR like Fusion Molecules has the structure disclosed in Section 5.2.3.

In certain embodiments, the extracellular antigen-binding domain of the ADGRE2-targeted chimeric receptor (*e.g.*, an ADGRE2-targeted scFv) binds to ADGRE2 (*e.g.*, human ADGRE2) with a dissociation constant (K_D) of at least about 1×10^{-6} M, at least about 1×10^{-7} M, at least about 1×10^{-8} M, at least about 1×10^{-9} M, or at least about 1×10^{-10} M. In certain embodiments, the extracellular antigen-binding domain of the ADGRE2-targeted chimeric receptor (*e.g.*, an ADGRE2-targeted scFv) binds to ADGRE2 (*e.g.*, human ADGRE2) with a dissociation constant (K_D) of at least about 2×10^{-8} M. In certain embodiments, the extracellular antigen-binding domain of the ADGRE2-targeted chimeric receptor (*e.g.*, an ADGRE2-targeted scFv) to ADGRE2 (*e.g.*, human ADGRE2) with a dissociation constant (K_D) of between about 2×10^{-8} M and about 8×10^{-9} M.

In certain embodiments, the extracellular antigen-binding domain of the ADGRE2-targeted chimeric receptor (*e.g.*, an ADGRE2-targeted scFv) binds to ADGRE2 (*e.g.*, human ADGRE2) with a dissociation constant (K_D) between about 1 nM and about 50 nM, between about 5 nM and about 30 nM, between about 5 nM and about 25 nM, or between about 8 nM and about 20 nM. In certain embodiments, the extracellular antigen-binding domain of the ADGRE2-targeted chimeric receptor (*e.g.*, an ADGRE2-targeted scFv) binds to ADGRE2 (*e.g.*, human ADGRE2) with a dissociation constant (K_D) of at least about 50 nM, at least about 40 nM, at least about 35 nM, at least about 30 nM, at least about 25 nM, at least about 20 nM, at least about 19 nM, at least about 18 nM, at least about 17 nM, at least about 16 nM, at least

about 15 nM, at least about 14 nM, at least about 13 nM, at least about 12 nM, at least about 11 nM, at least about 10 nM, at least about 9 nM, at least about 8 nM, at least about 7 nM, at least about 6 nM, or at least about 5 nM.

5 In certain embodiments, the extracellular antigen-binding domain of the ADGRE2-targeted chimeric receptor (*e.g.*, an ADGRE2-targeted scFv) comprises a V_H CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 33 or a conservative modification thereof, a V_H CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 34 or a conservative modification thereof, and a V_H CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 35 or a conservative modification thereof. SEQ ID NOs: 33-35 are provided in Table 1.

10 In certain embodiments, the extracellular antigen-binding domain of the ADGRE2-targeted chimeric receptor (*e.g.*, an ADGRE2-targeted scFv) comprises a V_L CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 36 or a conservative modification thereof, a V_L CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 37 or a conservative modification thereof, and a V_L CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 38 or a conservative modification thereof. SEQ ID NOs: 36-38 are provided in Table 1.

15 In certain embodiments, the extracellular antigen-binding domain of the ADGRE2-targeted chimeric receptor (*e.g.*, an ADGRE2-targeted scFv) comprises a V_H CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 33 or a conservative modification thereof, a V_H CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 34 or a conservative modification thereof, a V_H CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 35 or a conservative modification thereof, a V_L CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 36 or a conservative modification thereof, a V_L CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 37 or a conservative modification, and a V_L CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 38 or a conservative modification thereof.

20 In certain embodiments, the extracellular antigen-binding domain of the ADGRE2-targeted chimeric receptor (*e.g.*, an ADGRE2-targeted scFv) comprises a V_H CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 33, a V_H CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 34, a V_H CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 35, a V_L CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 36, a V_L CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 37, and a V_L CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 38.

25 In certain embodiments, the extracellular antigen-binding domain of the ADGRE2-targeted chimeric receptor (*e.g.*, an ADGRE2-targeted scFv) comprises a V_H comprising an

amino acid sequence that is at least about 80% (*e.g.*, at least about 85%, at least about 90%, or at least about 95%) homologous or identical to the amino acid sequence set forth in SEQ ID NO: 39. For example, the extracellular antigen-binding domain of the ADGRE2-targeted chimeric receptor (*e.g.*, an ADGRE2-targeted scFv) comprises a V_H comprising an amino acid sequence that is about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99% or about 100% homologous or identical to SEQ ID NO: 39. In certain embodiments, the extracellular antigen-binding domain of the ADGRE2-targeted chimeric receptor (*e.g.*, an ADGRE2-targeted scFv) comprises a V_H comprising the amino acid sequence set forth in SEQ ID NO: 39. SEQ ID NO: 39 is provided in Table 1 below.

In certain embodiments, the extracellular antigen-binding domain of the ADGRE2-targeted chimeric receptor (*e.g.*, an ADGRE2-targeted scFv) comprises a V_L comprising an amino acid sequence that is at least about 80% (*e.g.*, at least about 85%, at least about 90%, or at least about 95%) homologous or identical to the amino acid sequence set forth in SEQ ID NO: 40. For example, the extracellular antigen-binding domain of the ADGRE2-targeted chimeric receptor (*e.g.*, an ADGRE2-targeted scFv) comprises a V_L comprising an amino acid sequence that is about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99% or about 100% homologous or identical to SEQ ID NO: 40. In certain embodiments, the extracellular antigen-binding domain of the ADGRE2-targeted chimeric receptor (*e.g.*, an ADGRE2-targeted scFv) comprises a V_L comprising the amino acid sequence set forth in SEQ ID NO: 40. SEQ ID NO: 40 is provided in Table 1 below.

In certain embodiments, the extracellular antigen-binding domain of the ADGRE2-targeted chimeric receptor (*e.g.*, an ADGRE2-targeted scFv) comprises a V_H comprising the amino acid sequence set forth in SEQ ID NO: 39, and a V_L comprising the amino acid sequence set forth in SEQ ID NO: 40. In certain embodiments, the V_H and V_L are linked via a linker. In certain embodiments, the linker comprises the amino acid sequence set forth in SEQ ID NO: 2. In certain embodiments, the linker comprises the amino acid sequence set forth in SEQ ID NO: 149.

In certain embodiments, the variable regions within the extracellular antigen-binding domain of the ADGRE2-targeted chimeric receptor have to be linked one after another such that at the N-terminus of the extracellular antigen-binding domain, a heavy chain variable region

(V_H) is positioned. In certain embodiments, if the extracellular antigen-binding domain of the ADGRE2-targeted chimeric receptor is an scFv, the variable regions are positioned from the N- to the C-terminus: V_H-V_L. In certain embodiments, the ADGRE2-targeted scFv comprises or consists of the amino acid sequence set forth in SEQ ID NO: 41. In certain embodiments, the ADGRE2-targeted scFv is designated as “ADGRE2-A”. An exemplary nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 41 is set forth in SEQ ID NO: 42. SEQ ID NOs: 41 and 42 are provided in Table 1. The CDRs provided in Table 1 are identified according to the IMGT numbering system.

Table 1 (ADGRE2-A)

CDRs	1	2	3
V _H	GYTFTNYW [SEQ ID NO: 33]	VYPGDGDT [SEQ ID NO: 34]	ARGFTAYGMDY [SEQ ID NO: 35]
V _L	SSVSY [SEQ ID NO: 36]	DTS [SEQ ID NO: 37]	QQWSSNPLT [SEQ ID NO: 38]
Full V _H	QVQLQQSGAEVAKPGASVKLSCKASGYFTFTNYWMQWIKQAPGQGLEWIGAVYPGDGDT RHTQKFKGKATLTADKSTSTAYMEVSSLRSEDVAVYYCARGFTAYGMDYWGQGTITVTS S [SEQ ID NO: 39]		
Full V _L	EIVLTQSPATMSASPGERVTMSSASSSVSYMHYQQKSGQSPKRWIYDTSKLSGVPA RFSGSGSGTDYFTFTISSMEPEDFATYYCQQWSSNPLTFGGGKLEIK [SEQ ID NO: 40]		
DNA Full V _H	caagttcagctccagcagagcggcgccgaagtggcaaagcctggagcgtcagtcgaagct gtccctgcaaagcgagtggtatatacgttcacgaactactggatgcagtggtataaagcagg ctcccgggcagggtctggagtggtattggagcgtctaccaggggacggcgacaccggg cacactcaaaagttcaaggccaaggccaccctgaccgctgacaagagcacaagcacagc gtacatggaggtgtcctctttgagatccgaagataaccgctgtgtattattgtgccggg gcttcactgcatacgggatggattactgggacaaggcactaccgtgactgtcagctcc [SEQ ID NO: 144]		
DNA Full V _L	gaaattgtgctgacacagagccctgccacaatgtctgctagccctggcgagcgcgtgac catgtctttagcgcagcagcagcgtgtcctacatgattggtatcaacagaagtcgg gccagtcctcccaagcgggtggatctacgatacaagcaagctggcctccggcgtgccgcc agattttctggcagcgggtcttggaaacagattacaccttcaccatctctagcatggaacc tgaggattttgccactactattgccagcagtggtccagcaatccctgacatttgag gaggcaccaagctggaaattaag [SEQ ID NO: 145]		
V _H -V _L scFv	QVQLQQSGAEVAKPGASVKLSCKASGYFTFTNYWMQWIKQAPGQGLEWIGAVYPGDGDT RHTQKFKGKATLTADKSTSTAYMEVSSLRSEDVAVYYCARGFTAYGMDYWGQGTITVTS SGGGGSGGGSGGGGSEIVLTQSPATMSASPGERVTMSSASSSVSYMHYQQKSGQSP KRWIYDTSKLSGVPARFSGSGSGTDYFTFTISSMEPEDFATYYCQQWSSNPLTFGGGK LEIK [SEQ ID NO: 41]		
DNA for V _H -V _L scFv	caagttcagctccagcagagcggcgccgaagtggcaaagcctggagcgtcagtcgaagct gtccctgcaaagcgagtggtatatacgttcacgaactactggatgcagtggtataaagcagg ctcccgggcagggtctggagtggtattggagcgtctaccaggggacggcgacaccggg cacactcaaaagttcaaggccaaggccaccctgaccgctgacaagagcacaagcacagc gtacatggaggtgtcctctttgagatccgaagataaccgctgtgtattattgtgccggg gcttcactgcatacgggatggattactgggacaaggcactaccgtgactgtcagctcc ggggggtggaggtcaggcggggggttcaggagggggggatctgaaattgtgctgac acagagccctgccacaatgtctgctagccctggcgagcgcgtgacctgtctttagcgc ccagcagcagcgtgtcctacatgattggtatcaacagaagtcggcgccagtcctccaa ggggtggatctacgatacaagcaagctggcctccggcgtgcccgccagattttctggcag cggtcttggaaacagattacaccttcaccatctctagcatggaacctgaggattttgccg cctactattgccagcagtggtccagcaatccctgacatttgaggaggacaccaagctg gaaattaag [SEQ ID NO: 42]		

In certain embodiments, the extracellular antigen-binding domain of the ADGRE2-targeted chimeric receptor (*e.g.*, an ADGRE2-targeted scFv) comprises a V_H CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 33 or a conservative modification thereof, a V_H CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 34 or a conservative modification thereof, and a V_H CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 35 or a conservative modification thereof. SEQ ID NOs: 33-35 are provided in Tables 1 and 2.

In certain embodiments, the extracellular antigen-binding domain of the ADGRE2-targeted chimeric receptor (*e.g.*, an ADGRE2-targeted scFv) comprises a V_L CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 36 or a conservative modification thereof, a V_L CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 37 or a conservative modification thereof, and a V_L CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 38 or a conservative modification thereof. SEQ ID NOs: 36-38 are provided in Tables 1 and 2.

In certain embodiments, the extracellular antigen-binding domain of the ADGRE2-targeted chimeric receptor (*e.g.*, an ADGRE2-targeted scFv) comprises a V_H CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 33 or a conservative modification thereof, a V_H CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 34 or a conservative modification thereof, a V_H CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 35 or a conservative modification thereof, a V_L CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 36 or a conservative modification thereof, a V_L CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 37 or a conservative modification thereof, and a V_L CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 38 or a conservative modification thereof.

In certain embodiments, the extracellular antigen-binding domain of the ADGRE2-targeted chimeric receptor (*e.g.*, an ADGRE2-targeted scFv) comprises a V_H CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 33, a V_H CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 34, a V_H CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 35, a V_L CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 36, a V_L CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 37, and a V_L CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 38.

In certain embodiments, the extracellular antigen-binding domain of the ADGRE2-targeted chimeric receptor (*e.g.*, an ADGRE2-targeted scFv) comprises a V_H comprising an amino acid sequence that is at least about 80% (*e.g.*, at least about 85%, at least about 90%, or at

least about 95%) homologous or identical to the amino acid sequence set forth in SEQ ID NO: 43. For example, the extracellular antigen-binding domain of the ADGRE2-targeted chimeric receptor (*e.g.*, an ADGRE2-targeted scFv) comprises a V_H comprising an amino acid sequence that is about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99% or about 100% homologous or identical to the amino acid sequence set forth in SEQ ID NO: 43. In certain embodiments, the extracellular antigen-binding domain of the ADGRE2-targeted chimeric receptor comprises a V_H comprising the amino acid sequence set forth in SEQ ID NO: 43. SEQ ID NO: 43 is provided in Table 2 below.

In certain embodiments, the extracellular antigen-binding domain of the ADGRE2-targeted chimeric receptor (*e.g.*, an ADGRE2-targeted scFv) comprises a V_L comprising an amino acid sequence that is at least about 80% (*e.g.*, at least about 85%, at least about 90%, or at least about 95%) homologous or identical to the amino acid sequence set forth in SEQ ID NO: 44. For example, the extracellular antigen-binding domain of the chimeric receptor (*e.g.*, an scFv) comprises a V_L comprising an amino acid sequence that is about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99% or about 100% homologous or identical to the amino acid sequence set forth in SEQ ID NO: 44. In certain embodiments, the extracellular antigen-binding domain of the ADGRE2-targeted chimeric receptor comprises a V_L comprising the amino acid sequence set forth in SEQ ID NO: 44. SEQ ID NO: 44 is provided in Table 2 below.

In certain embodiments, the extracellular antigen-binding domain of the ADGRE2-targeted chimeric receptor (*e.g.*, an ADGRE2-targeted scFv) comprises a V_H comprising the amino acid sequence set forth in SEQ ID NO: 43, and a V_L comprising the amino acid sequence set forth in SEQ ID NO: 44. In certain embodiments, the V_H and V_L are linked via a linker. In certain embodiments, the linker comprises the amino acid sequence set forth in SEQ ID NO: 2. In certain embodiments, the linker comprises the amino acid sequence set forth in SEQ ID NO: 149.

In certain embodiments, the variable regions within the extracellular antigen-binding domain of the ADGRE2-targeted chimeric receptor have to be linked one after another such that at the N-terminus of the extracellular antigen-binding domain, a heavy chain variable region (V_H) is positioned. In certain embodiments, if the extracellular antigen-binding domain of the ADGRE2-targeted chimeric receptor is an scFv, the variable regions are positioned from the N-

to the C-terminus: V_H-V_L. In certain embodiments, the ADGRE2-targeted scFv comprises or consists of the amino acid sequence set forth in SEQ ID NO: 45, which is provided in Table 2. In certain embodiments, the ADGRE2-targeted scFv is designated as “ADGRE2-B”. The CDRs provided in Table 2 are identified according to the IMGT numbering system.

5

Table 2 (ADGRE2-B)

CDRs	1	2	3
V _H	GYTFTNYW [SEQ ID NO: 33]	VYPGDGDT [SEQ ID NO: 34]	ARGFTAYGMDY [SEQ ID NO: 35]
V _L	SSVSY [SEQ ID NO: 36]	DTS [SEQ ID NO: 37]	QQWSSNPLT [SEQ ID NO: 38]
Full V _H	QVQLQQSGAEVKKPGASVKLSCKASGYTFTNYWMQWIRQAPGGGLEWIGAVYPGDGDTTRYT QKFQGRATLTADTSISTAYMEVSRRLRSDDTAVYYCARGFTAYGMDYWGQGT TVTVSS [SEQ ID NO: 43]		
Full V _L	EIVLTQSPATMSASPGERVTMSCSASSSVSYMHWYQQKSGLSPKRWIYDTSKLASGVPDRF SGSGSGTDYFTISRMEPEDFATYYCQQWSSNPLTFGGGTKLEIK [SEQ ID NO: 44]		
V _H -V _L scFv	QVQLQQSGAEVKKPGASVKLSCKASGYTFTNYWMQWIRQAPGGGLEWIGAVYPGDGDTTRYT QKFQGRATLTADTSISTAYMEVSRRLRSDDTAVYYCARGFTAYGMDYWGQGT TVTVSSGGGG SGSGSGGGGGSEIVLTQSPATMSASPGERVTMSCSASSSVSYMHWYQQKSGLSPKRWIYDT SKLASGVPDRFSGSGSGTDYFTISRMEPEDFATYYCQQWSSNPLTFGGGTKLEIK [SEQ ID NO: 45]		

In certain embodiments, the extracellular antigen-binding domain of the ADGRE2-targeted chimeric receptor (*e.g.*, an ADGRE2-targeted scFv) comprises a V_H CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 33 or a conservative modification thereof, a V_H CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 345 or a conservative modification thereof, and a V_H CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 35 or a conservative modification thereof. SEQ ID NOS: 33-35 are provided in Tables 1-3.

In certain embodiments, the extracellular antigen-binding domain of the ADGRE2-targeted chimeric receptor (*e.g.*, an ADGRE2-targeted scFv) comprises a V_L CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 36 or a conservative modification thereof, a V_L CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 37 or a conservative modification thereof, and a V_L CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 38 or a conservative modification thereof. SEQ ID NOS: 36-38 are provided in Tables 1-3.

In certain embodiments, the extracellular antigen-binding domain of the ADGRE2-targeted chimeric receptor (*e.g.*, an ADGRE2-targeted scFv) comprises a V_H CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 33 or a conservative modification thereof, a V_H CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 34 or a conservative modification thereof, a V_H CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 35 or a conservative modification thereof, a V_L CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 36 or a conservative modification thereof, a V_L CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 37 or a conservative modification thereof, and a

V_L CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 38 or a conservative modification thereof.

In certain embodiments, the extracellular antigen-binding domain of the ADGRE2-targeted chimeric receptor (*e.g.*, an ADGRE2-targeted scFv) comprises a V_H CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 33, a V_H CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 34, a V_H CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 35, a V_L CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 36, a V_L CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 37, and a V_L CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 38.

In certain embodiments, the extracellular antigen-binding domain of the ADGRE2-targeted chimeric receptor (*e.g.*, an ADGRE2-targeted scFv) comprises a V_H comprising an amino acid sequence that is at least about 80% (*e.g.*, at least about 85%, at least about 90%, or at least about 95%) homologous or identical to the amino acid sequence set forth in SEQ ID NO: 46. For example, the extracellular antigen-binding domain of the chimeric receptor (*e.g.*, an scFv) comprises a V_H comprising an amino acid sequence that is about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99% or about 100% homologous or identical to the amino acid sequence set forth in SEQ ID NO: 46. In certain embodiments, the extracellular antigen-binding domain of the ADGRE2-targeted chimeric receptor comprises a V_H comprising the amino acid sequence set forth in SEQ ID NO: 46. SEQ ID NO: 46 is provided in Table 3 below.

In certain embodiments, the extracellular antigen-binding domain of the ADGRE2-targeted chimeric receptor (*e.g.*, an ADGRE2-targeted scFv) comprises a V_L comprising an amino acid sequence that is at least about 80% (*e.g.*, at least about 85%, at least about 90%, or at least about 95%) homologous or identical to the amino acid sequence set forth in SEQ ID NO: 47. For example, the extracellular antigen-binding domain of the ADGRE2-targeted chimeric receptor (*e.g.*, an ADGRE2-targeted scFv) comprises a V_L comprising an amino acid sequence that is about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99% or about 100% homologous or identical to the amino acid sequence set forth in SEQ ID NO: 47. In certain embodiments, the extracellular antigen-binding domain of the ADGRE2-targeted chimeric receptor comprises a V_L comprising the amino acid sequence set forth in SEQ ID NO: 47. SEQ ID NO: 47 is provided in Table 3 below.

In certain embodiments, the extracellular antigen-binding domain of the ADGRE2-targeted chimeric receptor (*e.g.*, an ADGRE2-targeted scFv) comprises a V_H comprising the amino acid sequence set forth in SEQ ID NO: 46, and a V_L comprising the amino acid sequence set forth in SEQ ID NO: 47. In certain embodiments, the V_H and V_L are linked via a linker. In certain embodiments, the linker comprises the amino acid sequence set forth in SEQ ID NO: 2. In certain embodiments, the linker comprises the amino acid sequence set forth in SEQ ID NO: 149.

In certain embodiments, the variable regions within the extracellular antigen-binding domain of the ADGRE2-targeted chimeric receptor have to be linked one after another such that at the N-terminus of the extracellular antigen-binding domain, a heavy chain variable region (V_H) is positioned. In certain embodiments, if the extracellular antigen-binding domain of the ADGRE2-targeted chimeric receptor is an scFv, the variable regions are positioned from the N- to the C-terminus: V_H-V_L. In certain embodiments, the ADGRE2-targeted scFv comprises or consists of the amino acid sequence set forth in SEQ ID NO: 48, which is provided in Table 3. In certain embodiments, the ADGRE2-targeted scFv is designated as “ADGRE2-C”. The CDRs provided in Table 3 are identified according to the IMGT numbering system.

Table 3 (ADGRE2-C)

CDRs	1	2	3
V _H	GYTFNYYW [SEQ ID NO: 33]	VYPGDGDT [SEQ ID NO: 34]	ARGFTAYGMDY [SEQ ID NO: 35]
V _L	SSVSY [SEQ ID NO: 36]	DTS [SEQ ID NO: 37]	QQWSSNPLT [SEQ ID NO: 38]
Full V _H	QVQLQQSGAEVKKPGASVKLSCKASGYTFNYYWMQWVRQAPGGGLEWIGAVYPGDGDTTRYTQKFQGRATLTADTSTSTVYMEVSSLRSEDTAVYYCARGFTAYGMDYWGQGTTVTVSS [SEQ ID NO: 46]		
Full V _L	EIVLTQSPATMSASPGERVTMSCSASSSVSYMHYQQKSGLSPKRWIYDTSKLASGVPDRFSGSGSGTDYFTISRMEPEDFATYYCQQWSSNPLTFGGGKLEIK [SEQ ID NO: 47]		
V _H -V _L scFv	QVQLQQSGAEVKKPGASVKLSCKASGYTFNYYWMQWVRQAPGGGLEWIGAVYPGDGDTTRYTQKFQGRATLTADTSTSTVYMEVSSLRSEDTAVYYCARGFTAYGMDYWGQGTTVTVSSGGGSGGGSGGGGSEIVLTQSPATMSASPGERVTMSCSASSSVSYMHYQQKSGLSPKRWIYDTSKLASGVPDRFSGSGSGTDYFTISRMEPEDFATYYCQQWSSNPLTFGGGKLEIK [SEQ ID NO: 48]		

In certain embodiments, the extracellular antigen-binding domain of the ADGRE2-targeted chimeric receptor (*e.g.*, an ADGRE2-targeted scFv) comprises a V_H CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 33 or a conservative modification thereof, a V_H CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 34 or a conservative modification thereof, and a V_H CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 35 or a conservative modification thereof. SEQ ID NOS: 33-35 are provided in Tables 1-4.

In certain embodiments, the extracellular antigen-binding domain of the ADGRE2-targeted chimeric receptor (*e.g.*, an ADGRE2-targeted scFv) comprises a V_L CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 36 or a conservative modification thereof, a V_L CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 37 or a conservative modification thereof, and a V_L CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 38 or a conservative modification thereof. SEQ ID NOs: 36-38 are provided in Tables 1-4.

In certain embodiments, the extracellular antigen-binding domain of the ADGRE2-targeted chimeric receptor (*e.g.*, an ADGRE2-targeted scFv) comprises a V_H CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 33 or a conservative modification thereof, a V_H CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 34 or a conservative modification thereof, a V_H CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 35 or a conservative modification thereof, a V_L CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 36 or a conservative modification thereof, a V_L CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 37 or a conservative modification thereof, and a V_L CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 38 or a conservative modification thereof.

In certain embodiments, the extracellular antigen-binding domain of the ADGRE2-targeted chimeric receptor (*e.g.*, an ADGRE2-targeted scFv) comprises a V_H CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 33, a V_H CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 34, a V_H CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 35, a V_L CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 36, a V_L CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 37, and a V_L CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 38.

In certain embodiments, the extracellular antigen-binding domain of the ADGRE2-targeted chimeric receptor (*e.g.*, an ADGRE2-targeted scFv) comprises a V_H comprising an amino acid sequence that is at least about 80% (*e.g.*, at least about 85%, at least about 90%, or at least about 95%) homologous or identical to the amino acid sequence set forth in SEQ ID NO: 49. For example, the extracellular antigen-binding domain of the ADGRE2-targeted chimeric receptor (*e.g.*, an ADGRE2-targeted scFv) comprises a V_H comprising an amino acid sequence that is about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99% or about 100% homologous or identical to the amino acid sequence set forth in SEQ ID NO: 49. In certain embodiments, the extracellular

antigen-binding domain of ADGRE2-targeted chimeric receptor comprises a V_H comprising the amino acid sequence set forth in SEQ ID NO: 49. SEQ ID NO: 49 is provided in Table 4 below.

In certain embodiments, the extracellular antigen-binding domain of the ADGRE2-targeted chimeric receptor (*e.g.*, an ADGRE2-targeted scFv) comprises a V_L comprising an amino acid sequence that is at least about 80% (*e.g.*, at least about 85%, at least about 90%, or at least about 95%) homologous or identical to the amino acid sequence set forth in SEQ ID NO: 50. For example, the extracellular antigen-binding domain of the ADGRE2-targeted chimeric receptor (*e.g.*, an ADGRE2-targeted scFv) comprises a V_L comprising an amino acid sequence that is about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99% or about 100% homologous or identical to the amino acid sequence set forth in SEQ ID NO: 50. In certain embodiments, the extracellular antigen-binding domain of the ADGRE2-targeted chimeric receptor comprises a V_L comprising the amino acid sequence set forth in SEQ ID NO: 50. SEQ ID NO: 50 is provided in Table 4 below.

In certain embodiments, the extracellular antigen-binding domain of the ADGRE2-targeted chimeric receptor (*e.g.*, an ADGRE2-targeted scFv) comprises a V_H comprising the amino acid sequence set forth in SEQ ID NO: 49, and a V_L comprising the amino acid sequence set forth in SEQ ID NO: 50. In certain embodiments, the V_H and V_L are linked via a linker. In certain embodiments, the linker comprises the amino acid sequence set forth in SEQ ID NO: 149. In certain embodiments, the linker comprises the amino acid sequence set forth in SEQ ID NO: 2.

In certain embodiments, the variable regions within the extracellular antigen-binding domain of the ADGRE2-targeted chimeric receptor have to be linked one after another such that at the N-terminus of the extracellular antigen-binding domain, a heavy chain variable region (V_H) is positioned. In certain embodiments, if the extracellular antigen-binding domain of the ADGRE2-targeted chimeric receptor is an scFv, the variable regions are positioned from the N- to the C-terminus: V_H-V_L. In certain embodiments, the ADGRE2-targeted scFv comprises or consists of the amino acid sequence set forth in SEQ ID NO: 51, which is provided in Table 4. In certain embodiments, the ADGRE2-targeted scFv is designated as “ADGRE2-D”. The CDRs provided in Table 4 are identified according to the IMGT numbering system.

Table 4 (ADGRE2-D)

CDRs	1	2	3
------	---	---	---

V _H	GYTFTNYW [SEQ ID NO: 33]	VYPGDGDT [SEQ ID NO: 34]	ARGFTAYGMDY [SEQ ID NO: 35]
V _L	SSVSY [SEQ ID NO: 36]	DTS [SEQ ID NO: 37]	QQWSSNPLT [SEQ ID NO: 38]
Full V _H	QVQLQQSGAEVKKPGASVKVSKASGYTFTNYWMQWVRQAPGQGLEWMGAVYPGDGDTTRHTQKFKGRVTMTTRDTSTSTVYMEISSLRSEDYAVYYCARGFTAYGMDYWGQGTILVTVSS [SEQ ID NO: 49]		
Full V _L	EIVLTQSPATLSLSPGERATLSCSASSSVSYMHYQQKPLAPRLLIYDTSKLASGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQWSSNPLTFGQGTKVEIK [SEQ ID NO: 50]		
V _H -V _L scFv	QVQLQQSGAEVKKPGASVKVSKASGYTFTNYWMQWVRQAPGQGLEWMGAVYPGDGDTTRHTQKFKGRVTMTTRDTSTSTVYMEISSLRSEDYAVYYCARGFTAYGMDYWGQGTILVTVSSASTGGGGSGGGSGGGGSEIVLTQSPATLSLSPGERATLSCSASSSVSYMHYQQKPLAPRLLIYDTSKLASGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQWSSNPLTFGQGTKVEIK [SEQ ID NO: 51]		

In certain embodiments, the extracellular antigen-binding domain of the ADGRE2-targeted chimeric receptor (*e.g.*, an ADGRE2-targeted scFv) comprises a V_H CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 33 or a conservative modification thereof, a V_H CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 34 or a conservative modification thereof, and a V_H CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 35 or a conservative modification thereof. SEQ ID NOS: 34-36 are provided in Tables 1-5.

In certain embodiments, the extracellular antigen-binding domain of the ADGRE2-targeted chimeric receptor (*e.g.*, an ADGRE2-targeted scFv) comprises a V_L CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 36 or a conservative modification thereof, a V_L CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 37 or a conservative modification thereof, and a V_L CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 38 or a conservative modification thereof. SEQ ID NOS: 36-38 are provided in Tables 1-5.

In certain embodiments, the extracellular antigen-binding domain of the ADGRE2-targeted chimeric receptor (*e.g.*, an ADGRE2-targeted scFv) comprises a V_H CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 33 or a conservative modification thereof, a V_H CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 34 or a conservative modification thereof, a V_H CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 35 or a conservative modification thereof, a V_L CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 36 or a conservative modification thereof, a V_L CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 37 or a conservative modification thereof, and a V_L CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 38 or a conservative modification thereof.

In certain embodiments, the extracellular antigen-binding domain of the ADGRE2-targeted chimeric receptor (*e.g.*, an ADGRE2-targeted scFv) comprises a V_H CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 33, a V_H CDR2 comprising the amino acid

sequence set forth in SEQ ID NO: 34, a V_H CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 35, a V_L CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 36, a V_L CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 37, and a V_L CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 38.

5 In certain embodiments, the extracellular antigen-binding domain of the ADGRE2-targeted chimeric receptor (*e.g.*, an ADGRE2-targeted scFv) comprises a V_H comprising an amino acid sequence that is at least about 80% (*e.g.*, at least about 85%, at least about 90%, or at least about 95%) homologous or identical to the amino acid sequence set forth in SEQ ID NO: 52. For example, the extracellular antigen-binding domain of the ADGRE2-targeted chimeric
10 receptor (*e.g.*, an ADGRE2-targeted scFv) comprises a V_H comprising an amino acid sequence that is about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99% or about 100% homologous or identical to the amino acid sequence set forth in SEQ ID NO: 52. In certain embodiments, the extracellular
15 antigen-binding domain of the ADGRE2-targeted chimeric receptor comprises a V_H comprising the amino acid sequence set forth in SEQ ID NO: 52. SEQ ID NO: 52 is provided in Table 5 below.

 In certain embodiments, the extracellular antigen-binding domain of the ADGRE2-targeted chimeric receptor (*e.g.*, an ADGRE2-targeted scFv) comprises a V_L comprising an
20 amino acid sequence that is at least about 80% (*e.g.*, at least about 85%, at least about 90%, or at least about 95%) homologous or identical to the amino acid sequence set forth in SEQ ID NO: 53. For example, the extracellular antigen-binding domain of the ADGRE2-targeted chimeric receptor (*e.g.*, an ADGRE2-targeted scFv) comprises a V_L comprising an amino acid sequence that is about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about
25 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99% or about 100% homologous or identical to the amino acid sequence set forth in SEQ ID NO: 53. In certain embodiments, the extracellular antigen-binding domain of the ADGRE2-targeted chimeric receptor comprises a V_L comprising the amino acid sequence set forth in SEQ ID NO: 53. SEQ ID NO: 53 is provided in Table 5
30 below.

 In certain embodiments, the extracellular antigen-binding domain of the ADGRE2-targeted chimeric receptor (*e.g.*, an ADGRE2-targeted scFv) comprises a V_H comprising the amino acid sequence set forth in SEQ ID NO: 52, and a V_L comprising the amino acid sequence set forth in SEQ ID NO: 53. In certain embodiments, the V_H and V_L are linked via a linker. In

certain embodiments, the linker comprises the amino acid sequence set forth in SEQ ID NO: 149. In certain embodiments, the linker comprises the amino acid sequence set forth in SEQ ID NO: 2.

In certain embodiments, the variable regions within the extracellular antigen-binding domain of the ADGRE2-targeted chimeric receptor have to be linked one after another such that at the N-terminus of the extracellular antigen-binding domain, a heavy chain variable region (V_H) is positioned. In certain embodiments, if the extracellular antigen-binding domain of the ADGRE2-targeted chimeric receptor is an scFv, the variable regions are positioned from the N- to the C-terminus: V_H-V_L. In certain embodiments, the ADGRE2-targeted scFv comprises or consists of the amino acid sequence set forth in EQ ID NO: 54, which is provided in Table 5. In certain embodiments, the ADGRE2-targeted scFv is designated as “ADGRE2-E”. The CDRs provided in Table 5 are identified according to the IMGT numbering system.

Table 5 (ADGRE2-E)

CDRs	1	2	3
V _H	GYTFTNYW [SEQ ID NO: 33]	VYPGDGDT [SEQ ID NO: 34]	ARGFTAYGMDY [SEQ ID NO: 35]
V _L	SSVSY [SEQ ID NO: 36]	DTS [SEQ ID NO: 37]	QQWSSNPLT [SEQ ID NO: 38]
Full V _H	QVQLQQSGAEVKKPGASVKVSKASGYTFTNYWMQWVRQAPGGGLEWIGAVYPGDGDTTRHTQKFKGRVTMTADKSTSTVYMEISSLRSEDTAVYYCARGFTAYGMDYWGQGTLLTVSS [SEQ ID NO: 52]		
Full V _L	QIVLTQSPATLSLSPGERATLTCSASSSVSYMHYQQKPLSPKRWIYDTSKLAGVPDRFSGSGSGTDYFTFTIRLEPEDFATYYCQQWSSNPLTFGQGTKVEIK [SEQ ID NO: 53]		
V _H -V _L scFv	QVQLQQSGAEVKKPGASVKVSKASGYTFTNYWMQWVRQAPGGGLEWIGAVYPGDGDTTRHTQKFKGRVTMTADKSTSTVYMEISSLRSEDTAVYYCARGFTAYGMDYWGQGTLLTVSSASTGGGGSGGGSGGGGQIVLTQSPATLSLSPGERATLTCSASSSVSYMHYQQKPLSPKRWIYDTSKLAGVPDRFSGSGSGTDYFTFTIRLEPEDFATYYCQQWSSNPLTFGQGTKVEIK [SEQ ID NO: 54]		

In certain embodiments, the extracellular antigen-binding domain of the ADGRE2-targeted chimeric receptor (*e.g.*, an ADGRE2-targeted scFv) comprises a V_H CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 33 or a conservative modification thereof, a V_H CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 34 or a conservative modification thereof, and a V_H CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 35 or a conservative modification thereof. SEQ ID NOS: 33-35 are provided in Tables 1-6.

In certain embodiments, the extracellular antigen-binding domain of the ADGRE2-targeted chimeric receptor (*e.g.*, an ADGRE2-targeted scFv) comprises a V_L CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 36 or a conservative modification thereof, a V_L CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 37 or a conservative

modification thereof, and a V_L CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 38 or a conservative modification thereof. SEQ ID NOs: 36-38 are provided in Tables 1-6.

In certain embodiments, the extracellular antigen-binding domain of the ADGRE2-targeted chimeric receptor (*e.g.*, an ADGRE2-targeted scFv) comprises a V_H CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 33 or a conservative modification thereof, a V_H CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 34 or a conservative modification thereof, a V_H CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 35 or a conservative modification thereof, a V_L CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 36 or a conservative modification thereof, a V_L CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 37 or a conservative modification thereof, and a V_L CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 38 or a conservative modification thereof.

In certain embodiments, the extracellular antigen-binding domain of the ADGRE2-targeted chimeric receptor (*e.g.*, an ADGRE2-targeted scFv) comprises a V_H CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 33, a V_H CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 34, a V_H CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 35, a V_L CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 36, a V_L CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 37, and a V_L CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 38.

In certain embodiments, the extracellular antigen-binding domain of the ADGRE2-targeted chimeric receptor (*e.g.*, an ADGRE2-targeted scFv) comprises a V_H comprising an amino acid sequence that is at least about 80% (*e.g.*, at least about 85%, at least about 90%, or at least about 95%) homologous or identical to the amino acid sequence set forth in SEQ ID NO: 55. For example, the extracellular antigen-binding domain of the ADGRE2-targeted chimeric receptor (*e.g.*, an ADGRE2-targeted scFv) comprises a V_H comprising an amino acid sequence that is about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99% or about 100% homologous or identical to the amino acid sequence set forth in SEQ ID NO: 55. In certain embodiments, the extracellular antigen-binding domain of the ADGRE2-targeted chimeric receptor comprises a V_H comprising the amino acid sequence set forth in SEQ ID NO: 55. SEQ ID NO: 55 is provided in Table 6 below.

In certain embodiments, the extracellular antigen-binding domain of the ADGRE2-targeted chimeric receptor (*e.g.*, an ADGRE2-targeted scFv) comprises a V_L comprising an

amino acid sequence that is at least about 80% (*e.g.*, at least about 85%, at least about 90%, or at least about 95%) homologous or identical to the amino acid sequence set forth in SEQ ID NO: 56. For example, the extracellular antigen-binding domain of the ADGRE2-targeted chimeric receptor (*e.g.*, an ADGRE2-targeted scFv) comprises a V_L comprising an amino acid sequence

5 that is about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99% or about 100% homologous or identical to the amino acid sequence set forth in SEQ ID NO: 56. In certain embodiments, the extracellular antigen-binding domain of the ADGRE2-targeted chimeric receptor comprises a V_L comprising

10 the amino acid sequence set forth in SEQ ID NO: 56. SEQ ID NO: 56 is provided in Table 6 below.

In certain embodiments, the extracellular antigen-binding domain of the ADGRE2-targeted chimeric receptor (*e.g.*, an ADGRE2-targeted scFv) comprises a V_H comprising the amino acid sequence set forth in SEQ ID NO: 55, and a V_L comprising the amino acid sequence

15 set forth in SEQ ID NO: 56. In certain embodiments, the V_H and V_L are linked via a linker. In certain embodiments, the linker comprises the amino acid sequence set forth in SEQ ID NO: 2. In certain embodiments, the linker comprises the amino acid sequence set forth in SEQ ID NO: 149.

In certain embodiments, the variable regions within the extracellular antigen-binding domain of the ADGRE2-targeted chimeric receptor have to be linked one after another such that at the N-terminus of the extracellular antigen-binding domain, a heavy chain variable region (V_H) is positioned. In certain embodiments, if the extracellular antigen-binding domain of the ADGRE2-targeted chimeric receptor is an scFv, the variable regions are positioned from the N- to the C-terminus: V_H-V_L. In certain embodiments, the ADGRE2-targeted scFv comprises or

25 consists of the amino acid sequence set forth in in SEQ ID NO: 57, which is provided in Table 6. In certain embodiments, the ADGRE2-targeted scFv is designated as “ADGRE2-F”. The CDRs provided in Table 6 are identified according to the IMGT numbering system.

Table 6 (ADGRE2-F)

CDRs	1	2	3
V _H	GYTFTNYW [SEQ ID NO: 33]	VYPGDGDT [SEQ ID NO: 34]	ARGFTAYGMDY [SEQ ID NO: 35]
V _L	SSVS [SEQ ID NO: 36]	DTS [SEQ ID NO: 37]	QQWSSNPLT [SEQ ID NO: 38]
Full V _H	QVQLQQSGAEVKKPGASVKLSCKASGYTFTNYWMQWIRQAPGQGLEWIGAVYPGDGDTTRYTQKFQGRATLTADTSTSTAYMEVSSLRSEDFAVYYCARGFTAYGMDYWGQGTTVTVSS [SEQ ID NO: 55]		
Full V _L	EIVLTQSPATLSASPGERVMTSCSASSSVSYMHYQQKPLAPRRWIYDTSKLASGVPDRFSGSGSGTDYFTISRMEPEDFATYYCQQWSSNPLTFGGGTKLEIK [SEQ ID NO: 56]		

V _H -V _L scFv	QVQLQQSGAEVKKPGASVKLSCKASGYTFTNYWMQWIRQAPGQGLEWIGAVYFGDGDTRYTQ KFQGRATLTADTSTSTAYMEVSSLRSEDVAVYYCARGFTAYGMDYWGQGTITVTVSSGGGGSG GGSGGGGSEIVLTQSPATLSASPGERVMTSCSASSSVSYMHYQQKPLAPRRWIYDTSKL ASGVPDFRFGSGSGTDYFTFTISRMEPEDFATYYCQQWSSNPLTFGGGTKLEIK [SEQ ID NO: 57]
--	---

In certain embodiments, the extracellular antigen-binding domain of the ADGRE2-targeted chimeric receptor (*e.g.*, an ADGRE2-targeted scFv) comprises a V_H CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 33 or a conservative modification thereof, a V_H CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 34 or a conservative modification thereof, and a V_H CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 35 or a conservative modification thereof. SEQ ID NOS: 33-35 are provided in Tables 1-7.

In certain embodiments, the extracellular antigen-binding domain of the ADGRE2-targeted chimeric receptor (*e.g.*, an ADGRE2-targeted scFv) comprises a V_L CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 36 or a conservative modification thereof, a V_L CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 37 or a conservative modification thereof, and a V_L CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 38 or a conservative modification thereof. SEQ ID NOS: 36-38 are provided in Tables 1-7.

In certain embodiments, the extracellular antigen-binding domain of the ADGRE2-targeted chimeric receptor (*e.g.*, an ADGRE2-targeted scFv) comprises a V_H CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 33 or a conservative modification thereof, a V_H CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 34 or a conservative modification thereof, a V_H CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 35 or a conservative modification thereof, a V_L CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 36 or a conservative modification thereof, a V_L CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 37 or a conservative modification thereof, and a V_L CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 38 or a conservative modification thereof.

In certain embodiments, the extracellular antigen-binding domain of the ADGRE2-targeted chimeric receptor (*e.g.*, an ADGRE2-targeted scFv) comprises a V_H CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 33, a V_H CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 34, a V_H CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 35, a V_L CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 36, a V_L CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 37, and a V_L CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 38.

In certain embodiments, the extracellular antigen-binding domain of the ADGRE2-targeted chimeric receptor (*e.g.*, an ADGRE2-targeted scFv) comprises a V_H comprising an

amino acid sequence that is at least about 80% (*e.g.*, at least about 85%, at least about 90%, or at least about 95%) homologous or identical to the amino acid sequence set forth in SEQ ID NO: 146. For example, the extracellular antigen-binding domain of the ADGRE2-targeted chimeric receptor (*e.g.*, an ADGRE2-targeted scFv) comprises a V_H comprising an amino acid sequence
5 that is about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99% or about 100% homologous or identical to the amino acid sequence set forth in SEQ ID NO: 146. In certain embodiments, the extracellular antigen-binding domain of the ADGRE2-targeted chimeric receptor comprises a V_H comprising
10 the amino acid sequence set forth in SEQ ID NO: 146. SEQ ID NO: 146 is provided in Table 7 below.

In certain embodiments, the extracellular antigen-binding domain of the ADGRE2-targeted chimeric receptor (*e.g.*, an ADGRE2-targeted scFv) comprises a V_L comprising an amino acid sequence that is at least about 80% (*e.g.*, at least about 85%, at least about 90%, or at
15 least about 95%) homologous or identical to the amino acid sequence set forth in SEQ ID NO: 147. For example, the extracellular antigen-binding domain of the ADGRE2-targeted chimeric receptor (*e.g.*, an ADGRE2-targeted scFv) comprises a V_L comprising an amino acid sequence that is about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about
20 95%, about 96%, about 97%, about 98%, about 99% or about 100% homologous or identical to the amino acid sequence set forth in SEQ ID NO: 147. In certain embodiments, the extracellular antigen-binding domain of the ADGRE2-targeted chimeric receptor comprises a V_L comprising the amino acid sequence set forth in SEQ ID NO: 147. SEQ ID NO: 147 is provided in Table 7 below.

25 In certain embodiments, the extracellular antigen-binding domain of the ADGRE2-targeted chimeric receptor (*e.g.*, an ADGRE2-targeted scFv) comprises a V_H comprising the amino acid sequence set forth in SEQ ID NO: 146, and a V_L comprising the amino acid sequence set forth in SEQ ID NO: 147. In certain embodiments, the V_H and V_L are linked via a linker. In certain embodiments, the linker comprises the amino acid sequence set forth in SEQ
30 ID NO: 2. In certain embodiments, the linker comprises the amino acid sequence set forth in SEQ ID NO: 149.

In certain embodiments, the variable regions within the extracellular antigen-binding domain of the ADGRE2-targeted chimeric receptor have to be linked one after another such that at the N-terminus of the extracellular antigen-binding domain, a heavy chain variable region

(V_H) is positioned. In certain embodiments, if the extracellular antigen-binding domain of the ADGRE2-targeted chimeric receptor is an scFv, the variable regions are positioned from the N- to the C-terminus: V_H-V_L. In certain embodiments, the ADGRE2-targeted scFv comprises or consists of the amino acid sequence set forth in in SEQ ID NO: 148, which is provided in Table 7. In certain embodiments, the ADGRE2-targeted scFv is designated as “ADGRE2-G”. The CDRs provided in Table 7 are identified according to the IMGT numbering system.

Table 7 (ADGRE2-G)

CDRs	1	2	3
V _H	GYTFTNYW [SEQ ID NO: 33]	VYPGDGDT [SEQ ID NO: 34]	ARGFTAYGMDY [SEQ ID NO: 35]
V _L	SSVSY [SEQ ID NO: 36]	DTS [SEQ ID NO: 37]	QQWSSNPLT [SEQ ID NO: 38]
Full V _H	QVQLVQSGAEVAKPGASVKLSCKASGYTFTNYWMQWIKQAPGGGLEWIGAVYPGDGDTRHTQ KFKGKATLTADKSTSTAYMEVSSLRSEDVAVYYCARGFTAYGMDYWGQGTITVTVSS [SEQ ID NO: 146]		
Full V _L	EIVLTQSPATMSASPGERVTMSSCASSSVSYMHWYQQKSGQSPKRWIYDTSKLASGVPARFS GSGSGTDYFTFTISSMEPEDFATYYCQQWSSNPLTFGGGTKLEIK [SEQ ID NO: 147]		
V _H -V _L scFv	QVQLVQSGAEVAKPGASVKLSCKASGYTFTNYWMQWIKQAPGGGLEWIGAVYPGDGDTRHTQ KFKGKATLTADKSTSTAYMEVSSLRSEDVAVYYCARGFTAYGMDYWGQGTITVTVSSGGGGSG GGGSGGGGSEIVLTQSPATMSASPGERVTMSSCASSSVSYMHWYQQKSGQSPKRWIYDTSKL ASGVPARFSGSGSGTDYFTFTISSMEPEDFATYYCQQWSSNPLTFGGGTKLEIK [SEQ ID NO: 148]		

The V_H and/or V_L amino acid sequences comprising or consisting of at least about 80%, at least about 80%, at least about 85%, at least about 90%, or at least about 95% (*e.g.*, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, or about 99%) homology or identity to a specific sequence (*e.g.*, SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 46, SEQ ID NO: 47, SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 52, SEQ ID NO: 53, SEQ ID NO: 55, SEQ ID NO: 56, SEQ ID NO: 146, or SEQ ID NO: 147) may contain substitutions (*e.g.*, conservative substitutions), insertions, or deletions relative to the specified sequence(s), but retain the ability to bind to a target antigen (*e.g.*, ADGRE2). In certain embodiments, a total of 1 to 10 amino acids are substituted, inserted and/or deleted in a specific sequence (*e.g.*, SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 46, SEQ ID NO: 47, SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 52, SEQ ID NO: 53, SEQ ID NO: 55, SEQ ID NO: 56, SEQ ID NO: 146, or SEQ ID NO: 147). In certain embodiments, substitutions, insertions, or deletions occur in regions outside the CDRs (*e.g.*, in the FRs) of the extracellular antigen-binding domain. In certain embodiments, the extracellular antigen-binding domain comprises V_H and/or V_L sequence selected from SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 46, SEQ ID NO: 47, SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO:

52, SEQ ID NO: 53, SEQ ID NO: 55, SEQ ID NO: 56, SEQ ID NO: 146, or SEQ ID NO: 147, including post-translational modifications of that sequence (SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 46, SEQ ID NO: 47, SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 52, SEQ ID NO: 53, SEQ ID NO: 55, SEQ ID NO: 56, SEQ ID NO: 146, or SEQ ID NO: 147).

In certain embodiments, the extracellular antigen-binding domain of a presently disclosed ADGRE2-targeted chimeric receptor cross-competes for binding to ADGRE2 with a reference antibody or an antigen-binding portion thereof comprising the a V_H CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 33, a V_H CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 34; a V_H CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 35; a V_L CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 36; a V_L CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 37; and a V_L CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 38. In certain embodiments, the extracellular antigen-binding domain of a presently disclosed ADGRE2-targeted chimeric receptor cross-competes for binding to ADGRE2 with a reference antibody or an antigen-binding portion thereof comprising the V_H and V_L sequences of, for example, any one of the presently disclosed scFvs (*e.g.*, ADGRE2-A, ADGRE2-B, ADGRE2-C, ADGRE2-D, ADGRE2-E, ADGRE2-F, and ADGRE2-G).

In certain embodiments, the extracellular antigen-binding domain of a presently disclosed ADGRE2-targeted chimeric receptor binds to the same or substantially the same epitope region on ADGRE2 with a reference antibody or an antigen-binding portion thereof comprising the a V_H CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 33, a V_H CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 34; a V_H CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 35; a V_L CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 36; a V_L CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 37; and a V_L CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 38. In certain embodiments, the extracellular antigen-binding domain of a presently disclosed ADGRE2-targeted chimeric receptor binds to the same or substantially the same epitope region on ADGRE2 with a reference antibody or an antigen-binding portion thereof comprising the V_H and V_L sequences of, for example, any one of the presently disclosed scFvs (*e.g.*, ADGRE2-A, ADGRE2-B, ADGRE2-C, ADGRE2-D, ADGRE2-E, ADGRE2-F, and ADGRE2-G).

Extracellular antigen-binding domains of the presently disclosed ADGRE2-targeted chimeric receptors that cross-compete or compete with the reference antibody or antigen-binding

portions thereof for binding to ADGRE2 can be identified by using routine methods known in the art, including, but not limited to, ELISAs, radioimmunoassay (RIAs), Biacore, flow cytometry, Western blotting, and any other suitable quantitative or qualitative antibody-binding assays. Competition ELISA is described in Morris, "Epitope Mapping of Protein Antigens by Competition ELISA", *The Protein Protocols Handbook* (1996), pp 595-600, edited by J. Walker, which is incorporated by reference in its entirety. In certain embodiments, the antibody-binding assay comprises measuring an initial binding of a reference antibody to an ADGRE2, admixing the reference antibody with a test extracellular antigen-binding domain, measuring a second binding of the reference antibody to the ADGRE2 in the presence of the test extracellular antigen-binding domain, and comparing the initial binding with the second binding of the reference antibody, wherein a decreased second binding of the reference antibody to the ADGRE2 in comparison to the initial binding indicates that the test extracellular antigen-binding domain cross-competes with the reference antibody for binding to ADGRE2, *e.g.*, one that recognizes the same or substantially the same epitope, an overlapping epitope, or an adjacent epitope. In certain embodiments, the reference antibody is labeled, *e.g.*, with a fluorochrome, biotin, or peroxidase. In certain embodiments, the ADGRE2 is expressed in cells, *e.g.*, in a flow cytometry test. In certain embodiments, the ADGRE2 is immobilized onto a surface, including a Biacore chip (*e.g.*, in a Biacore test), or other media suitable for surface plasmon resonance analysis. The binding of the reference antibody in the presence of a completely irrelevant antibody (that does not bind to ADGRE2) can serve as the control high value. The control low value can be obtained by incubating a labeled reference antibody with an unlabeled reference antibody, where competition and reduced binding of the labeled reference antibody would occur. In certain embodiments, a test extracellular antigen-binding domain that reduces the binding of the reference antibody to ADGRE2 by at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, or at least about 95% is considered to be an extracellular antigen-binding domain that cross-competes with the reference antibody for binding to ADGRE2. In certain embodiments, the assays are performed at room temperature.

In certain embodiments, the antibody-binding assay comprises measuring an initial binding of a test extracellular antigen-binding domain to ADGRE2, admixing the test extracellular antigen-binding domain with a reference antibody, measuring a second binding of the test extracellular antigen-binding domain to ADGRE2 in the presence of the reference antibody, and comparing the initial binding with the second binding of the test extracellular antigen-binding domain, where a decreased second binding of the test extracellular antigen-

binding domain to ADGRE2 in comparison to the initial binding indicates that the test extracellular antigen-binding domain cross-competes with the reference antibody for binding to ADGRE2, *e.g.*, one that recognizes the same or substantially the same epitope, an overlapping epitope, or an adjacent epitope. In certain embodiments, the test extracellular antigen-binding domain is labeled, *e.g.*, with a fluorochrome, biotin, or peroxidase. In certain embodiments, the ADGRE2 is expressed in cells, *e.g.*, in a flow cytometry test. In certain embodiments, the ADGRE2 is immobilized onto a surface, including a Biacore ship (*e.g.*, in a Biacore test), or other media suitable for surface plasmon resonance analysis. The binding of the test extracellular antigen-binding domain in the presence of a completely irrelevant antibody (that does not bind to ADGRE2) can serve as the control high value. The control low value can be obtained by incubating a labeled test extracellular antigen-binding domain with an unlabeled test extracellular antigen-binding domain, where competition and reduced binding of the labeled test extracellular antigen-binding domain would occur. In certain embodiments, a test extracellular antigen-binding domain, whose binding to ADGRE2 is decreased by at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, or at least about 95% in the presence of a reference antibody, is considered to be an extracellular antigen-binding domain that cross-competes with the reference antibody for binding to ADGRE2. In certain embodiments, the assays are performed at room temperature.

In certain embodiments, the extracellular antigen-binding domain of the presently disclosed ADGRE2-targeted chimeric receptor comprises a linker connecting the heavy chain variable region and light chain variable region of the extracellular antigen-binding domain. In certain embodiments, the linker comprises the amino acid sequence set forth in SEQ ID NO: 1. In certain embodiments, the linker comprises the amino acid sequence set forth in SEQ ID NO: 2. In certain embodiments, the linker comprises the amino acid sequence set forth in SEQ ID NO: 3. In certain embodiments, the linker comprises the amino acid sequence set forth in SEQ ID NO: 4. In certain embodiments, the linker comprises the amino acid sequence set forth in SEQ ID NO: 5. In certain embodiments, the linker comprises the amino acid sequence set forth in SEQ ID NO: 6. In certain embodiments, the linker comprises the amino acid sequence set forth in SEQ ID NO: 149.

In certain embodiments, the variable regions within the extracellular antigen-binding domain of the ADGRE2-targeted chimeric receptor have to be linked one after another such that at the N-terminus of the extracellular antigen-binding domain, a heavy chain variable region (V_H) is positioned. In certain embodiments, if the extracellular antigen-binding domain of the

ADGRE2-targeted chimeric receptor is an scFv, the variable regions are positioned from the N- to the C-terminus: V_H-V_L.

In certain embodiments, the variable regions within the extracellular antigen-binding domain of the ADGRE2-targeted chimeric receptor have to be linked one after another such that
 5 at the N-terminus of the extracellular antigen-binding domain, a light chain variable region (V_L) is positioned. In certain embodiments, if the extracellular antigen-binding domain of the ADGRE2-targeted chimeric receptor is an scFv, the variable regions are positioned from the N- to the C-terminus: V_L-V_H.

In addition, the ADGRE2-targeted chimeric receptor can comprise a leader or a signal
 10 peptide that directs the nascent protein into the endoplasmic reticulum. In certain embodiments, the leader or signal peptide is positioned at (e.g., covalently joined to) the N-terminus of the extracellular antigen-binding domain of the ADGRE2-targeted chimeric receptor. Signal peptide or leader can be essential if the chimeric receptor is to be glycosylated and anchored in the cell membrane. The signal sequence or leader can be a peptide sequence (about 5, about 10,
 15 about 15, about 20, about 25, or about 30 amino acids long) present at the N-terminus of newly synthesized proteins that directs their entry to the secretory pathway. Non-limiting examples of signal peptides or leader sequences include an IL-2 signal sequence, a CD8 leader sequence, a kappa leader sequence, an albumin leader sequence, and a prolactin leader sequence. In certain embodiments, the IL-2 signal sequence comprises or consists of the amino acid sequence set
 20 forth in SEQ ID NO. 58 or SEQ ID NO: 59. In certain embodiments, the kappa leader sequence comprises or consists of the amino acid sequence set forth in SEQ ID NO. 60 or SEQ ID NO: 61. In certain embodiments, the CD8 signal sequence comprises or consists of the amino acid sequence set forth in SEQ ID NO. 62 or SEQ ID NO: 63. In certain embodiments, the albumin leader sequence comprises or consists of the amino acid sequence set forth in SEQ ID NO: 64.
 25 In certain embodiments, the prolactin leader sequence comprises or consists of the amino acid sequence set forth in SEQ ID NO: 65. In certain embodiments, the ADGRE2-targeted chimeric receptor comprises a signal peptide that comprises a CD8 polypeptide. In certain embodiments, the ADGRE2-targeted chimeric receptor comprises a signal peptide that comprises a CD8 polypeptide comprising or consisting of the amino acid sequence set forth in SEQ ID NO: 63.

30 MYRMQLLSICIALSLALVTNS [SEQ ID NO: 58]
 MYSMQLASCVTLTLLVLLVNS [SEQ ID NO: 59]
 METPAQLLFLLLLLWLPDTTG [SEQ ID NO: 60]
 METDTLLLWVLLLWVPGSTG [SEQ ID NO: 61]
 MALPVTALLPLALLHAARP [SEQ ID NO: 62]
 35 MALPVTALLPLALLHA [SEQ ID NO: 63]

MKWVTFISLLEFSSAYS [SEQ ID NO: 64]

MDSKGSSQKGSRLLLLLLVSNLLLCQGVVS [SEQ ID NO: 65]

5.4. Exemplified ADGRE2-Targeted Chimeric Receptors

In certain embodiments, the ADGRE2-targeted chimeric receptor is an ADGRE2-targeted CAR. In certain embodiments, the ADGRE2-targeted CAR comprises (a) an extracellular antigen-binding domain comprising (i) a V_H that comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 33, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 34, and a V_H CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 35, and (ii) a V_L that comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 36, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 37, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 38; (b) a hinge/spacer region comprising a CD28 polypeptide, (c) a transmembrane domain comprising a CD28 polypeptide (*e.g.*, a transmembrane domain of human CD28 or a fragment thereof), and (d) an intracellular signaling domain comprising (i) a CD3ζ polypeptide, and (ii) a co-stimulatory signaling region comprising a CD28 polypeptide (*e.g.*, an intracellular domain of human CD28 or a fragment thereof). In certain embodiments, the V_H and V_L are linked via a linker comprising or consisting of the amino acid sequence set forth in SEQ ID NO: 2. In certain embodiments, the V_H and V_L are positioned from the N- to the C-terminus: V_H-V_L. In certain embodiments, the transmembrane domain comprises a CD28 polypeptide comprising or consisting of the amino acids 153 to 179 of SEQ ID NO: 10. In certain embodiments, the co-stimulatory signaling region comprises a CD28 polypeptide comprising or consisting of the amino acids 180 to 220 of SEQ ID NO: 10. In certain embodiments, the hinge/spacer region comprises a CD28 polypeptide comprising or consisting of the amino acids 114 to 152 of SEQ ID NO: 10. In certain embodiments, the extracellular antigen-binding domain and transmembrane domain are linked via a linker. In certain embodiments, the linker consists of the amino acid sequence set forth in SEQ ID NO: 150. SEQ ID NO: 150 is provided below. In certain embodiments, the ADGRE2-targeted CAR comprises or consists of the amino acid sequence set forth in SEQ ID NO: 66, which is provided below.

QVQLQQSGAEVAKPGASVKLSCKASGYTFTNYWMQWIKQAPGQGLEWIGAVYPGDGTRHTQKFKGKATLTADKSTS
TAYMEVSSLRSED TAVYYCARGFTAYGMDYWGQGT VTVSSGGGGSGGGSGGGGSEIVLTQSPATMSASPGERV
TMSCSASSSVSYMHWYQQKSGQSPKRWIYDTSKLASGVPARFSGSGTDTYFTISSMEPEDFATYYCQWSSNPLTFG
GGTKLEIKRAAAIEVMYPPPYLDNEKSGTIIHVKGKHLCPSPLPFGPSKPFVVLVVGVLACYSLLVTVAFTIIFW
VRSKRSLHSDYMNMTPRRPGPTRKHYPYAPPRDFAAYRSRVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVL
DKRRGRDPENGGKPRRKNPQEGLFNELQDKMAEAFSEIGMKGERRRRGKGDGLFQGLSTATKDTFDALHMQALPPR
[SEQ ID NO: 66]

RAAA [SEQ ID NO: 150]

An exemplary nucleic acid sequence the amino acid sequence of SEQ ID NO: 66 is set forth in SEQ ID NO: 67, which is provided below.

5 caagttcagctccagcagagcggcgccgaagtggcaaaagcctggagcgtcagtcagctgctcctgcaaagcagtggt
ctatacgttcacgaactactggatgcagtggtataaagcaggctcccgggcagggtctggagtggttgagccgtct
accaggggagcggcgacacccggcacactcaaaagttcaagggcaagggccaccctgaccgctgacaagagcacaagc
acagcgtacatggaggtgtcctcctttgagatccgaagataccgctgtgtattattgtgcccggggccttactgcata
cgggatggattactggggacaaggcactaccgtgactgtcagctccgggggtggaggtcaggcggggggggttcag
10 gagggggggggtatctgaaattgtgctgacacagagccctgccacaatgtctgctagccctggcgagcgcgtgaccatg
tcttgtagcggcagcagcagcgtgtcctacatgcattgggtatcaacagaagtccggccagtcctccaagcgggtgat
ctacgatacaagcaagctggcctccggcgtgcccgccagatcttctggcagcggctctggaacagattacaccttca
ccatctctagcatggaacctgaggatcttgcacctaactattgccagcagtggtccagcaatcccctgacatttgga
ggaggcaccaagctggaaattaagagagcggcgcaattgaagtattgtatcctcctccttacatagacaatgagaa
15 gagcaatggaaccattatccatgtgaaagggaaacacctttgtccaagtcctcctatttcccgaccttctaagcct
tttgggtgctggtggtggtggtggagtcctggcttgcctatagcttgcctagtaacagtggtcctttattatcttctgg
gtgaggagtaagaggagcaggctcctgcacagtgcacatgaacatgactccccgcgcgccccgggcccaccgcgaa
gcattaccagccctatgccccaccacgcgacttcgcagcctatcgctccagagtgaagttcagcaggagcgcagacg
ccccgcgtaccagcagggccagaaccagctctataacgagctcaatctaggacgaagagaggagtacgatgttttg
20 gacaagagacgtggccgggaccctgagatgggggaaagccgagaaggaagaacctcaggaaggcctgttcaatga
actgcagaaagataagatggcggaggccttcagtgcagattgggatgaaaggcgagcgcggagggggcaaggggcacg
atggccttttccagggtctcagtcagccaccaaggacaccttcgacgccttcacatgcaggccctgccccctgcg
[SEQ ID NO: 67]

In certain embodiments, the ADGRE2-targeted chimeric receptor comprises a signal
25 peptide at the N-terminus of the extracellular antigen-binding domain. In certain embodiments,
the signal peptide comprises a CD8 polypeptide comprising or consisting of the amino acid
sequence set forth in SEQ ID NO: 63.

5.5. *Extracellular Antigen-binding Domain of CLEC12A-Targeted Chimeric Receptors*

In certain embodiments, the presently disclosed chimeric receptor targets CLEC12A. In
30 certain embodiments, the presently disclosed chimeric receptor comprises an extracellular
antigen-binding domain that binds to CLEC12A.

C-type lectin domain family 12 member A (CLEC12A), also known as CLL-1, CLL1,
DCAL-2, MICL, CD371, is a 30 kD C-type lectin transmembrane glycoprotein. It is expressed
on monocytes, granulocytes, natural killer (NK) cells, and basophils. CLEC12A is an
35 immunoinhibitory receptor that recruits Src homology phosphatases SHP-1 and SHP-2 to its
phosphorylated cytoplasmic immunoreceptor tyrosine-based inhibitory motif (ITIM) (Sancho et
al., *Annu Rev. Immunol* (2012); 30:491-529; Yan et al., *Front Immunol* (2015);6:408; Lahoud et

al., *J Immunol* (2011);187:842). CLEC12A has been implicated as a negative regulatory uric acid crystals (monosodium urate, MSU) receptor that controls autoimmunity and inflammatory disease (Neumann et al., *Immunity* (2014);40:389-99). CLEC12A is a negative regulator of granulocyte and monocyte function (Marshall et al., *J Biol Chem* (2004);279(15):14792-802; 5 Pyz et al., *Eur J Immunol* (2008);38(4):1157-63).

In certain embodiments, the presently disclosed chimeric receptor targets human CLEC12A. In certain embodiments, the presently disclosed chimeric receptor comprises an extracellular antigen-binding domain that binds to human CLEC12A. In certain embodiments, the human CLEC12A comprises or consists of the amino acid sequence with a UniProt 10 Reference No: Q5QGZ9-2 (SEQ ID NO: 68), or a fragment thereof. SEQ ID NO: 68 is provided below:

```

MSEEVTYADLQFQNSSEMEKIPEIGKFGEKAPPAPSHVWRPAALFTLLCLLLLIIGVLASMFHVTLKI
EMKMKMNLQNISEELQRNISLQLMSNMNISNKIRNLSTTLQTIATKLCRELYSKEQEHKCKPCPRRWIWH
KDSCYFLSDDVQVTQWESKMACAAQNASLLKINNKNLEFIKSQSRSDYWLGLSPEEDSTRGMRVDNIIN
15 SSAWVIRNAPDLNNMYCGYINRLYVQYYHCTYKKRMICEKMANPVLGSTYFREA
[SEQ ID NO: 68]
```

Human CLEC12A comprises a cytoplasmic domain, a transmembrane domain, and an extracellular domain. In certain embodiments, the cytoplasmic domain comprises or consists of amino acids 1 to 43 of SEQ ID NO: 68. In certain embodiments, the transmembrane domain 20 comprises or consists of amino acid 44 to 64 of SEQ ID NO: 68. In certain embodiments, the extracellular domain comprises or consists of amino acid 65 to 265 of SEQ ID NO: 68.

In certain embodiments, the presently disclosed chimeric receptor targets a CLECL12A polypeptide comprising or consisting of an amino acid sequence that is at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, 25 at least about 98%, or at least about 99%, at least about 100% identical to the amino acid sequence set forth in SEQ ID NO: 68 or a fragment thereof.

In certain embodiments, the extracellular antigen-binding domain of a presently disclosed CLEC12A-targeted chimeric receptor binds to the extracellular domain of CLEC12A.

In certain embodiments, the CLEC12A-targeted chimeric receptor is a chimeric antigen 30 receptor (CAR). In certain embodiments, the CLEC12A-targeted CAR has the structure disclosed in Section 5.2.1. In certain embodiments, the CLEC12A-targeted CAR comprises an extracellular antigen-binding domain that binds to CLEC12A, a transmembrane domain, and an intracellular signaling domain.

In certain embodiments, the CLEC12A -targeted chimeric receptor is a Chimeric Co- 35 Stimulatory Receptor (CCR). In certain embodiments, the CLEC12A-targeted CCR has the

structure disclosed in Section 5.2.2. In certain embodiments, the CLEC12A-targeted CCR comprises an extracellular antigen-binding domain that binds to CLEC12A, a transmembrane domain, and an intracellular signaling domain that does not provide an activation signal to an immunoresponsive cell, e.g., the intracellular signaling domain does not comprise a CD3 ζ polypeptide.

In certain embodiments, the CLEC12A-targeted chimeric receptor is a TCR like Fusion Molecules. In certain embodiments, the CLEC12A-targeted TCR like Fusion Molecules has the structure disclosed in Section 5.2.3.

In certain embodiments, the extracellular antigen-binding domain of the CLEC12A-targeted chimeric receptor (*e.g.*, a CLEC12A-targeted scFv) binds to CLEC12A (*e.g.*, human CLEC12A) with a dissociation constant (K_D) of at least about 1×10^{-6} M, at least about 1×10^{-7} M, at least about 1×10^{-8} M, at least about 1×10^{-9} M, or at least about 1×10^{-10} M. In certain embodiments, the extracellular antigen-binding domain of the CLEC12A-targeted chimeric receptor (*e.g.*, a CLEC12A-targeted scFv) binds to CLEC12A (*e.g.*, human CLEC12A) with a dissociation constant (K_D) of at least about 2×10^{-8} M. In certain embodiments, the extracellular antigen-binding domain of the CLEC12A-targeted chimeric receptor (*e.g.*, a CLEC12A-targeted scFv) binds to CLEC12A (*e.g.*, human CLEC12A) with a dissociation constant (K_D) of between about 2×10^{-8} M and about 8×10^{-9} M.

In certain embodiments, the extracellular antigen-binding domain of the CLEC12A-targeted chimeric receptor (*e.g.*, a CLEC12A-targeted scFv) binds to CLEC12A (*e.g.*, human CLEC12A) with a dissociation constant (K_D) between about 1 nM and about 50 nM, between about 5 nM and 30 nM, between about 5 nM and about 25 nM, or between about 8 nM and about 20 nM. In certain embodiments, the extracellular antigen-binding domain of the CLEC12A-targeted chimeric receptor (*e.g.*, a CLEC12A-targeted scFv) binds to CLEC12A (*e.g.*, human CLEC12A) with a dissociation constant (K_D) of at least about 50 nM, at least about 40 nM, at least about 35 nM, at least about 30 nM, at least about 25 nM, at least about 20 nM, at least about 19 nM, at least about 18 nM, at least about 17 nM, at least about 16 nM, at least about 15 nM, at least about 14 nM, at least about 13 nM, at least about 12 nM, at least about 11 nM, at least about 10 nM, at least about 9 nM, at least about 8 nM, at least about 7 nM, at least about 6 nM, at least about 5 nM.

In certain embodiments, the extracellular antigen-binding domain of the CLEC12A-targeted chimeric receptor (*e.g.*, a CLEC12A-targeted scFv) comprises a V_H CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 69 or a conservative modification thereof, a V_H CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 70 or a conservative

modification thereof, and a V_H CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 71 or a conservative modification thereof. SEQ ID NOs: 69-71 are provided in Table 8.

In certain embodiments, the extracellular antigen-binding domain of the CLEC12A-targeted chimeric receptor (*e.g.*, a CLEC12A-targeted scFv) comprises a V_L CDR1 comprising
 5 the amino acid sequence set forth in SEQ ID NO: 72 or a conservative modification thereof, a V_L CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 73 or a conservative modification thereof, and a V_L CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 74 or a conservative modification thereof. SEQ ID NOs: 72-74 are provided in Table 8.

In certain embodiments, the extracellular antigen-binding domain of the CLEC12A-targeted chimeric receptor (*e.g.*, a CLEC12A-targeted scFv) comprises a V_H CDR1 comprising
 10 the amino acid sequence set forth in SEQ ID NO: 69 or a conservative modification thereof, a V_H CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 70 or a conservative modification thereof, a V_H CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 71 or a conservative modification thereof, a V_L CDR1 comprising the amino acid sequence set
 15 forth in SEQ ID NO: 72 or a conservative modification thereof, a V_L CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 73 or a conservative modification, and a V_L CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 74 or a conservative modification thereof.

In certain embodiments, the extracellular antigen-binding domain of the CLEC12A-targeted chimeric receptor (*e.g.*, a CLEC12A-targeted scFv) comprises a V_H CDR1 comprising
 20 the amino acid sequence set forth in SEQ ID NO: 69, a V_H CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 70, a V_H CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 71, a V_L CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 72, a V_L CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 73, and a V_L
 25 CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 74.

In certain embodiments, the extracellular antigen-binding domain of the CLEC12A-targeted chimeric receptor (*e.g.*, a CLEC12A-targeted scFv) comprises a V_H comprising an amino acid sequence that is at least about 80% (*e.g.*, at least about 85%, at least about 90%, or at least about 95%) homologous or identical to the amino acid sequence set forth in SEQ ID NO:
 30 75. For example, the extracellular antigen-binding domain of the CLEC12A-targeted chimeric receptor (*e.g.*, a CLEC12A-targeted scFv) comprises a V_H comprising an amino acid sequence that is about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99% or about 100% homologous or identical to

SEQ ID NO: 108. In certain embodiments, the extracellular antigen-binding domain of the CLEC12A-targeted chimeric receptor comprises a V_H comprising the amino acid sequence set forth in SEQ ID NO: 75. SEQ ID NO: 75 is provided in Table 8 below.

In certain embodiments, the extracellular antigen-binding domain of the CLEC12A-targeted chimeric receptor (*e.g.*, a CLEC12A-targeted scFv) comprises a V_L comprising an amino acid sequence that is at least about 80% (*e.g.*, at least about 85%, at least about 90%, or at least about 95%) homologous or identical to the amino acid sequence set forth in SEQ ID NO: 76. For example, the extracellular antigen-binding domain of the CLEC12A-targeted chimeric receptor (*e.g.*, a CLEC12A-targeted scFv) comprises a V_L comprising an amino acid sequence that is about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99% or about 100% homologous or identical to SEQ ID NO: 109. In certain embodiments, the extracellular antigen-binding domain of the CLEC12A-targeted chimeric receptor comprises a V_L comprising the amino acid sequence set forth in SEQ ID NO: 76. SEQ ID NO: 76 is provided in Table 8 below.

In certain embodiments, the extracellular antigen-binding domain of the CLEC12A-targeted chimeric receptor (*e.g.*, a CLEC12A-targeted scFv) comprises a V_H comprising the amino acid sequence set forth in SEQ ID NO: 75, and a V_L comprising the amino acid sequence set forth in SEQ ID NO: 76. In certain embodiments, the V_H and V_L are linked via a linker. In certain embodiments, the linker comprises the amino acid sequence set forth in SEQ ID NO: 149. In certain embodiments, the linker comprises the amino acid sequence set forth in SEQ ID NO: 2.

In certain embodiments, the variable regions within the extracellular antigen-binding domain of the CLEC12A-targeted chimeric receptor have to be linked one after another such that at the N-terminus of the extracellular antigen-binding domain, a heavy chain variable region (V_H) is positioned. In certain embodiments, if the extracellular antigen-binding domain of the CLEC12A-targeted chimeric receptor is an scFv, the variable regions are positioned from the N- to the C-terminus: V_H-V_L. In certain embodiments, the CLEC12A-targeted scFv comprises or consists of the amino acid sequence set forth in SEQ ID NO: 79. In certain embodiments, the CLEC12A-targeted scFv is designated as “CLEC12A-A”. An exemplary nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 79 is set forth in SEQ ID NO: 80. SEQ ID NOs: 79 and 80 are provided in Table 8. The CDRs provided in Table 8 are identified according to the IMGT numbering system.

Table 8 (CLEC12A-A)

CDRs	1	2	3
V _H	GGSSISSTYY [SEQ ID NO: 69]	THYRGST [SEQ ID NO: 70]	ARELTGEVFDY [SEQ ID NO: 71]
V _L	QSISSY [SEQ ID NO: 72]	AAS [SEQ ID NO: 73]	QQSYSTPFT [SEQ ID NO: 74]
Full V _H	QLQLQESGPGLVKPSSETLSLTCTVSGGSISSTYYWGWIRQPPRKGLEWIGSTHYRGSTYYNPSLKSRTISVDTSKNQFSLKVSSVTAADTAVYYCARELTGEVFDYWGQGTILVTVS [SEQ ID NO: 75]		
Full V _L	DIQMTQSPSSLSASVGDRTITCRASQSISSYLNWYQQKPKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISLQPEDFATYYCQQSYSTPFTFGPGTKVDIK [SEQ ID NO: 76]		
DNA for Full V _H	Cagctccagctccaagagtcagggccaggtctcgtgaaaccgagtgagaccctgtccctgacctgcacagtgagtggtggatcaatctcaagctctacctaactattgggggtggattcggcagccccctagaaagggcttgagtgattggcagcactcattatcgaggatctaccattataatccttctctgaaaagcagagttaccatctctgtggatacgtccaaaaatcagttcagctctgaaggtatcatccgtgactgctgccgacacggccgtgtactattgcgcgagggagctgacaggtgaggtctttgactactggggccagggcacactcgtgaccgtgtcttct [SEQ ID NO: 77]		
DNA for Full V _L	Gacatccagatgacgcagtcctccctccagcttgctccgcatctgtgggtgatagggtcacgattacatgtagggctagtcagagtatcttagttacctaattgggtaccagcagaaacaggcaaggcaccaaagttgctcatctatgcggcctcctctctgcaatctggcgtgccgtccagatttagtgatcaggctccggaaccgatttcacccttacgatctcctcacttcaaccgaggatttcgccacatattactgtcaacaaagctattctacacggttcaccttcggaccggggacaaaagtggatattaaa [SEQ ID NO: 78]		
V _H -V _L scFv	QLQLQESGPGLVKPSSETLSLTCTVSGGSISSTYYWGWIRQPPRKGLEWIGSTHYRGSTYYNPSLKSRTISVDTSKNQFSLKVSSVTAADTAVYYCARELTGEVFDYWGQGTILVTVSASTGGGGSGGGSGGGSDIQMTQSPSSLSASVGDRTITCRASQSISSYLNWYQQKPKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISLQPEDFATYYCQQSYSTPFTFGPGTKVDIK [SEQ ID NO: 79]		
DNA for V _H -V _L scFv	Cagctccagctccaagagtcagggccaggtctcgtgaaaccgagtgagaccctgtccctgacctgcacagtgagtggtggatcaatctcaagctctacctaactattgggggtggattcggcagccccctagaaagggcttgagtgattggcagcactcattatcgaggatctaccattataatccttctctgaaaagcagagttaccatctctgtggatacgtccaaaaatcagttcagctctgaaggtatcatccgtgactgctgccgacacggccgtgtactattgcgcgagggagctgacaggtgaggtctttgactactggggccagggcacactcgtgaccgtgtctctgcctcaacaggaggggggtggagtgaggcggtggatcagggggaggagggagtgacatccagatgacgcagtcctccctccagcttgctccgcatctgtgggtgatagggtcacgattacatgtagggctagtcagagtatcttagttacctaattgggtaccagcagaaacaggcaaggcaccaaagttgctcatctatgcggcctcctctctgcaatctggcgtgccgtccagatttagtgatcaggctccggaaccgatttcacccttacgatctcctcacttcaaccgaggatttcgccacatattactgtcaacaaagctattctacacggttcaccttcggaaccggggacaaaagtggatattaaa [SEQ ID NO: 80]		

In certain embodiments, the extracellular antigen-binding domain of the CLEC12A-targeted chimeric receptor (*e.g.*, a CLEC12A-targeted scFv) comprises a V_H CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 81 or a conservative modification thereof, a V_H CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 82 or a conservative modification thereof, and a V_H CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 83 or a conservative modification thereof. SEQ ID NOs: 81-83 are provided in Table 9.

In certain embodiments, the extracellular antigen-binding domain of the CLEC12A-targeted chimeric receptor (*e.g.*, a CLEC12A-targeted scFv) comprises a V_L CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 84 or a conservative modification thereof, a

V_L CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 73 or a conservative modification thereof, and a V_L CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 85 or a conservative modification thereof. SEQ ID NOs: 73, 84 and 85 are provided in Table 9.

5 In certain embodiments, the extracellular antigen-binding domain of the CLEC12A-targeted chimeric receptor (*e.g.*, a CLEC12A-targeted scFv) comprises a V_H CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 81 or a conservative modification thereof, a V_H CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 82 or a conservative modification thereof, a V_H CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 83 or a conservative modification thereof, a V_L CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 84 or a conservative modification thereof, a V_L CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 73 or a conservative modification, and a V_L CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 85 or a conservative modification thereof.

15 In certain embodiments, the extracellular antigen-binding domain of the CLEC12A-targeted chimeric receptor (*e.g.*, a CLEC12A-targeted scFv) comprises a V_H CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 81, a V_H CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 82, a V_H CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 83, a V_L CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 84, a V_L CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 73, and a V_L CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 85.

In certain embodiments, the extracellular antigen-binding domain of the CLEC12A-targeted chimeric receptor (*e.g.*, a CLEC12A-targeted scFv) comprises a V_H comprising an amino acid sequence that is at least about 80% (*e.g.*, at least about 85%, at least about 90%, or at least about 95%) homologous or identical to the amino acid sequence set forth in SEQ ID NO: 86. For example, the extracellular antigen-binding domain of the CLEC12A-targeted chimeric receptor (*e.g.*, an scFv) comprises a V_H comprising an amino acid sequence that is about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99% or about 100% homologous or identical to SEQ ID NO: 86.

25 In certain embodiments, the extracellular antigen-binding domain of the CLEC12A-targeted chimeric receptor comprises a V_H comprising the amino acid sequence set forth in SEQ ID NO: 86. SEQ ID NO: 86 is provided in Table 9 below.

In certain embodiments, the extracellular antigen-binding domain of the CLEC12A-targeted chimeric receptor (*e.g.*, a CLEC12A-targeted scFv) comprises a V_L comprising an amino acid sequence that is at least about 80% (*e.g.*, at least about 85%, at least about 90%, or at least about 95%) homologous or identical to the amino acid sequence set forth in SEQ ID NO:

- 5 87. For example, the extracellular antigen-binding domain of the CLEC12A-targeted chimeric receptor (*e.g.*, a CLEC12A-targeted scFv) comprises a V_L comprising an amino acid sequence that is about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99% or about 100% homologous or identical to
- 10 SEQ ID NO: 87. In certain embodiments, the extracellular antigen-binding domain of the CLEC12A-targeted chimeric receptor comprises a V_L comprising the amino acid sequence set forth in SEQ ID NO: 87. SEQ ID NO: 87 is provided in Table 9 below.

- In certain embodiments, the extracellular antigen-binding domain of the CLEC12A-targeted chimeric receptor (*e.g.*, a CLEC12A-targeted scFv) comprises a V_H comprising the
- 15 amino acid sequence set forth in SEQ ID NO: 86, and a V_L comprising the amino acid sequence set forth in SEQ ID NO: 87. In certain embodiments, the V_H and V_L are linked via a linker. In certain embodiments, the linker comprises the amino acid sequence set forth in SEQ ID NO: 149. In certain embodiments, the linker comprises the amino acid sequence set forth in SEQ ID NO: 2.

- 20 In certain embodiments, the variable regions within the extracellular antigen-binding domain of the CLEC12A-targeted chimeric receptor have to be linked one after another such that at the N-terminus of the extracellular antigen-binding domain, a heavy chain variable region (V_H) is positioned. In certain embodiments, if the extracellular antigen-binding domain of the CLEC12A-targeted chimeric receptor is an scFv, the variable regions are positioned from the N-
- 25 to the C-terminus: V_H-V_L. In certain embodiments, the CLEC12A-targeted scFv comprises or consists of the amino acid sequence set forth in SEQ ID NO: 88, which is provided in Table 9. In certain embodiments, the CLEC12A-targeted scFv is designated as “CLEC12A-B”. The CDRs provided in Table 9 are identified according to the IMGT numbering system.

Table 9 (CLEC12A-B)

CDRs	1	2	3
V _H	GGISTYY [SEQ ID NO: 81]	IYYSGST [SEQ ID NO: 82]	AREYYGSGSPFDY [SEQ ID NO: 83]
V _L	QGIRYD [SEQ ID NO: 84]	AAS [SEQ ID NO: 73]	LQDYNFPRT [SEQ ID NO: 85]

Full V _H	QVQLQESGPGGLVKPSETLSLTCTVSGGSISTYYWSWIRQPPGKGLEWIGYIYYSGSTKY NPSLKSRVTISVDTSKNLFSKLSSVTAADTAVYYCAREDDYSGSPFDYWGQGLVTV SS [SEQ ID NO: 86]
Full V _L	AIQMTQSPSSLSASVGDRTITCRASQGIRYDLGWYQQKPGKAPKLLIYAASSLQSGVP SRFSGSGSGTDFTLTISLQPEDFATYYCLQDYNFPRTFGQGTKVEIK [SEQ ID NO: 87]
V _H -V _L scFv	QVQLQESGPGGLVKPSETLSLTCTVSGGSISTYYWSWIRQPPGKGLEWIGYIYYSGSTKY NPSLKSRVTISVDTSKNLFSKLSSVTAADTAVYYCAREDDYSGSPFDYWGQGLVTV SSASTGGGGSGGGSGGGGSAIQMTQSPSSLSASVGDRTITCRASQGIRYDLGWYQQK PGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISLQPEDFATYYCLQDYNFPRTF GQGTKVEIK [SEQ ID NO: 88]

In certain embodiments, the extracellular antigen-binding domain of the CLEC12A-targeted chimeric receptor (*e.g.*, a CLEC12A-targeted scFv) comprises a V_H CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 89 or a conservative modification thereof, a V_H CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 90 or a conservative modification thereof, and a V_H CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 91 or a conservative modification thereof. SEQ ID NOs: 89-91 are provided in Table 10.

In certain embodiments, the extracellular antigen-binding domain of the CLEC12A-targeted chimeric receptor (*e.g.*, a CLEC12A-targeted scFv) comprises a V_L CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 92 or a conservative modification thereof, a V_L CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 93 or a conservative modification thereof, and a V_L CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 94 or a conservative modification thereof. SEQ ID NOs: 92-94 are provided in Table 10.

In certain embodiments, the extracellular antigen-binding domain of the CLEC12A-targeted chimeric receptor (*e.g.*, an scFv) comprises a V_H CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 89 or a conservative modification thereof, a V_H CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 90 or a conservative modification thereof, a V_H CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 91 or a conservative modification thereof, a V_L CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 92 or a conservative modification thereof, a V_L CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 93 or a conservative modification, and a V_L CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 94 or a conservative modification thereof.

In certain embodiments, the extracellular antigen-binding domain of the CLEC12A-targeted chimeric receptor (*e.g.*, a CLEC12A-targeted scFv) comprises a V_H CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 89, a V_H CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 90, a V_H CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 91, a V_L CDR1 comprising the amino acid sequence set forth in SEQ ID NO:

92, a V_L CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 93, and a V_L CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 94.

In certain embodiments, the extracellular antigen-binding domain of the CLEC12A-targeted chimeric receptor (*e.g.*, a CLEC12A-targeted scFv) comprises a V_H comprising an amino acid sequence that is at least about 80% (*e.g.*, at least about 85%, at least about 90%, or at least about 95%) homologous or identical to the amino acid sequence set forth in SEQ ID NO: 95. For example, the extracellular antigen-binding domain of the CLEC12A-targeted chimeric receptor (*e.g.*, a CLEC12A-targeted scFv) comprises a V_H comprising an amino acid sequence that is about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99% or about 100% homologous or identical to SEQ ID NO: 95. In certain embodiments, the extracellular antigen-binding domain of the CLEC12A-targeted chimeric receptor comprises a V_H comprising the amino acid sequence set forth in SEQ ID NO: 95. SEQ ID NO: 95 is provided in Table 10 below.

In certain embodiments, the extracellular antigen-binding domain of the CLEC12A-targeted chimeric receptor (*e.g.*, a CLEC12A-targeted scFv) comprises a V_L comprising an amino acid sequence that is at least about 80% (*e.g.*, at least about 85%, at least about 90%, or at least about 95%) homologous or identical to the amino acid sequence set forth in SEQ ID NO: 96. For example, the extracellular antigen-binding domain of the CLEC12A-targeted chimeric receptor (*e.g.*, a CLEC12A-targeted scFv) comprises a V_L comprising an amino acid sequence that is about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99% or about 100% homologous or identical to SEQ ID NO: 96. In certain embodiments, the extracellular antigen-binding domain of the CLEC12A-targeted chimeric receptor comprises a V_L comprising the amino acid sequence set forth in SEQ ID NO: 96. SEQ ID NO: 96 is provided in Table 10 below.

In certain embodiments, the extracellular antigen-binding domain of the CLEC12A-targeted chimeric receptor (*e.g.*, a CLEC12A-targeted scFv) comprises a V_H comprising the amino acid sequence set forth in SEQ ID NO: 96, and a V_L comprising the amino acid sequence set forth in SEQ ID NO: 96. In certain embodiments, the V_H and V_L are linked via a linker. In certain embodiments, the linker comprises the amino acid sequence set forth in SEQ ID NO: 149. In certain embodiments, the linker comprises the amino acid sequence set forth in SEQ ID NO: 2.

In certain embodiments, the variable regions within the extracellular antigen-binding domain of the CLEC12A-targeted chimeric receptor have to be linked one after another such that at the N-terminus of the extracellular antigen-binding domain, a heavy chain variable region (V_H) is positioned. In certain embodiments, if the extracellular antigen-binding domain of the CLEC12A-targeted chimeric receptor is an scFv, the variable regions are positioned from the N- to the C-terminus: V_H-V_L. In certain embodiments, the CLEC12A-targeted scFv comprises the amino acid sequence set forth in SEQ ID NO: 97, which is provided in Table 10. In certain embodiments, the CLEC12A-targeted scFv is designated as “CLEC12A-C”. The CDRs provided in Table 10 are identified according to the IMGT numbering system.

Table 10 (CLEC12A-C)

CDRs	1	2	3
V _H	GFTFSSYG [SEQ ID NO: 89]	ISYDGSDK [SEQ ID NO: 90]	ARDKGYFDY [SEQ ID NO: 91]
V _L	QSVGNRY [SEQ ID NO: 92]	GAS [SEQ ID NO: 93]	QQDYNLPLT [SEQ ID NO: 94]
Full V _H	QVQLVESGGGVVQPGKSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVISYDGSDKY YVDSVKGRFTISRDNKNTLYLHMNSLRAEDTAVYYCARDKGYFDYWGQGLTVTVSS [SEQ ID NO: 95]		
Full V _L	EIVMTQSPATLSLSPGERATLSCRASQSVGNRYLSWYQQKPGQAPRLLIYGASTRATGIPARFSGSGSGTDFTLTISLQPEDFAVYYCQQDYNLPLTFGGGTKVEIK [SEQ ID NO: 96]		
V _H -V _L scFv	QVQLVESGGGVVQPGKSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVISYDGSDKY YVDSVKGRFTISRDNKNTLYLHMNSLRAEDTAVYYCARDKGYFDYWGQGLTVTVSSA STGGGSGGGGSGGGSEIVMTQSPATLSLSPGERATLSCRASQSVGNRYLSWYQQKPG QAPRLLIYGASTRATGIPARFSGSGSGTDFTLTISLQPEDFAVYYCQQDYNLPLTFGG GTKVEIK [SEQ ID NO: 97]		

In certain embodiments, the extracellular antigen-binding domain of the CLEC12A-targeted chimeric receptor (*e.g.*, a CLEC12A-targeted scFv) comprises a V_H CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 89 or a conservative modification thereof, a V_H CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 90 or a conservative modification thereof, and a V_H CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 91 or a conservative modification thereof. SEQ ID NOs: 89, 90, and 91 are provided in Table 11.

In certain embodiments, the extracellular antigen-binding domain of the CLEC12A-targeted chimeric receptor (*e.g.*, a CLEC12A-targeted scFv) comprises a V_L CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 92 or a conservative modification thereof, a V_L CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 93 or a conservative modification thereof, and a V_L CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 94 or a conservative modification thereof. SEQ ID NOs: 92, 93, and 94 are provided in Table 11.

NO: 151 or a conservative modification thereof. SEQ ID NOs: 93, 99, and 151 are provided in Table 11.

In certain embodiments, the extracellular antigen-binding domain of the CLEC12A-targeted chimeric receptor (*e.g.*, a CLEC12A-targeted scFv) comprises a V_H CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 89 or a conservative modification thereof, a V_H CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 90 or a conservative modification thereof, a V_H CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 98 or a conservative modification thereof, a V_L CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 99 or a conservative modification thereof, a V_L CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 93 or a conservative modification, and a V_L CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 151 or a conservative modification thereof.

In certain embodiments, the extracellular antigen-binding domain of the CLEC12A-targeted chimeric receptor (*e.g.*, a CLEC12A-targeted scFv) comprises a V_H CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 89, a V_H CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 90, a V_H CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 98, a V_L CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 99, a V_L CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 93, and a V_L CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 151.

In certain embodiments, the extracellular antigen-binding domain of the CLEC12A-targeted chimeric receptor (*e.g.*, a CLEC12A-targeted scFv) comprises a V_H comprising an amino acid sequence that is at least about 80% (*e.g.*, at least about 85%, at least about 90%, or at least about 95%) homologous or identical to the amino acid sequence set forth in SEQ ID NO: 100. For example, the extracellular antigen-binding domain of the CLEC12A-targeted chimeric receptor (*e.g.*, a CLEC12A-targeted scFv) comprises a V_H comprising an amino acid sequence that is about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99% or about 100% homologous or identical to SEQ ID NO: 100. In certain embodiments, the extracellular antigen-binding domain of the CLEC12A-targeted chimeric receptor comprises a V_H comprising the amino acid sequence set forth in SEQ ID NO: 100. SEQ ID NO: 100 is provided in Table 11 below.

In certain embodiments, the extracellular antigen-binding domain of the CLEC12A-targeted chimeric receptor (*e.g.*, a CLEC12A-targeted scFv) comprises a V_L comprising an amino acid sequence that is at least about 80% (*e.g.*, at least about 85%, at least about 90%, or at

least about 95%) homologous or identical to the amino acid sequence set forth in SEQ ID NO: 101. For example, the extracellular antigen-binding domain of the CLEC12A-targeted chimeric receptor (*e.g.*, a CLEC12A-targeted scFv) comprises a V_L comprising an amino acid sequence that is about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99% or about 100% homologous or identical to SEQ ID NO: 101. In certain embodiments, the extracellular antigen-binding domain of the CLEC12A-targeted chimeric receptor comprises a V_L comprising the amino acid sequence set forth in SEQ ID NO: 101. SEQ ID NO: 101 is provided in Table 11 below.

In certain embodiments, the extracellular antigen-binding domain of the CLEC12A-targeted chimeric receptor (*e.g.*, a CLEC12A-targeted scFv) comprises a V_H comprising the amino acid sequence set forth in SEQ ID NO: 100, and a V_L comprising the amino acid sequence set forth in SEQ ID NO: 101. In certain embodiments, the V_H and V_L are linked via a linker. In certain embodiments, the linker comprises the amino acid sequence set forth in SEQ ID NO: 149. In certain embodiments, the linker comprises the amino acid sequence set forth in SEQ ID NO: 2.

In certain embodiments, the variable regions within the extracellular antigen-binding domain of the CLEC12A-targeted chimeric receptor have to be linked one after another such that at the N-terminus of the extracellular antigen-binding domain, a heavy chain variable region (V_H) is positioned. In certain embodiments, if the extracellular antigen-binding domain of the CLEC12A-targeted chimeric receptor is an scFv, the variable regions are positioned from the N- to the C-terminus: V_H-V_L. In certain embodiments, the CLEC12A-targeted scFv comprises the amino acid sequence set forth in SEQ ID NO: 102, which is provided in Table 11. In certain embodiments, the CLEC12A-targeted scFv is designated as “CLEC12A-D”. The CDRs provided in Table 11 are identified according to the IMGT numbering system.

Table 11 (CLEC12A-D)

CDRs	1	2	3
V _H	GFTFSSYG [SEQ ID NO: 89]	ISYDGSDK [SEQ ID NO: 90]	ARDGSRYFDY [SEQ ID NO: 98]
V _L	QSVHISKY [SEQ ID NO: 99]	GAS [SEQ ID NO: 93]	QQDYNLPIT [SEQ ID NO: 151]
Full V _H	QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVISYDGSDKY SADS VKGRFNISRDN SKNTLYLQMN SLRAEDTAVYYCARDGSRYFDYWGQGTLT VSS [SEQ ID NO: 100]		
Full V _L	EIFMTQSPATLSLSPGERATLSCRASQSVHISKYLSWYQQKPGQAPSLLIYGASTRATGI PARFSGSGSGTDFTLTISSLQPEDFAVYYCQQDYNLPITFGQGRLEIK [SEQ ID NO: 101]		

V _H -V _L scFv	QVQLVESGGGVVQPGKSLRLSCAASGFTFSSYGMHWVRQAPGKLEWVAVISYDGSDKY SADSVKGRFNI SRDNSKNTLYLQMNSLRAEDTAVYYCARDGSRFYFDYWGQGLTVTVSSA STGGGGSGGGSGGGGSEIFMTQSPATLSLSPGERATLSCRASQSVHSKYLSWYQQKPG QAPSLLIYGASTRATGIPAREFSGSGSGTDFTLTITSSLPEDFAVYYCQQDYNLPITFGQ GTRLEIK [SEQ ID NO: 102]
--	---

In certain embodiments, the extracellular antigen-binding domain of the CLEC12A-targeted chimeric receptor (*e.g.*, a CLEC12A-targeted scFv) comprises a V_H CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 81 or a conservative modification thereof, a

5 V_H CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 103 or a conservative modification thereof, and a V_H CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 83 or a conservative modification thereof. SEQ ID NOs: 81, 83, and 103 are provided in Table 12.

In certain embodiments, the extracellular antigen-binding domain of the CLEC12A-targeted chimeric receptor (*e.g.*, a CLEC12A-targeted scFv) comprises a V_L CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 104 or a conservative modification thereof, a

10 V_L CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 73 or a conservative modification thereof, and a V_L CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 105 or a conservative modification thereof. SEQ ID NOs: 73, 104, and 105 are provided in

15 Table 12.

In certain embodiments, the extracellular antigen-binding domain of the CLEC12A-targeted chimeric receptor (*e.g.*, a CLEC12A-targeted scFv) comprises a V_H CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 81 or a conservative modification thereof, a

20 V_H CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 103 or a conservative modification thereof, a V_H CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 83 or a conservative modification thereof, a V_L CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 104 or a conservative modification thereof, a V_L CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 73 or a conservative modification, and a V_L CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 105 or a conservative

25 modification thereof.

In certain embodiments, the extracellular antigen-binding domain of the CLEC12A-targeted chimeric receptor (*e.g.*, a CLEC12A-targeted scFv) comprises a V_H CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 81, a V_H CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 103, a V_H CDR3 comprising the amino acid sequence set

30 forth in SEQ ID NO: 83, a V_L CDR1 comprising the amino acid sequence set forth in SEQ ID

NO: 104, a V_L CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 73, and a V_L CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 105.

In certain embodiments, the extracellular antigen-binding domain of the CLEC12A-targeted chimeric receptor (*e.g.*, a CLEC12A-targeted scFv) comprises a V_H comprising an amino acid sequence that is at least about 80% (*e.g.*, at least about 85%, at least about 90%, or at least about 95%) homologous or identical to the amino acid sequence set forth in SEQ ID NO: 106. For example, the extracellular antigen-binding domain of the CLEC12A-targeted chimeric receptor (*e.g.*, a CLEC12A-targeted scFv) comprises a V_H comprising an amino acid sequence that is about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99% or about 100% homologous or identical to SEQ ID NO: 106. In certain embodiments, the extracellular antigen-binding domain of the CLEC12A-targeted chimeric receptor comprises a V_H comprising the amino acid sequence set forth in SEQ ID NO: 106. SEQ ID NO: 106 is provided in Table 12 below.

In certain embodiments, the extracellular antigen-binding domain of the CLEC12A-targeted chimeric receptor (*e.g.*, a CLEC12A-targeted scFv) comprises a V_L comprising an amino acid sequence that is at least about 80% (*e.g.*, at least about 85%, at least about 90%, or at least about 95%) homologous or identical to the amino acid sequence set forth in SEQ ID NO: 107. For example, the extracellular antigen-binding domain of the CLEC12A-targeted chimeric receptor (*e.g.*, a CLEC12A-targeted scFv) comprises a V_L comprising an amino acid sequence that is about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99% or about 100% homologous or identical to SEQ ID NO: 107. In certain embodiments, the extracellular antigen-binding domain of the CLEC12A-targeted chimeric receptor comprises a V_L comprising the amino acid sequence set forth in SEQ ID NO: 107. SEQ ID NO: 107 is provided in Table 12 below.

In certain embodiments, the extracellular antigen-binding domain of the CLEC12A-targeted chimeric receptor (*e.g.*, a CLEC12A-targeted scFv) comprises a V_H comprising the amino acid sequence set forth in SEQ ID NO: 106, and a V_L comprising the amino acid sequence set forth in SEQ ID NO: 107. In certain embodiments, the V_H and V_L are linked via a linker. In certain embodiments, the linker comprises the amino acid sequence set forth in SEQ ID NO: 149. In certain embodiments, the linker comprises the amino acid sequence set forth in SEQ ID NO: 2.

In certain embodiments, the variable regions within the extracellular antigen-binding domain of the CLEC12A-targeted chimeric receptor have to be linked one after another such that at the N-terminus of the extracellular antigen-binding domain, a heavy chain variable region (V_H) is positioned. In certain embodiments, if the extracellular antigen-binding domain of the CLEC12A-targeted chimeric receptor is an scFv, the variable regions are positioned from the N- to the C-terminus: V_H-V_L. In certain embodiments, the CLEC12A-targeted scFv comprises the amino acid sequence set forth in SEQ ID NO: 108, which is provided in Table 12. In certain embodiments, the CLEC12A-targeted scFv is designated as “CLEC12A-E”. The CDRs provided in Table 12 are identified according to the IMGT numbering system.

Table 12 (CLEC12A-E)

CDRs	1	2	3
V _H	GGSISTYY [SEQ ID NO: 81]	IYFSGST [SEQ ID NO: 103]	AREDY YGSGSPFDY [SEQ ID NO: 83]
V _L	QGIRND [SEQ ID NO: 104]	AAS [SEQ ID NO: 73]	LQDYNYPRT [SEQ ID NO: 105]
Full V _H	QVQLQESGPGLVKPSSETLSLTCTVSGGSISTYYWSWIRQPPGKGLEWLGYYIFSGSTNY NPSLKSRLTISVAASKSQFSLKLSSVTAADTAVYYCAREDY YGSGSPFDYWGQGTLVTVSS [SEQ ID NO: 106]		
Full V _L	AIQMTQSPSSLSASVGDRVTITCRASQGIRNDLGWFQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTYFTLTISLQPEDSATYYCLQDYNYPRTFGQGTKVEIK [SEQ ID NO: 107]		
V _H -V _L scFv	QVQLQESGPGLVKPSSETLSLTCTVSGGSISTYYWSWIRQPPGKGLEWLGYYIFSGSTNY NPSLKSRLTISVAASKSQFSLKLSSVTAADTAVYYCAREDY YGSGSPFDYWGQGTLVTVSSASTGGGSGGGGSGGGGSAIQMTQSPSSLSASVGDRVTITCRASQGIRNDLGWFQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTYFTLTISLQPEDSATYYCLQDYNYPRTFGQGTKVEIK [SEQ ID NO: 108]		

In certain embodiments, the extracellular antigen-binding domain of the CLEC12A-targeted chimeric receptor (*e.g.*, a CLEC12A-targeted scFv) comprises a V_H CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 109 or a conservative modification thereof, a V_H CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 103 or a conservative modification thereof, and a V_H CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 83 or a conservative modification thereof. SEQ ID NOs: 83, 103, and 109 are provided in Table 13.

In certain embodiments, the extracellular antigen-binding domain of the CLEC12A-targeted chimeric receptor (*e.g.*, a CLEC12A-targeted scFv) comprises a V_L CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 110 or a conservative modification thereof, a V_L CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 73 or a conservative modification thereof, and a V_L CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 85 or a conservative modification thereof. SEQ ID NOs: 73, 85, and 110 are provided in Table 13.

In certain embodiments, the extracellular antigen-binding domain of the CLEC12A-targeted chimeric receptor (*e.g.*, a CLEC12A-targeted scFv) comprises a V_H CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 109 or a conservative modification thereof, a V_H CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 103 or a conservative modification thereof, a V_H CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 83 or a conservative modification thereof, a V_L CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 110 or a conservative modification thereof, a V_L CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 73 or a conservative modification, and a V_L CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 85 or a conservative modification thereof.

In certain embodiments, the extracellular antigen-binding domain of the CLEC12A-targeted chimeric receptor (*e.g.*, a CLEC12A-targeted scFv) comprises a V_H CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 109, a V_H CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 103, a V_H CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 83, a V_L CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 110, a V_L CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 73, and a V_L CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 85.

In certain embodiments, the extracellular antigen-binding domain of the CLEC12A-targeted chimeric receptor (*e.g.*, a CLEC12A-targeted scFv) comprises a V_H comprising an amino acid sequence that is at least about 80% (*e.g.*, at least about 85%, at least about 90%, or at least about 95%) homologous or identical to the amino acid sequence set forth in SEQ ID NO: 111. For example, the extracellular antigen-binding domain of the CLEC12A-targeted chimeric receptor (*e.g.*, a CLEC12A-targeted scFv) comprises a V_H comprising an amino acid sequence that is about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99% or about 100% homologous or identical to SEQ ID NO: 111. In certain embodiments, the extracellular antigen-binding domain of the CLEC12A-targeted chimeric receptor comprises a V_H comprising the amino acid sequence set forth in SEQ ID NO: 111. SEQ ID NO: 111 is provided in Table 13 below.

In certain embodiments, the extracellular antigen-binding domain of the CLEC12A-targeted chimeric receptor (*e.g.*, a CLEC12A-targeted scFv) comprises a V_L comprising an amino acid sequence that is at least about 80% (*e.g.*, at least about 85%, at least about 90%, or at least about 95%) homologous or identical to the amino acid sequence set forth in SEQ ID NO: 112. For example, the extracellular antigen-binding domain of the CLEC12A-targeted chimeric

receptor (*e.g.*, a CLEC12A-targeted scFv) comprises a V_L comprising an amino acid sequence that is about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99% or about 100% homologous or identical to SEQ ID NO: 112. In certain embodiments, the extracellular antigen-binding domain of the CLEC12A-targeted chimeric receptor comprises a V_L comprising the amino acid sequence set forth in SEQ ID NO: 112. SEQ ID NO: 112 is provided in Table 13 below.

In certain embodiments, the extracellular antigen-binding domain of the CLEC12A-targeted chimeric receptor (*e.g.*, a CLEC12A-targeted scFv) comprises a V_H comprising the amino acid sequence set forth in SEQ ID NO: 111, and a V_L comprising the amino acid sequence set forth in SEQ ID NO: 112. In certain embodiments, the V_H and V_L are linked via a linker. In certain embodiments, the linker comprises the amino acid sequence set forth in SEQ ID NO: 149. In certain embodiments, the linker comprises the amino acid sequence set forth in SEQ ID NO: 2.

In certain embodiments, the variable regions within the extracellular antigen-binding domain of the CLEC12A-targeted chimeric receptor have to be linked one after another such that at the N-terminus of the extracellular antigen-binding domain, a heavy chain variable region (V_H) is positioned. In certain embodiments, if the extracellular antigen-binding domain of the CLEC12A-targeted chimeric receptor is an scFv, the variable regions are positioned from the N- to the C-terminus: V_H-V_L. In certain embodiments, the CLEC12A-targeted scFv comprises the amino acid sequence set forth in SEQ ID NO: 113, which is provided in Table 13. In certain embodiments, the CLEC12A-targeted scFv is designated as “CLEC12A-F”. The CDRs provided in Table 13 are identified according to the IMGT numbering system.

Table 13 (CLEC12A-F)

CDRs	1	2	3
V _H	GGISTDY [SEQ ID NO: 109]	IYFSGST [SEQ ID NO: 103]	AREDDYGGSPFDY [SEQ ID NO: 83]
V _L	QDIRND [SEQ ID NO: 110]	AAS [SEQ ID NO: 73]	LQDYNFPRT [SEQ ID NO: 85]
Full V _H	QVQLQESGPGLVKPSSETLSLTCTVSGGSISTDYWSWIRQPPGKGLEWIGYIYFSGSTKY NPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCAREDDYGGSPFDYWGQGTIVTVSS [SEQ ID NO: 111]		
Full V _L	AIQMTQSPSSLSASVGDRVTITCRASQDIRNDLGWFQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISLQPEDFATYYCLQDYNFPRTFGQGTKVEIK [SEQ ID NO: 112]		
V _H -V _L scFv	QVQLQESGPGLVKPSSETLSLTCTVSGGSISTDYWSWIRQPPGKGLEWIGYIYFSGSTKY NPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCAREDDYGGSPFDYWGQGTIVTVSSASTGGGGSGGGSGGGSAIQMTQSPSSLSASVGDRVTITCRASQDIRNDLGWFQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISLQPEDFATYYCLQDYNFPRTFGQGTKVEIK [SEQ ID NO: 113]		

In certain embodiments, the extracellular antigen-binding domain of the CLEC12A-targeted chimeric receptor (*e.g.*, a CLEC12A-targeted scFv) comprises a V_H CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 89 or a conservative modification thereof, a V_H CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 90 or a conservative
5 modification thereof, and a V_H CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 114 or a conservative modification thereof. SEQ ID NOs: 89, 90, and 114 are provided in Table 14.

In certain embodiments, the extracellular antigen-binding domain of the CLEC12A-targeted chimeric receptor (*e.g.*, a CLEC12A-targeted scFv) comprises a V_L CDR1 comprising
10 the amino acid sequence set forth in SEQ ID NO: 115 or a conservative modification thereof, a V_L CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 93 or a conservative modification thereof, and a V_L CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 116 or a conservative modification thereof. SEQ ID NOs: 93, 115, and 116 are provided in Table 14.

15 In certain embodiments, the extracellular antigen-binding domain of the CLEC12A-targeted chimeric receptor (*e.g.*, a CLEC12A-targeted scFv) comprises a V_H CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 89 or a conservative modification thereof, a V_H CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 90 or a conservative modification thereof, a V_H CDR3 comprising the amino acid sequence set forth in SEQ ID NO:
20 114 or a conservative modification thereof, a V_L CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 115 or a conservative modification thereof, a V_L CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 93 or a conservative modification, and a V_L CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 116 or a conservative modification thereof.

25 In certain embodiments, the extracellular antigen-binding domain of the CLEC12A-targeted chimeric receptor (*e.g.*, a CLEC12A-targeted scFv) comprises a V_H CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 89, a V_H CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 90, a V_H CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 114, a V_L CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
30 115, a V_L CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 93, and a V_L CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 116.

In certain embodiments, the extracellular antigen-binding domain of the CLEC12A-targeted chimeric receptor (*e.g.*, a CLEC12A-targeted scFv) comprises a V_H comprising an amino acid sequence that is at least about 80% (*e.g.*, at least about 85%, at least about 90%, or at

least about 95%) homologous or identical to the amino acid sequence set forth in SEQ ID NO: 117. For example, the extracellular antigen-binding domain of the CLEC12A-targeted chimeric receptor (*e.g.*, a CLEC12A-targeted scFv) comprises a V_H comprising an amino acid sequence that is about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99% or about 100% homologous or identical to SEQ ID NO: 117. In certain embodiments, the extracellular antigen-binding domain of the CLEC12A-targeted chimeric receptor comprises a V_H comprising the amino acid sequence set forth in SEQ ID NO: 117. SEQ ID NO: 117 is provided in Table 14 below.

In certain embodiments, the extracellular antigen-binding domain of the CLEC12A-targeted chimeric receptor (*e.g.*, a CLEC12A-targeted scFv) comprises a V_L comprising an amino acid sequence that is at least about 80% (*e.g.*, at least about 85%, at least about 90%, or at least about 95%) homologous or identical to the amino acid sequence set forth in SEQ ID NO: 118. For example, the extracellular antigen-binding domain of the CLEC12A-targeted chimeric receptor (*e.g.*, a CLEC12A-targeted scFv) comprises a V_L comprising an amino acid sequence that is about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99% or about 100% homologous or identical to SEQ ID NO: 118. In certain embodiments, the extracellular antigen-binding domain of the CLEC12A-targeted chimeric receptor comprises a V_L comprising the amino acid sequence set forth in SEQ ID NO: 118. SEQ ID NO: 118 is provided in Table 14 below.

In certain embodiments, the extracellular antigen-binding domain of the CLEC12A-targeted chimeric receptor (*e.g.*, a CLEC12A-targeted scFv) comprises a V_H comprising the amino acid sequence set forth in SEQ ID NO: 117, and a V_L comprising the amino acid sequence set forth in SEQ ID NO: 118. In certain embodiments, the V_H and V_L are linked via a linker. In certain embodiments, the linker comprises the amino acid sequence set forth in SEQ ID NO: 149. In certain embodiments, the linker comprises the amino acid sequence set forth in SEQ ID NO: 2.

In certain embodiments, the variable regions within the extracellular antigen-binding domain of the CLEC12A-targeted chimeric receptor have to be linked one after another such that at the N-terminus of the extracellular antigen-binding domain, a heavy chain variable region (V_H) is positioned. In certain embodiments, if the extracellular antigen-binding domain of the CLEC12A-targeted chimeric receptor is an scFv, the variable regions are positioned from the N- to the C-terminus: V_H-V_L. In certain embodiments, the CLEC12A-targeted scFv comprises the

amino acid sequence set forth in SEQ ID NO: 119, which is provided in Table 14. In certain embodiments, the CLEC12A-targeted scFv is designated as “CLEC12A-G”. The CDRs provided in Table 14 are identified according to the IMGT numbering system.

Table 14 (CLEC12A-G)

CDRs	1	2	3
V _H	GFTFSSYG [SEQ ID NO: 89]	ISYDGSDK [SEQ ID NO: 90]	ARDGQFYFDY [SEQ ID NO: 114]
V _L	QSVTSRY [SEQ ID NO: 115]	GAS [SEQ ID NO: 93]	QQDYNLPLT [SEQ ID NO: 116]
Full V _H	QVQLVESGGGVVQPGKSLRLSCAASGFTFSSYGMHWVRQAPGEGLEWTVISYDGSDKY YADSVKGRFTISRDNKSTLFLQMNSLRAEDTAVYYCARDGQFYFDYWGQGLTVTVSS [SEQ ID NO: 117]		
Full V _L	EIVMTQSPATLSLSPGESATLSCRASQSVTSRYLSWYQQKPGQAPRLMYGASTRPTGI PARFSGSGSGTDFTLTISLQPEDFAVYYCQQDYNLPLTFGGGTKVEIK [SEQ ID NO: 118]		
V _H -V _L scFv	QVQLVESGGGVVQPGKSLRLSCAASGFTFSSYGMHWVRQAPGEGLEWTVISYDGSDKY YADSVKGRFTISRDNKSTLFLQMNSLRAEDTAVYYCARDGQFYFDYWGQGLTVTVSSA STGGGSGGGSGGGSGGGSEIVMTQSPATLSLSPGESATLSCRASQSVTSRYLSWYQQKPG QAPRLMYGASTRPTGI PARFSGSGSGTDFTLTISLQPEDFAVYYCQQDYNLPLTFGG GTKVEIK [SEQ ID NO: 119]		

5

In certain embodiments, the extracellular antigen-binding domain of the CLEC12A-targeted chimeric receptor (*e.g.*, a CLEC12A-targeted scFv) comprises a V_H CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 120 or a conservative modification thereof, a V_H CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 121 or a conservative modification thereof, and a V_H CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 122 or a conservative modification thereof. SEQ ID NOs: 120-122 are provided in Table 15.

In certain embodiments, the extracellular antigen-binding domain of the CLEC12A-targeted chimeric receptor (*e.g.*, a CLEC12A-targeted scFv) comprises a V_L CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 123 or a conservative modification thereof, a V_L CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 124 or a conservative modification thereof, and a V_L CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 125 or a conservative modification thereof. SEQ ID NOs: 123-125 are provided in Table 15.

In certain embodiments, the extracellular antigen-binding domain of the CLEC12A-targeted chimeric receptor (*e.g.*, a CLEC12A-targeted scFv) comprises a V_H CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 120 or a conservative modification thereof, a V_H CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 121 or a conservative modification thereof, a V_H CDR3 comprising the amino acid sequence set forth in SEQ ID NO:

122 or a conservative modification thereof, a V_L CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 123 or a conservative modification thereof, a V_L CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 124 or a conservative modification, and a V_L CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 125 or a conservative
 5 modification thereof.

In certain embodiments, the extracellular antigen-binding domain of the CLEC12A-targeted chimeric receptor (*e.g.*, a CLEC12A-targeted scFv) comprises a V_H CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 120, a V_H CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 121, a V_H CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 122, a V_L CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 123, a V_L CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 124, and a V_L CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 125.
 10

In certain embodiments, the extracellular antigen-binding domain of the chimeric receptor (*e.g.*, an scFv) comprises a V_H comprising an amino acid sequence that is at least about 80% (*e.g.*, at least about 85%, at least about 90%, or at least about 95%) homologous or
 15 identical to the amino acid sequence set forth in SEQ ID NO: 126. For example, the extracellular antigen-binding domain of the chimeric receptor (*e.g.*, an scFv) comprises a V_H comprising an amino acid sequence that is about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about
 20 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99% or about 100% homologous or identical to SEQ ID NO: 126. In certain embodiments, the extracellular antigen-binding domain comprises a V_H comprising the amino acid sequence set forth in SEQ ID NO: 126. SEQ ID NO: 126 is provided in Table 15 below.

In certain embodiments, the extracellular antigen-binding domain of the chimeric
 25 receptor (*e.g.*, an scFv) comprises a V_L comprising an amino acid sequence that is at least about 80% (*e.g.*, at least about 85%, at least about 90%, or at least about 95%) homologous or identical to the amino acid sequence set forth in SEQ ID NO: 127. For example, the extracellular antigen-binding domain of the chimeric receptor (*e.g.*, an scFv) comprises a V_L comprising an amino acid sequence that is about 80%, about 81%, about 82%, about 83%, about
 30 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99% or about 100% homologous or identical to SEQ ID NO: 127. In certain embodiments, the extracellular antigen-binding domain comprises a V_L comprising the amino acid sequence set forth in SEQ ID NO: 127. SEQ ID NO: 127 is provided in Table 15 below.

In certain embodiments, the extracellular antigen-binding domain of the CLEC12A-targeted chimeric receptor (*e.g.*, a CLEC12A-targeted scFv) comprises a V_H comprising the amino acid sequence set forth in SEQ ID NO: 126, and a V_L comprising the amino acid sequence set forth in SEQ ID NO: 127. In certain embodiments, the V_H and V_L are linked via a linker. In certain embodiments, the linker comprises the amino acid sequence set forth in SEQ ID NO: 149. In certain embodiments, the linker comprises the amino acid sequence set forth in SEQ ID NO: 2.

In certain embodiments, the variable regions within the extracellular antigen-binding domain of the CLEC12A-targeted chimeric receptor have to be linked one after another such that at the N-terminus of the extracellular antigen-binding domain, a heavy chain variable region (V_H) is positioned. In certain embodiments, if the extracellular antigen-binding domain of the CLEC12A-targeted chimeric receptor is an scFv, the variable regions are positioned from the N- to the C-terminus: V_H-V_L. In certain embodiments, the CLEC12A-targeted scFv comprises the amino acid sequence set forth in SEQ ID NO: 128, which is provided in Table 15. In certain embodiments, the CLEC12A-targeted scFv is designated as “CLEC12A-H”. The CDRs provided in Table 15 are identified according to the IMGT numbering system.

Table 15 (CLEC12A-H)

CDRs	1	2	3
V _H	GFTFSNYG [SEQ ID NO: 120]	ISYDGSDK [SEQ ID NO: 121]	ARDSGRYFFDY [SEQ ID NO: 122]
V _L	QSVSSRS [SEQ ID NO: 123]	GPS [SEQ ID NO: 124]	HQDYNLPLT [SEQ ID NO: 125]
Full V _H	QVQLVESGGGVVQPGRSLRLSCAASGFTFSNYGMHWVRQAPGKGLEWVAVISYDGSDKSYKDSVKGRFTIARDNSKNTLYLQMNSLRAEDTAVYYCARDSGRYFFDYWGQGTTLTVSS [SEQ ID NO: 126]		
Full V _L	EIIMTQSPATLSLSPGERATLSCRASQSVSSRSLSWYQHKGQAPRLIIYGPSTRATGIPAREFGSGSGTDFTLTISSLQPEDFAVYYCHQDYNLPLTFGGGKVEIK [SEQ ID NO: 127]		
V _H -V _L scFv	QVQLVESGGGVVQPGRSLRLSCAASGFTFSNYGMHWVRQAPGKGLEWVAVISYDGSDKSYKDSVKGRFTIARDNSKNTLYLQMNSLRAEDTAVYYCARDSGRYFFDYWGQGTTLTVSSASTGGGGSGGGSGGGGSEIIMTQSPATLSLSPGERATLSCRASQSVSSRSLSWYQHKPGQAPRLIIYGPSTRATGIPAREFGSGSGTDFTLTISSLQPEDFAVYYCHQDYNLPLTFGGGKVEIK [SEQ ID NO: 128]		

In certain embodiments, the extracellular antigen-binding domain of the CLEC12A-targeted chimeric receptor (*e.g.*, a CLEC12A-targeted scFv) comprises a V_H CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 129 or a conservative modification thereof, a V_H CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 130 or a conservative modification thereof, and a V_H CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 131 or a conservative modification thereof. SEQ ID NOs: 129-131 are provided in Table 16.

In certain embodiments, the extracellular antigen-binding domain of the CLEC12A-targeted chimeric receptor (*e.g.*, a CLEC12A-targeted scFv) comprises a V_L CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 132 or a conservative modification thereof, a V_L CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 133 or a conservative modification thereof, and a V_L CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 134 or a conservative modification thereof. SEQ ID NOs: 132-134 are provided in Table 16.

In certain embodiments, the extracellular antigen-binding domain of the CLEC12A-targeted chimeric receptor (*e.g.*, a CLEC12A-targeted scFv) comprises a V_H CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 129 or a conservative modification thereof, a V_H CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 130 or a conservative modification thereof, a V_H CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 131 or a conservative modification thereof, a V_L CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 132 or a conservative modification thereof, a V_L CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 133 or a conservative modification, and a V_L CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 134 or a conservative modification thereof.

In certain embodiments, the extracellular antigen-binding domain of the CLEC12A-targeted chimeric receptor (*e.g.*, a CLEC12A-targeted scFv) comprises a V_H CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 129, a V_H CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 130, a V_H CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 131, a V_L CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 132, a V_L CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 133, and a V_L CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 134.

In certain embodiments, the extracellular antigen-binding domain of the CLEC12A-targeted chimeric receptor (*e.g.*, a CLEC12A-targeted scFv) comprises a V_H comprising an amino acid sequence that is at least about 80% (*e.g.*, at least about 85%, at least about 90%, or at least about 95%) homologous or identical to the amino acid sequence set forth in SEQ ID NO: 135. For example, the extracellular antigen-binding domain of the CLEC12A-targeted chimeric receptor (*e.g.*, a CLEC12A-targeted scFv) comprises a V_H comprising an amino acid sequence that is about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99% or about 100% homologous or identical to SEQ ID NO: 135. In certain embodiments, the extracellular antigen-binding domain of the

CLEC12A-targeted chimeric receptor comprises a V_H comprising the amino acid sequence set forth in SEQ ID NO: 135. SEQ ID NO: 135 is provided in Table 16 below.

In certain embodiments, the extracellular antigen-binding domain of the CLEC12A-targeted chimeric receptor (*e.g.*, a CLEC12A-targeted scFv) comprises a V_L comprising an amino acid sequence that is at least about 80% (*e.g.*, at least about 85%, at least about 90%, or at least about 95%) homologous or identical to the amino acid sequence set forth in SEQ ID NO: 136. For example, the extracellular antigen-binding domain of the CLEC12A-targeted chimeric receptor (*e.g.*, a CLEC12A-targeted scFv) comprises a V_L comprising an amino acid sequence that is about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99% or about 100% homologous or identical to SEQ ID NO: 136. In certain embodiments, the extracellular antigen-binding domain of the CLEC12A-targeted chimeric receptor comprises a V_L comprising the amino acid sequence set forth in SEQ ID NO: 136. SEQ ID NO: 136 is provided in Table 16 below.

In certain embodiments, the extracellular antigen-binding domain of the CLEC12A-targeted chimeric receptor (*e.g.*, a CLEC12A-targeted scFv) comprises a V_H comprising the amino acid sequence set forth in SEQ ID NO: 135, and a V_L comprising the amino acid sequence set forth in SEQ ID NO: 136. In certain embodiments, the V_H and V_L are linked via a linker. In certain embodiments, the linker comprises the amino acid sequence set forth in SEQ ID NO: 149. In certain embodiments, the linker comprises the amino acid sequence set forth in SEQ ID NO: 2.

In certain embodiments, the variable regions within the extracellular antigen-binding domain of the CLEC12A-targeted chimeric receptor have to be linked one after another such that at the N-terminus of the extracellular antigen-binding domain, a heavy chain variable region (V_H) is positioned. In certain embodiments, if the extracellular antigen-binding domain of the CLEC12A-targeted chimeric receptor is an scFv, the variable regions are positioned from the N- to the C-terminus: V_H-V_L. In certain embodiments, the scFv comprises the amino acid sequence set forth in SEQ ID NO: 137, which is provided in Table 16. In certain embodiments, the CLEC12A-targeted scFv is designated as “CLEC12A-J”. The CDRs provided in Table 16 are identified according to the IMGT numbering system.

Table 16 (CLEC12A-J)

CDRs	1	2	3
V _H	GFTFSKYG [SEQ ID NO: 129]	IWYDGSIK [SEQ ID NO: 130]	ARGSLWFGEFYFDY [SEQ ID NO: 131]

V _L	QGISSA [SEQ ID NO: 132]	DAS [SEQ ID NO: 133]	QQFNYPRT [SEQ ID NO: 134]
Full V _H	QVKLVESGGGVVQPGRSRLRLSCAASGFTFSKYGMHWVRQAPGKGLEWVAFIWDGSIKN YADSVKGRFTTSRDNSKNTLYLQMNSLRAEDTAVYYCARGSLWFGGEFYFDYWGQGTTLVT VSS [SEQ ID NO: 135]		
Full V _L	AIQLTQSPSSLSASVGDRTITCRTSQGISSALAWYQQKPGKTPKLLIYDASSLESGVP SRFSGSGSGTDFTLTISLQPEDFATYYCQQFNYPRTFGQGTKVEIK [SEQ ID NO: 136]		
V _H -V _L scFv	QVKLVESGGGVVQPGRSRLRLSCAASGFTFSKYGMHWVRQAPGKGLEWVAFIWDGSIKN YADSVKGRFTTSRDNSKNTLYLQMNSLRAEDTAVYYCARGSLWFGGEFYFDYWGQGTTLVT VSSASTGGGGSGGGSGGGGSAIQLTQSPSSLSASVGDRTITCRTSQGISSALAWYQQ KPGKTPKLLIYDASSLESGVPSRFSGSGSGTDFTLTISLQPEDFATYYCQQFNYPRT FGQGTKVEIK [SEQ ID NO: 137]		

The V_H and/or V_L amino acid sequences having at least about 80%, at least about 80%, at least about 85%, at least about 90%, or at least about 95% (*e.g.*, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, or about 99%) homology or identity to a specific sequence (*e.g.*, SEQ ID NO: 75, SEQ ID NO: 76, SEQ ID NO: 86, SEQ ID NO: 87, SEQ ID NO: 95, SEQ ID NO: 96, SEQ ID NO: 100, SEQ ID NO: 101, SEQ ID NO: 106, SEQ ID NO: 107, SEQ ID NO: 111, SEQ ID NO: 112, SEQ ID NO: 117, SEQ ID NO: 118, SEQ ID NO: 126, SEQ ID NO: 127, SEQ ID NO: 135, or SEQ ID NO: 136) may contain substitutions (*e.g.*, conservative substitutions), insertions, or deletions relative to the specified sequence(s), but retain the ability to bind to a target antigen (*e.g.*, CLEC12A). In certain embodiments, a total of 1 to 10 amino acids are substituted, inserted and/or deleted in a specific sequence (*e.g.*, SEQ ID NO: 75, SEQ ID NO: 76, SEQ ID NO: 86, SEQ ID NO: 87, SEQ ID NO: 95, SEQ ID NO: 96, SEQ ID NO: 100, SEQ ID NO: 101, SEQ ID NO: 106, SEQ ID NO: 107, SEQ ID NO: 111, SEQ ID NO: 112, SEQ ID NO: 117, SEQ ID NO: 118, SEQ ID NO: 126, SEQ ID NO: 127, SEQ ID NO: 135, or SEQ ID NO: 136). In certain embodiments, substitutions, insertions, or deletions occur in regions outside the CDRs (*e.g.*, in the FRs) of the extracellular antigen-binding domain. In certain embodiments, the extracellular antigen-binding domain comprises V_H and/or V_L sequence selected from SEQ ID NO: 75, SEQ ID NO: 76, SEQ ID NO: 86, SEQ ID NO: 87, SEQ ID NO: 95, SEQ ID NO: 96, SEQ ID NO: 100, SEQ ID NO: 101, SEQ ID NO: 106, SEQ ID NO: 107, SEQ ID NO: 111, SEQ ID NO: 112, SEQ ID NO: 117, SEQ ID NO: 118, SEQ ID NO: 126, SEQ ID NO: 127, SEQ ID NO: 135, or SEQ ID NO: 136, including post-translational modifications of that sequence (SEQ ID NO: 75, SEQ ID NO: 76, SEQ ID NO: 86, SEQ ID NO: 87, SEQ ID NO: 95, SEQ ID NO: 96, SEQ ID NO: 100, SEQ ID NO: 101, SEQ ID NO: 106, SEQ ID NO: 107, SEQ ID NO: 111, SEQ ID NO: 112, SEQ ID

NO: 117, SEQ ID NO: 118, SEQ ID NO: 126, SEQ ID NO: 127, SEQ ID NO: 135, or SEQ ID NO: 136).

In certain embodiments, the extracellular antigen-binding domain of a presently disclosed CLEC12A-targeted chimeric receptor cross-competes for binding to CLEC12A with a reference antibody or an antigen-binding fragment thereof comprising the V_H CDR1, CDR2, and CDR3 sequences and the V_L CDR1, CDR2, and CDR3 sequences of, for example, any one of the presently disclosed scFvs (*e.g.*, CLEC12A-A, CLEC12A-B, CLEC12A-C, CLEC12A-D, CLEC12A-E, CLEC12A-F, CLEC12A-G, CLEC12A-H, and CLEC12A-J). In certain embodiments, the extracellular antigen-binding domain of a presently disclosed chimeric receptor cross-competes for binding to CLEC12A with a reference antibody or an antigen-binding portion thereof comprising the V_H and V_L sequences of, for example, any one of the presently disclosed scFvs (*e.g.*, CLEC12A-A, CLEC12A-B, CLEC12A-C, CLEC12A-D, CLEC12A-E, CLEC12A-F, CLEC12A-G, CLEC12A-H, and CLEC12A-J).

In certain embodiments, the extracellular antigen-binding domain of a presently disclosed CLEC12A-targeted chimeric receptor cross-competes for binding to CLEC12A with a reference antibody or an antigen-binding portion thereof comprising the V_H CDR1, CDR2, and CDR3 sequences and the V_L CDR1, CDR2, and CDR3 sequences of scFv CLEC12A-A. For example, the extracellular antigen-binding domain of a presently disclosed CLEC12A-targeted chimeric receptor cross-competes for binding to CLEC12A with a reference antibody or an antigen-binding portion thereof comprising a V_H CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 69, a V_H CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 70; a V_H CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 71; a V_L CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 72; a V_L CDR2 comprising amino acids having the sequence set forth in SEQ ID NO: 73; and a V_L CDR3 comprising amino acids having the sequence set forth in SEQ ID NO: 74. In certain embodiments, the extracellular antigen-binding domain of a presently disclosed CLEC12A-targeted chimeric receptor cross-competes for binding to CLEC12A with a reference antibody or an antigen-binding portion thereof comprising the V_H and V_L sequences of scFv CLEC12A-A. For example, the extracellular antigen-binding domain of a presently disclosed CLEC12A-targeted chimeric receptor cross-competes for binding to CLEC12A with a reference antibody or an antigen-binding portion thereof comprising a V_H comprising amino acids having the sequence set forth in SEQ ID NO: 75, and a V_L comprising amino acids having the sequence set forth in SEQ ID NO: 76.

In certain embodiments, the extracellular antigen-binding domain of the presently disclosed CLEC12A-targeted chimeric receptors binds to the same epitope on CLEC12A as the reference antibody or antigen-binding portion thereof. For example, the extracellular antigen-binding domain of a presently disclosed CLEC12A-targeted chimeric receptor binds to the same epitope on CLEC12A as a reference antibody or an antigen-binding portion thereof comprising the V_H CDR1, CDR2, and CDR3 sequences and the V_L CDR1, CDR2, and CDR3 sequences of, for example, any one of the presently disclosed scFvs (*e.g.*, CLEC12A-A, CLEC12A-B, CLEC12A-C, CLEC12A-D, CLEC12A-E, CLEC12A-F, CLEC12A-G, CLEC12A-H, and CLEC12A-J). In certain embodiments, the extracellular antigen-binding domain of a presently disclosed CLEC12A-targeted chimeric receptor binds to the same epitope on CLEC12A as a reference antibody or an antigen-binding portion thereof comprising the V_H and V_L sequences of, for example, any one of the presently disclosed scFvs (*e.g.*, CLEC12A-A, CLEC12A-B, CLEC12A-C, CLEC12A-D, CLEC12A-E, CLEC12A-F, CLEC12A-G, CLEC12A-H, and CLEC12A-J).

In certain embodiments, the extracellular antigen-binding domain of a presently disclosed CLEC12A-targeted chimeric receptor binds to the same epitope on CLEC12A as a reference antibody or an antigen-binding fragment thereof comprising the V_H CDR1, CDR2, and CDR3 sequences and the V_L CDR1, CDR2, and CDR3 sequences of scFv CLEC12A-A. For example, the extracellular antigen-binding domain of a presently disclosed CLEC12A-targeted chimeric receptor binds to the same epitope on CLEC12A as a reference antibody or an antigen-binding fragment thereof comprising a V_H CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 69; a V_H CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 70; a V_H CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 71; a V_L CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 72; a V_L CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 73; and a V_L CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 74. In certain embodiments, the extracellular antigen-binding domain of a presently disclosed CLEC12A-targeted chimeric receptor binds to the same or substantially the same epitope on CLEC12A as a reference antibody or an antigen-binding fragment thereof comprising the V_H and V_L sequences of scFv CLEC12A-A. For example, the extracellular antigen-binding domain of a presently disclosed CLEC12A-targeted chimeric receptor binds to the same epitope on CLEC12A as a reference antibody or an antigen-binding fragment thereof comprising a V_H comprising the amino acid sequence set forth in SEQ ID NO: 75, and a V_L comprising the amino acid sequence set forth in SEQ ID NO: 76.

Extracellular antigen-binding domains of the presently disclosed CLEC12A-targeted chimeric receptors that cross-compete or compete with the reference antibody or antigen-binding portions thereof for binding to CLEC12A can be identified by using routine methods known in the art, e.g., those disclosed in Section 5.3.

5 In certain embodiments, the extracellular antigen-binding domain of the presently disclosed CLEC12A-targeted chimeric comprises a linker connecting the heavy chain variable region and light chain variable region of the extracellular antigen-binding domain. In certain embodiments, the linker comprises the amino acid sequence set forth in SEQ ID NO: 1. In certain embodiments, the linker comprises the amino acid sequence set forth in SEQ ID NO: 2. 10 In certain embodiments, the linker comprises the amino acid sequence set forth in SEQ ID NO: 3. In certain embodiments, the linker comprises the amino acid sequence set forth in SEQ ID NO: 4. In certain embodiments, the linker comprises the amino acid sequence set forth in SEQ ID NO: 5. In certain embodiments, the linker comprises the amino acid sequence set forth in SEQ ID NO: 6. In certain embodiments, the linker comprises the amino acid sequence set forth 15 in SEQ ID NO: 149.

 In certain embodiments, the variable regions within the extracellular antigen-binding domain of the CLEC12A-targeted chimeric receptor have to be linked one after another such that at the N-terminus of the extracellular antigen-binding domain, a heavy chain variable region (V_H) is positioned. In certain embodiments, if the extracellular antigen-binding domain of the 20 CLEC12A-targeted chimeric receptor is an scFv, the variable regions are positioned from the N- to the C-terminus: V_H - V_L .

 In certain embodiments, the variable regions within the extracellular antigen-binding domain of the CLEC12A-targeted chimeric receptor have to be linked one after another such that at the N-terminus of the extracellular antigen-binding domain, a light chain variable region 25 (V_L) is positioned. In certain embodiments, if the extracellular antigen-binding domain of the CLEC12A-targeted chimeric receptor is an scFv, the variable regions are positioned from the N- to the C-terminus: V_L - V_H .

 In addition, the CLEC12A-targeted chimeric receptor can comprise a leader or a signal peptide that directs the nascent protein into the endoplasmic reticulum. In certain embodiments, 30 the leader or signal peptide is positioned at (e.g., covalently joined to) the N-terminus of the extracellular antigen-binding domain of the CLEC12A-targeted chimeric receptor. In certain embodiments, the CLEC12A-targeted chimeric receptor comprises a leader or signal peptides disclosed in Section 5.3. In certain embodiments, the CLEC12A-targeted chimeric receptor comprises a signal peptide that comprises a CD8 polypeptide. In certain embodiments, the

CLEC12A-targeted chimeric receptor comprises a signal peptide that comprises a CD8 polypeptide comprising or consisting of the amino acid sequence set forth in SEQ ID NO: 63.

5.6. Exemplified CLEC12A-Targeted Chimeric Receptor

In certain embodiments, the CLEC12A-targeted chimeric receptor is a CCR. In certain
 5 embodiments, the CLEC12A-targeted CCR comprises (a) an extracellular antigen-binding domain comprising (i) a V_H that comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 69, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 70, and a V_H CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 71, and (ii) a V_L that comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 72, a
 10 CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 73, and a V_L CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 74; (b) an intracellular domain comprising a 4-1BB polypeptide (*e.g.*, a human 4-1BB polypeptide, *e.g.*, an intracellular domain of 4-1BB (*e.g.*, human 4-1BB) of a portion thereof). In certain embodiments, the CLEC12A-targeted CCR further comprises a transmembrane domain comprising a CD8 polypeptide (*e.g.*, a
 15 human CD8 polypeptide, *e.g.*, a transmembrane domain of CD8 (*e.g.*, human CD8) or a portion thereof). In certain embodiments, the intracellular domain comprises a 4-1BB polypeptide comprising or consisting of the amino acids 214 to 255 of SEQ ID NO: 30. In certain embodiments, the transmembrane domain comprises a CD8 polypeptide comprising or consisting of the amino acids 137 to 207 of SEQ ID NO: 7. In certain embodiments, the V_H and
 20 V_L are linked via a linker comprising or consisting of the amino acid sequence set forth in SEQ ID NO: 149. In certain embodiments, the V_H and V_L are positioned from the N- to the C-terminus: V_H-V_L. In certain embodiments, the extracellular antigen-binding domain and transmembrane domain are linked via a linker. In certain embodiments, the linker consists of the amino acid sequence set forth in SEQ ID NO: 150. In certain embodiments, the CLEC12A-
 25 targeted CCR comprises the amino acid sequence set forth in SEQ ID NO: 138, which is provided below.

QLQLQESGPGVLKPSSETLSLTCTVSGGSISSTYYGWIRQPPRKGLEWIGSTHYRGSTYYNPSLKSRVTISVDTSK
 NQFSLKVSSVTAADTAVYYCARELTGEVFDYWGQGLTVTVSSASTGGGGSGGGSGGGGSDIQMTQSPSSLSASVGD
 RVTITCRASQSISSYLNWYQQKPKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYST
 30 PFTFGPGTKVDIKRAAAPTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVL
 LLSLVITLYCNKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCEL [SEQ ID NO: 138]

An exemplary nucleic acid sequence the amino acid sequence of SEQ ID NO: 138 is set forth in SEQ ID NO: 139, which is provided below.

cagctccagctccaagagtcagggccaggtctcgtgaaaccgagtgagaccctgtccctgacctgcacagtgagtggtg
 35 tggatcaatctcaagctctacctactattgggggtggattcggcagccccctagaaaggggcttgagtggttgga

gcactcattatcgaggatctacctattataatccttctctgaaaagcagagttaccatctctgtggatacgtccaaa
aatcagttcagttcgaaggtatcatccgtgactgctgcccacacggccgtgtactattgcccagggagctgacagg
tgaggtctttgactactggggccagggcacactcgtgaccgtgtcttctgcctcaacaggaggggtgggagtgag
gcggtggatcagggggaggaggagtgacatccagatgacgcagtcctccagcttgctccgcatctgtgggtgat
5 aggtcacgattacatgtagggttagtcagagtatttctagttacctgaattggtaccagcagaaaccagggaaggg
accaaagttgtcatctatgcggcctcctctctgcaatctggcgtgcccgtccagatttagtggtatcaggctccggaa
ccgatttcacccttacgatctcctcacttcaaccgcaggatttcgccacatattactgtcaacaaagctattctaca
ccgttcaccttcggaccggggacaaaagtggatattaaacggggcgccgccccaccacgacgccagcgccgcgacc
accaaccccgccgcccacgatcgcgctcgagccctgtccctgcccagaggcggtgccggccagcgggggggcg
10 cagtgcacacaggggggctggacttcgcctgtgatatctacatctgggcgcccctggccgggacttggtgggtcctt
ctcctgtcactggttatccctttactgcaacaaacggggcagaaagaagctcctgtatatattcaacaaccatt
tatgagaccagtacaaactactcaagaggaagatggctgtagctgccgatttccagaagaagaaggaggatgtg
aactg [SEQ ID NO: 139]

In certain embodiments, the CLEC12A-targeted chimeric receptor comprises a signal
15 peptide at the N-terminus of the extracellular antigen-binding domain. In certain embodiments,
the signal peptide comprises a CD8 polypeptide comprising or consisting of the amino acid
sequence set forth in SEQ ID NO: 63.

5.7. Cells

The presently disclosed subject matter provides cells comprising a presently disclosed
20 ADGRE2-targeted chimeric receptor (*e.g.*, one disclosed in Sections 5.3 and 5.4). In addition,
the presently disclosed subject matter provides cells comprising a presently disclosed
CLEC12A-targeted chimeric receptor (*e.g.*, one disclosed in Sections 5.5 and 5.6).

In certain embodiments, the cell is selected from the group consisting of cells of
lymphoid lineage and cells of myeloid lineage. In certain embodiments, the cell is an
25 immunoresponsive cell. In certain embodiments, the immunoresponsive cell is a cell of
lymphoid lineage.

In certain embodiments, the cell is a cell of the lymphoid lineage. Cells of the lymphoid
lineage can provide production of antibodies, regulation of cellular immune system, detection of
foreign agents in the blood, detection of cells foreign to the host, and the like. Non-limiting
30 examples of cells of the lymphoid lineage include T cells, Natural Killer (NK) cells, B cells,
dendritic cells, stem cells from which lymphoid cells may be differentiated. In certain
embodiments, the stem cell is a pluripotent stem cell. In certain embodiments, the pluripotent
stem cell is an embryonic stem cell (ESC) or an induced pluripotent stem cell (iPSC).

In certain embodiments, the cell is a T cell. T cells can be lymphocytes that mature in
35 the thymus and are chiefly responsible for cell-mediated immunity. T cells are involved in the
adaptive immune system. The T cells of the presently disclosed subject matter can be any type

of T cells, including, but not limited to, helper T cells, cytotoxic T cells, memory T cells (including central memory T cells, stem-cell-like memory T cells (or stem-like memory T cells), and two types of effector memory T cells: *e.g.*, TEM cells and TEMRA cells, Regulatory T cells (also known as suppressor T cells), tumor-infiltrating lymphocyte (TIL), Natural killer T cells, 5 Mucosal associated invariant T cells, and $\gamma\delta$ T cells. Cytotoxic T cells (CTL or killer T cells) are a subset of T lymphocytes capable of inducing the death of infected somatic or tumor cells. A patient's own T cells may be genetically modified to target specific antigens through the introduction of a chimeric receptor, *e.g.*, a CAR or a CCR. In certain embodiments, the immunoresponsive cell is a T cell. The T cell can be a CD4⁺ T cell or a CD8⁺ T cell. In certain 10 embodiments, the T cell is a CD4⁺ T cell. In certain embodiments, the T cell is a CD8⁺ T cell.

In certain embodiments, the cell is a NK cell. Natural killer (NK) cells can be lymphocytes that are part of cell-mediated immunity and act during the innate immune response. NK cells do not require prior activation in order to perform their cytotoxic effect on target cells. In certain embodiments, the cell is a genetically modified NK cell. In certain embodiments, the 15 cell is an edited NK cell. In certain embodiments, the cell is a NK cell derived from a stem cell. In certain embodiments, the cell is a NK cell derived from a pluripotent stem cell. In certain embodiments, the cell is an induced pluripotent stem cell (iPSC)-derived NK cell.

Types of human lymphocytes of the presently disclosed subject matter include, without limitation, peripheral donor lymphocytes. *e.g.*, those disclosed in Sadelain et al., *Nat Rev Cancer* 20 (2003); 3:35-45 (disclosing peripheral donor lymphocytes genetically modified to express CARs), in Morgan, R.A., *et al.* 2006 *Science* 314:126-129 (disclosing peripheral donor lymphocytes genetically modified to express a full-length tumor antigen-recognizing T cell receptor complex comprising the α and β heterodimer), in Panelli et al., *J Immunol* (2000);164:495-504; Panelli et al., *J Immunol* (2000);164:4382-4392 (disclosing lymphocyte 25 cultures derived from tumor infiltrating lymphocytes (TILs) in tumor biopsies), and in Dupont et al., *Cancer Res* (2005);65:5417-5427; Papanicolaou et al., *Blood* (2003);102:2498-2505 (disclosing selectively *in vitro*-expanded antigen-specific peripheral blood leukocytes employing artificial antigen-presenting cells (AAPCs) or pulsed dendritic cells).

The cells (*e.g.*, T cells or NK cells) can be autologous, non-autologous (*e.g.*, allogeneic), 30 or derived *in vitro* from engineered progenitor or stem cells.

The cells of the presently disclosed subject matter can be cells of the myeloid lineage. Non-limiting examples of cells of the myeloid lineage include monocytes, macrophages, neutrophils, dendritic cells, basophils, neutrophils, eosinophils, megakaryocytes, mast cell, erythrocyte, thrombocytes, and stem cells from which myeloid cells may be differentiated. In

certain embodiments, the stem cell is a pluripotent stem cell (*e.g.*, an embryonic stem cell or an induced pluripotent stem cell).

In certain embodiments, the presently disclosed cells are capable of modulating the tumor microenvironment. Tumors have a microenvironment that is hostile to the host immune response involving a series of mechanisms by malignant cells to protect themselves from immune recognition and elimination. This “hostile tumor microenvironment” comprises a variety of immune suppressive factors including infiltrating regulatory CD4⁺ T cells (Tregs), myeloid derived suppressor cells (MDSCs), tumor associated macrophages (TAMs), immune suppressive cytokines including TGF- β , and expression of ligands targeted to immune suppressive receptors expressed by activated T cells (CTLA-4 and PD-1). These mechanisms of immune suppression play a role in the maintenance of tolerance and suppressing inappropriate immune responses, however within the tumor microenvironment these mechanisms prevent an effective anti-tumor immune response. Collectively these immune suppressive factors can induce either marked anergy or apoptosis of adoptively transferred modified T cells upon encounter with targeted tumor cells.

In certain embodiments, the cells can be transduced with the presently disclosed ADGRE2-targeted chimeric receptor and/or the presently disclosed CLEC12A-targeted chimeric receptor such that the cells express the chimeric receptor(s).

Furthermore, the presently disclosed subject matter provides cells comprising a presently disclosed ADGRE2-targeted chimeric receptor (*e.g.*, one disclosed in Section 5.3) and a presently disclosed CLEC12A-targeted chimeric receptor (*e.g.*, one disclosed in Section 5.4). In certain embodiments, the ADGRE2-targeted chimeric receptor is a CAR. In certain embodiments, the CLEC12-targeted chimeric receptor is a CCR. Thus, in certain embodiments, the presently disclosed subject matter provides cells comprising a presently disclosed CLEC12A-targeted CAR and a presently disclosed CLEC12A-targeted CCR.

In certain embodiments, the presently disclosed cells exhibit a greater degree of cytolytic activity against cells that are positive for both ADGRE2 and CLEC12A as compared to against cells that are singly positive for ADGRE2. In certain embodiments, the ADGRE2-targeted CAR binds to the ADGRE2 with a low binding affinity or a low binding avidity. In certain embodiments, the ADGRE2-targeted CAR binds to ADGRE2 at an epitope of low accessibility. In certain embodiments, the ADGRE2-targeted CAR binds to ADGRE2 with a binding affinity that is lower compared to the binding affinity with which the CLEC12A-targeted CCR binds to CLEC12A. In certain embodiments, the ADGRE2-targeted CAR binds to ADGRE2 with a binding affinity that is at least 5-fold lower compared to the binding affinity with which the

CLEC12A-targeted CCR binds to CLEC12A. In certain embodiments, the ADGRE2-targeted CAR binds to ADGRE2 with a binding affinity that is at least 10 fold, 20 fold, 30 fold, 40 fold, 50 fold, 60 fold, 70 fold, 80 fold, 90 fold, 100 fold, 200 fold, 5000 fold, 1000 fold, 5000 fold, or 10000 fold lower compared to the binding affinity with which the CLEC12A-targeted CCR
 5 binds to CLEC12A.

5.5.1. Exemplified Cells

In certain embodiments, the cell comprises an ADGRE2-targeted CAR and a CLEC12A-targeted CCR.

In certain embodiments, the ADGRE2-targeted CAR comprises (a) an extracellular
 10 antigen-binding domain comprising (i) a V_H that comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 33, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 34, and a V_H CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 35, and (ii) a V_L that comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 36, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 37, and a
 15 CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 38; (b) a hinge/spacer region comprising a CD28 polypeptide, (c) a transmembrane domain comprising a CD28 polypeptide (*e.g.*, a transmembrane domain of human CD28 or a fragment thereof), and (d) an intracellular signaling domain comprising (i) a CD3ζ polypeptide, and (ii) a co-stimulatory signaling region comprising a CD28 polypeptide (*e.g.*, an intracellular domain of human CD28
 20 or a fragment thereof). In certain embodiments, the V_H and V_L are linked via a linker comprising or consisting of the amino acid sequence set forth in SEQ ID NO: 2. In certain embodiments, the V_H and V_L are positioned from the N- to the C-terminus: V_H-V_L. In certain embodiments, the transmembrane domain comprises a CD28 polypeptide comprising or consisting of the amino acids 153 to 179 of SEQ ID NO: 10. In certain embodiments, the co-
 25 stimulatory signaling region comprises a CD28 polypeptide comprising or consisting of the amino acids 180 to 220 of SEQ ID NO: 10. In certain embodiments, the hinge/spacer region comprises a CD28 polypeptide comprising or consisting of the amino acids 114 to 152 of SEQ ID NO: 10. In certain embodiments, the ADGRE2-targeted CAR comprises or consists of the amino acid sequence set forth in SEQ ID NO: 66.

30 In certain embodiments, the CLEC12A-targeted CCR comprises (a) an extracellular antigen-binding domain comprising (i) a V_H that comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 69, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 70, and a V_H CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 71, and (ii) a V_L that comprises a CDR1 comprising the amino acid sequence set forth in SEQ

ID NO: 72, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 73, and a V_L CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 74; (b) an intracellular domain comprising a 4-1BB polypeptide (*e.g.*, a human 4-1BB polypeptide, *e.g.*, an intracellular domain of 4-1BB (*e.g.*, human 4-1BB) of a portion thereof). In certain embodiments, the CLEC12A-targeted CCR further comprises a transmembrane domain comprising a CD8 polypeptide (*e.g.*, a human CD8 polypeptide, *e.g.*, a transmembrane domain of CD8 (*e.g.*, human CD8) or a portion thereof). In certain embodiments, the intracellular domain comprises a 4-1BB polypeptide comprising or consisting of the amino acids 214 to 255 of SEQ ID NO: 30. In certain embodiments, the transmembrane domain comprises a CD8 polypeptide comprising or consisting of the amino acids 137 to 207 of SEQ ID NO: 7. In certain embodiments, the V_H and V_L are linked via a linker comprising or consisting of the amino acid sequence set forth in SEQ ID NO: 2. In certain embodiments, the V_H and V_L are positioned from the N- to the C-terminus: V_H-V_L. In certain embodiments, the CLEC12A-targeted CCR comprises the amino acid sequence set forth in SEQ ID NO: 136.

5.8. *Nucleic Acid Molecules, Vector and Genetic Modifications*

The presently disclosed subject matter provides nucleic acid molecules encoding the presently disclosed ADGRE2-targeted chimeric receptors (*e.g.*, those disclosed in Sections 5.3 and 5.4). In certain embodiments, the nucleic acid molecule further comprises a promoter that is operably linked to the presently disclosed ADGRE2-targeted CAR. Also provided are cells comprising such nucleic acid molecules.

In addition, the presently disclosed subject matter provides nucleic acid molecules encoding the presently disclosed CLEC12A-targeted chimeric receptors (*e.g.*, those disclosed in Sections 5.5 and 5.6). In certain embodiments, the nucleic acid molecule further comprises a promoter that is operably linked to the presently disclosed CLEC12A-targeted CAR. Also provided are cells comprising such nucleic acid molecules.

Furthermore, the presently disclosed subject matter provides nucleic acid compositions comprising a nucleic acid molecule encoding an ADGRE2-targeted chimeric receptor and a nucleic acid molecule encoding a CLEC12A-targeted chimeric receptor. Also provided are cells comprising such nucleic acid compositions.

In certain embodiments, the promoter is endogenous or exogenous. In certain embodiments, the exogenous promoter is selected from the group consisting of an elongation factor (EF)-1 promoter, a cytomegalovirus immediate-early promoter (CMV) promoter, a simian virus 40 early promoter (SV40) promoter, a phosphoglycerate kinase (PGK) promoter, a metallothionein promoter, and Ubiquitin C promoter. In certain embodiments, the endogenous

promoter is selected from a TCR alpha promoter, a TCR beta promoter, and a beta 2-microglobulin promoter. In certain embodiments, the promoter is an inducible promoter. In certain embodiment, the inducible promoter is selected from the group consisting of a NFAT transcriptional response element (TRE) promoter, a CD69 promoter, a CD25 promoter, an IL-2 promoter, a 4-1BB promoter, a PD1 promoter, and a LAG3 promoter.

The presently disclosed subject matter also provides vectors comprising the presently disclosed nucleic acid molecules. In certain embodiments, the vector is a viral vector. In certain embodiments, the viral vector is a retroviral vector. In certain embodiments, the retroviral vector is a gamma retroviral vector or lentiviral vector.

In certain embodiments, the vector comprises a nucleic acid molecule encoding a presently disclosed ADGRE2-targeted CAR and a presently disclosed CLEC12A-targeted CCR. In certain embodiments, the nucleic acid molecule encodes a polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 140. In certain embodiments, the nucleic acid molecule comprises the nucleotide sequence set forth in SEQ ID NO: 141. SEQ ID NOs: 140 and 141 are provided below.

MALPVTALLLPLALLLHAQVQLQQSGAEVAKPGASVKLSCKASGYFTFTNYWMQWIKQAPGQGLEWIGAVYPGDGDTHTQKFKGKATLTADKSTSTAYMEVSSSLRSED TAVYYCARGFTAYGMDYWGQGT TTVTVSSGGGGSGGGSGGGGSEIPLTQSPATMSASPGERVMTMSSASSSVSYMHWYQQKSGQSPKRWIYDTSKLASGVPARFSGSGSGTDYFTTISSEPEIDFATYYCQQWSSNPLTFGGGKTLEIKRAAAIEVMYPPPYLDNEKSNGTIIHVKGKHLCPSPFLFPGPSKPFWVLVVGGLVACYSLLVTVAFIIFWVRSKRSRL LHSDYMNMTPRRPGPTRKHYQPYAPPRDFAAYRSRVKFSRSADAPAYQQGNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGFLNELQDKMAEAFSEIGMKGERRRGKGHDGLFQGLSTATKDTFDALHMQALPPRGSGATNFSLLKQAGDVEENPGPMALPVTALLLPLALLLHAQLQLQESGPGLVKPSSETLSLTCTVSGGSISSSTYYGWIRQPPRKGLEWIGSTHYRGSTYYNPSLSKRVTISVDTSKNQFSLKVSSVTAADTAVYYCARELTGEVFDYWGQGT LVTVSSASTGGGGSGGGSGGGGSDIQMTQSPSSLSASVGDRTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPFTFGPGTKVDIKRAAAPTTFPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCNKRGRKKLLYIFKOPFMRPVOTTOEEDGCSCRFPEEEEEGGCEL [SEQ ID No: 140]

[illegible]

TGATTGTGTTTGTGTGTGTGATTGTGTATATGTGTGTATGGTGTGTGTGATTGTGTGTATGTATGTTTGTGTGTGA
TTGTGTGTGTGTGATTGTGTCATGTGTGTGTGTGTGATTGTGTTTATGTGTATGATTGTGTGTGTGTGTGTGTGTG
TGTGTGTGTGTGTGTGTGTGTGTGTGTTGTGTATATATATTTATGGTAGTGAGAGGCAACGCTCCGGCTCAGGTGTCAG
GTTGGTTTTTGTGACAGAGTCTTTCACTTAGCTTGGAAATCACTGGCCGTCGTTTTACAACGTCGTGACTGGGAAAA
5 CCTGGCGTTACCCAACCTAATCGCCTTGCAGCACATCCCCCTTTCGCCAGCTGGCGTAATAGCGAAGAGGCCCGCA
CCGATCGCCCTTCCCAACAGTTGCGCAGCCTGAATGGCGAATGGCGCCTGATGCGGTATTTTCTCCTTACGCATCTG
TGCGGTATTTACACCCGCATATGGTGCCTCTCAGTACAATCTGCTCTGATGCCGCATAGTTAAGCCAGCCCCGACA
CCCGCCAACACCCGCTGACGCGCCCTGACGGGCTTGTCTGCTCCCGCATCCGCTTACAGACAAGCTGTGACCGTCT
10 CCGGGAGCTGCATGTGTGAGAGTTTTTACCCTCATCACCGAAACGCGCAGACGAAAGGGCCTCGTGATACGCCTA
TTTTTATAGGTTAATGTCATGATAATAATGGTTTCTTAGACGTCAGGTGGCACTTTTCCGGGAAATGTGCGCGGAAC
CCCTATTTGTTATTTTTTTTAAATACATTCAAATATGTATCCGCTCATGAGACAATAACCCCTGATAAATGCTTCAAT
AATATTGAAAAAGGAAGATATGAGCCATATTCAACGGGAAACGTCGAGGCCGCGATTAAATTTCAACATGGATGCT
GATTTATATGGGTATAAATGGGCTCGCGATAATGTCGGGCAATCAGGTGCGACAATCTATCGCTTGTATGGGAAGCC
CGATGCGCCAGAGTTGTTTCTGAAACATGGCAAAGGTAGCGTTGCCAATGATGTTACAGATGAGATGGTCAGACTAA
15 ACTGGCTGACGGAATTTATGCCTCTTCCGACCATCAAGCATTTTATCCGTAATCCTGATGATGCATGGTTACTCACC
ACTGCGATCCCCGGAACAGCATTCCAGGTATTAGAAGAATATCCTGATTCAGGTGAAAATATTGTTGATGCGCT
GGCAGTGTTCTGCGCCGTTGCATTGCTTCTGTTGTAATTTGCTTTTAAACAGCGATCGCGTATTTCTGCTCTCG
CTCAGGCGCAATCACGAATGAATAACGGTTTGGTTGATGCGAGTGATTTTATGACGAGCGTAATGGCTGGCCTGTT
GAACAAGTCTGAAAGAAATGCATAAACTTTGCCATTCTCACCGGATTGAGTCGTCATCATGGTGATTTCTCACT
20 TGATAACCTTATTTTTTACGAGGGGAAATTAATAGTTTGTATTGATGTTGGACGAGTCGGAATCGCAGACCGAATAC
AGGATCTTGCCATCCTATGGAACGCTCGGTGAGTTTTCTCCTTCAATACAGAAACGGCTTTTTCAAAAATATGGT
ATTGATAATCCTGATATGAATAAATGTCAGTTTCTTGTGCTCGATGAGTTTTTCTAACTGTCAGACCAAGTTTA
CTCATATATCTTTAGATTGATTTAAACTTCTATTTTAAATTTAAAGGATCTAGGTGAAGATCCTTTTTGATAATC
TCATGACCAAAATCCCTTAACTGAGTTTTCTGTTCCACTGAGCGTCAGACCCCGTAGAAAAGATCAAAGGATCTTCT
25 TGAGATCCTTTTTTCTGCGCGTAATCTGCTGCTTGCAAACAAAAAACACCGCTACCAGCGGTGGTTTTGTTTGC
GGATCAAGAGTACCAACTCTTTTTCCGAAGGTAAGTGGCTTACGAGAGCGCAGATACCAAATACTGTTCTTCTAG
TGAGCCGTAGTTAGGCCACCACTTCAAGAACTCTGTAGCACCAGCTACATACCTCGCTCTGCTAATCCTGTTACCA
GTGGCTGCTGCCAGTGGCGATAAGTCTGCTTACCAGGTTGGACTCAAGACGATAGTTACCGGATAAGGCGCAGCG
30 GTCGGGCTGAACGGGGGTTTCGTGCACACAGCCAGCTTGGAGCGAACGACCTACACCGAAGTGAATACCTACAGC
GTGAGCTATGAGAAAGCGCCACGCTTCCCGAAGGGAGAAAGGCGGACAGGTATCCGGTAAGCGGCAGGGTCGGAACA
GGAGAGCGCAGGAGGAGCTTCCAGGGGAAACGCGTGGTATCTTTATAGTCCTGTCGGGTTTCCGCCACCTCTGACT
TGAGCGTCGATTTTTGTGATGCTCGTCAGGGGGCGGAGCCTATGGAAAAACGCCAGCAACCGCGCTTTTACGGT
TCCTGGCCTTTTGTGCTGGCCTTTTGTGCTCACATGTTCTTTCTGCGTTATCCCCTGATTCTGTGGATAACCGTATTACC
GCCTTTGAGTGAGCTGATACCGCTCGCCGAGCCGAACGACCGAGCGCAGCGAGTCAGTGAGCGAGGAAGCGGAAGA
35 GCGCCCAATACGCAAAACCGCTCTCCCGCGCGTTGGCCGATTCAATTAATGCAGCTGGCACGACAGGTTTCCCGACT
GGAAAGCGGGCAGTGAGCGCAACGCAATTAATGTGAGTTAGCTCACTCATTAGGCACCCAGGCTTTACACTTTATG
CTTCCGGCTCGATTGTTGTGGAATTTGAGCGGATACCAATTTACACAGGAACAGCTATGACCATGATTACGC
CAAGCTTTGCTCTTAGGAGTTTCTAATACATCCCAACTCAAATATATAAAGCATTTGACTTGTCTATGCCCTAG
GGGGCGGGGGAAGCTAAGCCAGCTTTTTTTAACTTTAAATGTTAATTCCATTTAAATGCACAGATGTTTTTAT
40 TTCATAAGGGTTTCAATGTGCATGAATGCTGCAATATTCCTGTTACCAAAGCTAGTATAAATAAAATAGATAAACG
TGGAATTACTTAGAGTTTCTGTCTTAACGTTTCTTCTCAGTTGACAACATAAATGCGCTGCTGAGAAGCCAGT
TTGCATCTGTCAGGATCAATTTCCATTATGCCAGTCATATTAATTACTAGTCAATTAGTTGATTTTTATTTTTGAC
ATATACCTTGAAAGACCCACCTGTAGTTTGGCAAGCTGATCTTAAGTAACGCCATTTTGCAGGCTTGAAAAAT
ACATAACTGAGAATAGAAAAGTTGAGATCAAGGTCAGGAACAGATGGAACAGCTGAATATGGGCCAAACAGGATATC
45 TGTGGTAAGCAGTTTCTGCCCGGCTCAGGGCCAAGAACAGATGGAACAGCTGAATATGGGCCAAACAGGATATCTG
TGGAAGCAGTTTCTGCCCGGCTCAGGGCCAAGAACAGATGGTCCCAGATGCGGTCCAGCCCTCAGCAGTTTCTA
GAGAACCATCAGATGTTTCCAGGGTGCCCAAGGACCTGAAATGACCCTGTGCCCTATTTGAACTAACCAATCAGTT
CGCTTCTCGCTTCTGTTGCGCGCTTCTGCTCCCGAGCTCAATAAAAGAGCCCAACCCCTCACTCGGCGCGCCA
50 GTCCCTCCGATTGACTGAGTCGCGCGGTACCCGCTGATCCAAATAAACCCCTCTGCAAGTTGCATCCGACTTGTGGTCT
CGCTGTTCTTGGGAGGGTCTCCTCTGAGTGATTGACTACCCGTGAGCGGGGCTTTTCAATTTGGGGGCTCGTCCGG
GATCGGGAGACCCCTGCCAGGGACACCGACCCACCGGGAGGTAAGCTGGCCAGCACTTATCTGTGCTGTCTGTC
CGATTGTCTAGTGTCTATGACTGATTTTATGCGCTGCGTCTGCTAGTTAGCTAACTAGCTCTGTATCTGGCGGA
CCCGTGGTGGAACTGACGAGTTGGAACACCCGCGCCGAACCCCTGGGAGACGTCCAGGGACTTCGGGGGCGGTTTT
TGTGGCCCGACCTGAGTCTAAATCCCGATCGTTTAGGACTCTTTGGTGCACCCCTTAGAGGAGGATATGTGG
55 TTCTGGTAGGAGACGAGAACCCTAAACAGTTCCCGCTCCGCTGTAATTTTTGCTTTTCGTTTTGGGACCGAAGCCGC
GCCGCGCGTCTGTCTGCTGCAGCATCGTTCTGTGTGTCTGTCTGACTGTGTTTCTGTATTTGTCTGAAAATAT
GGGCCCCGGGTAGACTGTTACCACTCCCTTAAGTTTACCTTAGGTCACTGGAAAGATGTCGAGCGGATCGCTCACA
ACCAGTCGGTAGATGTCAAGAAGAGACGTTGGGTTACCTTCTGCTCTGCAGAATGGCCAACTTTAACGTCGGATGG
CCGCGAGACGGCACCTTTAACCGAGACCTCATCACCGAGTTAAGATCAAGGTCCTTTTACCTGGCCCGCATGGACA
60 CCCAGAACAGGTCCCCTACATCGTGACCTGGGAAGCCTTGGCTTTTGACCCCTCCCTGGGTCAAGCCCTTTGTAC
ACCTTAAGCTCCGCTCTCTTCTCATCCGCGCTCTCTCCCTTGAACCTCCTCGTCTGACCCCGCTCGA
TCCTCCCTTTATCCAGCCCTCACTCCTTCTTAGGCGCCCCATATGGCCATATGAGATCTTATATGGGGCACCCCC

GCCCCTTGTAACCTCCCTGACCTGACATGACAAGAGTTACTAACAGCCCCCTCTCTCCAAGCTCACTTACAGGCTC
 TCTACTTAGTCCAGCACGAAGTCTGGAGACCTCTGGCGGCAGCCTACCAAGAACAACCTGGACCGACCGGTGGTACCT
 CACCCCTTACCAGTTCGGCGACACAGTGTGGGTCCGCGACACCAGACTAAGAACCCTAGAACCTCGCTGGAAAGGACC
 TTACACAGTCTGCTGACCACCCCCACCGCCCTCAAAGTAGACGGCATCGCAGCTTGGATACACGCCGCCACGTGA
 5 AGGCTGCCGACCCCGGGGTGGACCATCTCTAGACTGCCatggctctcccagtgactgcccactgcttcccctag
 cgcttctcctgcatgcacaagttcagctccagcagagcgcgccgaagtggaagcctggagcgtcagtcagctg
 tcctgcaaagcgagtggtctatacgttcacgaactactggatgcagtggaataagcaggctcccgggcagggtctgga
 gtggattggagccgtctacccaggggacggcgacaccggcacactcaaaagttcaagggaagggccaccctgaccg
 ctgacaagagcacaagcacagcgtacatggaggtgtcctctttgagatccgaagataaccgctgtgtattattgtgcc
 10 cggggcttctactgcatacgggatggattactggggacaaggcactaccgtgactgtcagctccgggggtggaggctc
 agggcgggggggttcaggaggggggggatctgaaattgtgctgacacagagccctgccacaatgtctgctagccctg
 gcgagcgctgaccatgtctttagcgcagcagcagcgtgtcctacatgcattggtatcaacagaagtcggccag
 tctcccaagcgggtgatctacgatacaagcaagctggcctccggcgtgcccgccagattttctggcagcggctctgg
 aacagattacaccttcaccaatctctagcatggaacctgaggattttgccacctactattggcagcagtggtccagca
 15 atccccctgacatttggaggaggcaccaagctggaataaagagagcgccgcaattgaagtattgtatcctcctcct
 tacctagacaatgagaagagcaatggaaccattatccatgtgaaaggaaacacctttgtccaagtcccctatttcc
 cggaccttctaagcccttttgggtgctggtggtggtggtgagtcctggcttgctatagcttgcctagtaaacgtgg
 cctttattattttctgggtgaggagtaagaggagcaggtcctgcacagtgactacatgaacatgactccccgcgcg
 cccgggcccaccgcgaagcattaccagccctatgccccaccacgcgacttccgagcctatcgctccagagtgaaagt
 20 cagcaggagcgcagacgccccgcgtaccagcagggccagaaccagctctataacgagctcaatctaggcaagag
 aggagtagcatgttttggacaagagacgtggcgggaccctgagatggggggaaagccgagaaggaagaaacccctcag
 gaaggcctgttcaatgaactgcagaaagataagatggcggaggccttcagtgagattgggatgaaaggcgagcgccg
 gaggggcaaggggcacgatggccttttccagggtctcagtagcaccaccaaggacaccttcgacgccccttcacatgc
 aggccctgccccctcgcggaagcggagctactaacttcagcctgctgaagcaggctggagacgtggaggagaacccct
 25 ggacccatggccctgcccgtcacccgttctgtctgccaactggccttgctgctccacgctcagctccagctccaaga
 gtcagggccagggtctcgtgaaaccgagtgagaccctgtccctgacctgcacagtgagtggtggatcaatctcaagct
 ctacctactattgggggtggttccggcagccccctagaaaggggcttgagtggttggcagcactcattatcgagga
 tctacctattataatccttctctgaaaagcagagttaccatctctgtggatacgtccaaaaatcagttcagctctgaa
 ggtatcatccgtgactgctgcccacacggcgtgtactattgcgcgagggagctgacaggtgaggtctttgactact
 30 ggggcccaggggcacactcgtgaccgtgtcttctgcctcaacaggagggggtgggagtgaggcggtggatcaggggga
 ggaggagtgacatccagatgacgcagtcctcctccagcttctgcgcacatctgtgggtgatagggtcacgattacatg
 tagggctagtcagagatttctagttacctgaattggtaccagcagaaaccaggcaaggcaccaaagttgctcatct
 atgcggcctcctctctgcaatctggcgtgcggtccagatttagtggtcaggtccggaaaccgatttcacccctacg
 atctcctcacttcaaccgaggatttccgacatattactgtcaacaaagctattctacaccgttcaccttcggacc
 35 ggggacaaaagtggatattaaacggggcgccgccccaccacgacgcgcgaccgaccccaaccccgcgcccca
 cgatcgctgcgagcccctgtccctgcgcccagaggcgtgcgggcccagcgggcgggggcgagtgcaacagaggggg
 ctggacttcgctgtgatatctacatctgggcgcccctggcgggacttgtgggtccttctcctgtcactgggttat
 caccctttactgcaacaaacggggcgagaagaagctcctgtatatattcaaacacaccatttatgagaccagtacaaa
 ctactcaagaggaagatggctgtagctgccgatttccagaagaagaagaggaggtgtaactgtaacAGCCACTC
 40 GAGGATCC [SEQ ID NO: 141]

The nucleic acid molecules can be delivered into cells by art-known methods or as
 described herein. Genetic modification of a cell can be accomplished by transducing a
 substantially homogeneous cell composition with a recombinant DNA construct. In certain
 embodiments, a retroviral vector (e.g., gammaretroviral vector or lentiviral vector) is employed
 45 for the introduction of the DNA construct into the cell. For example, a polynucleotide encoding
 a presently disclosed chimeric receptor can be cloned into a retroviral vector and expression can
 be driven from its endogenous promoter, from the retroviral long terminal repeat, or from a
 promoter specific for a target cell type of interest. Non-viral vectors may be used as well.

For initial genetic modification of a cell to include at least one presently disclosed
 50 chimeric receptor (e.g., two presently disclosed chimeric receptors, e.g., a presently disclosed
 ADGRE2-targeted chimeric receptor and a presently disclosed CLEC12A-targeted chimeric
 receptor), a retroviral vector can be employed for transduction, however any other suitable viral

vector or non-viral delivery system can be used. The chimeric receptor(s) can be constructed in a single, multicistronic expression cassette, in multiple expression cassettes of a single vector, or in multiple vectors. Examples of elements that create polycistronic expression cassette include, but is not limited to, various viral and non-viral Internal Ribosome Entry Sites (IRES, *e.g.*, FGF-1 IRES, FGF-2 IRES, VEGF IRES, IGF-II IRES, NF- κ B IRES, RUNX1 IRES, p53 IRES, hepatitis A IRES, hepatitis C IRES, pestivirus IRES, aphthovirus IRES, picornavirus IRES, poliovirus IRES and encephalomyocarditis virus IRES) and cleavable linkers (*e.g.*, 2A peptides, *e.g.*, P2A, T2A, E2A and F2A peptides). In certain embodiments, the P2A peptide comprises or consists of the amino acid sequence set forth in SEQ ID NO: 142, which is provided below:

10 GSGATNFSLLKQAGDVEENPGP [SEQ ID NO: 142]

An exemplary nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 142 is set forth in 143, which is provided below:

ggaagcggagctactaacttcagcctgctgaagcagcgtggagacgtggaggagaaccctggaccc [SEQ ID NO: 143]

15 Combinations of retroviral vector and an appropriate packaging line are also suitable, where the capsid proteins will be functional for infecting human cells. Various amphotropic virus-producing cell lines are known, including, but not limited to, PA12 (Miller *et al.*, (1985) *Mol Cell Biol* (1985);5:431-437); PA317 (Miller, *et al.*, *Mol Cell Biol* (1986); 6:2895-2902); and CRIP (Danos *et al.*, *Proc Natl Acad Sci USA* (1988);85:6460-6464). Non-amphotropic particles are suitable too, *e.g.*, particles pseudotyped with VSVG, RD114 or GALV envelope and any other known in the art.

Possible methods of transduction also include direct co-culture of the cells with producer cells (Bregni *et al.*, *Blood* (1992);80:1418-1422), or culturing with viral supernatant alone or concentrated vector stocks with or without appropriate growth factors and polycations (Xu *et al.*, 25 *Exp Hemat* (1994); 22:223-230; and Hughes *et al.* *J Clin Invest* (1992); 89:1817).

Other transducing viral vectors can be used to modify a cell. In certain embodiments, the chosen vector exhibits high efficiency of infection and stable integration and expression (*see, e.g.*, Cayouette *et al.*, *Human Gene Therapy* 8:423-430, 1997; Kido *et al.*, *Current Eye Research* 15:833-844, 1996; Bloomer *et al.*, *Journal of Virology* 71:6641-6649, 1997; Naldini *et al.*, 30 *Science* 272:263-267, 1996; and Miyoshi *et al.*, *Proc. Natl. Acad. Sci. U.S.A.* 94:10319, 1997). Other viral vectors that can be used include, for example, adenoviral, lentiviral, and adeno-associated viral vectors, vaccinia virus, a bovine papilloma virus, or a herpes virus, such as Epstein-Barr Virus (also see, for example, the vectors of Miller, *Human Gene Thera* (1990);15-14; Friedman, *Science* 244:1275-1281, 1989; Eglitis *et al.*, *BioTechniques* (1988);6:608-614;

Tolstoshev et al., *Cur Opin Biotechnol* (1990); 1:55-61; Sharp, *The Lancet* (1991);337:1277-78; Cornetta et al., *Nucleic Acid Research and Molecular Biology* 36:311-22, 1987; Anderson, *Science* (1984);226:401-409; Moen, *Blood Cells* 17:407-16, 1991; Miller et al., *Biotechnol* (1989);7:980-90; LeGal La Salle et al., *Science* (1993);259:988-90; and Johnson, *Chest* (1995)107:77S- 83S). Retroviral vectors are particularly well developed and have been used in clinical settings (Rosenberg et al., *N Engl J Med* (1990);323:370, 1990; Anderson et al., U.S. Patent. No. 5,399,346).

Non-viral approaches can also be employed for genetic modification of a cell. For example, a nucleic acid molecule can be introduced into a cell by administering the nucleic acid in the presence of lipofection (Feigner et al., *Proc Natl Acad Sci U.S.A.* (1987);84:7413; Ono et al., *Neurosci Lett* (1990);17:259; Brigham et al., *Am J Med Sci* (1989);298:278; Staubinger et al., *Methods in Enzymol* (1983);101:512, Wu et al., *J Biol Chem* (1988);263:14621; Wu et al., *J Biol Chem* (1989);264:16985), or by micro-injection under surgical conditions (Wolff et al., *Science* (1990);247:1465). Other non-viral means for gene transfer include transfection *in vitro* using calcium phosphate, DEAE dextran, electroporation, and protoplast fusion. Liposomes can also be potentially beneficial for delivery of DNA into a cell. Transplantation of normal genes into the affected tissues of a subject can also be accomplished by transferring a normal nucleic acid into a cultivatable cell type *ex vivo* (e.g., an autologous or heterologous primary cell or progeny thereof), after which the cell (or its descendants) are injected into a targeted tissue or are injected systemically. Recombinant receptors can also be derived or obtained using transposases or targeted nucleases (e.g. Zinc finger nucleases, meganucleases, or TALEN, CRISPR). Transient expression may be obtained by RNA electroporation.

Any targeted genome editing methods can also be used to deliver at least one presently disclosed chimeric receptor (e.g., two presently disclosed chimeric receptors, e.g., a presently disclosed ADGRE2-targeted chimeric receptor and a presently disclosed CLEC12A-targeted chimeric receptor) to a cell. In certain embodiments, a CRISPR system is used to deliver at least one presently disclosed chimeric receptor (e.g., two presently disclosed chimeric receptors, e.g., a presently disclosed ADGRE2-targeted chimeric receptor and a presently disclosed CLEC12A-targeted chimeric receptor). In certain embodiments, zinc-finger nucleases are used to deliver at least one presently disclosed chimeric receptor (e.g., two presently disclosed chimeric receptors, e.g., a presently disclosed ADGRE2-targeted chimeric receptor and a presently disclosed CLEC12A-targeted chimeric receptor). In certain embodiments, a TALEN system is used to deliver at least one presently disclosed chimeric receptor (e.g., two presently disclosed chimeric

receptors, e.g., a presently disclosed ADGRE2-targeted chimeric receptor and a presently disclosed CLEC12A-targeted chimeric receptor).

Clustered regularly-interspaced short palindromic repeats (CRISPR) system is a genome editing tool discovered in prokaryotic cells. When utilized for genome editing, the system includes Cas9 (a protein able to modify DNA utilizing crRNA as its guide), CRISPR RNA (crRNA, contains the RNA used by Cas9 to guide it to the correct section of host DNA along with a region that binds to tracrRNA (generally in a hairpin loop form) forming an active complex with Cas9), trans-activating crRNA (tracrRNA, binds to crRNA and forms an active complex with Cas9), and an optional section of DNA repair template (DNA that guides the cellular repair process allowing insertion of a specific DNA sequence). CRISPR/Cas9 often employs a plasmid to transfect the target cells. The crRNA needs to be designed for each application as this is the sequence that Cas9 uses to identify and directly bind to the target DNA in a cell. The repair template carrying CAR expression cassette need also be designed for each application, as it must overlap with the sequences on either side of the cut and code for the insertion sequence. Multiple crRNA's and the tracrRNA can be packaged together to form a single-guide RNA (sgRNA). This sgRNA can be joined together with the Cas9 gene and made into a plasmid in order to be transfected into cells.

A zinc-finger nuclease (ZFN) is an artificial restriction enzyme, which is generated by combining a zinc finger DNA-binding domain with a DNA-cleavage domain. A zinc finger domain can be engineered to target specific DNA sequences which allows a zinc-finger nuclease to target desired sequences within genomes. The DNA-binding domains of individual ZFNs typically contain a plurality of individual zinc finger repeats and can each recognize a plurality of base pairs. The most common method to generate new zinc-finger domain is to combine smaller zinc-finger "modules" of known specificity. The most common cleavage domain in ZFNs is the non-specific cleavage domain from the type IIs restriction endonuclease FokI. Using the endogenous homologous recombination (HR) machinery and a homologous DNA template carrying CAR expression cassette, ZFNs can be used to insert the CAR expression cassette into genome. When the targeted sequence is cleaved by ZFNs, the HR machinery searches for homology between the damaged chromosome and the homologous DNA template, and then copies the sequence of the template between the two broken ends of the chromosome, whereby the homologous DNA template is integrated into the genome.

Transcription activator-like effector nucleases (TALEN) are restriction enzymes that can be engineered to cut specific sequences of DNA. TALEN system operates on almost the same principle as ZFNs. They are generated by combining a transcription activator-like effectors

DNA-binding domain with a DNA cleavage domain. Transcription activator-like effectors (TALEs) are composed of 33-34 amino acid repeating motifs with two variable positions that have a strong recognition for specific nucleotides. By assembling arrays of these TALEs, the TALE DNA-binding domain can be engineered to bind desired DNA sequence, and thereby
5 guide the nuclease to cut at specific locations in genome. cDNA expression for use in polynucleotide therapy methods can be directed from any suitable promoter (e.g., the human cytomegalovirus (CMV), simian virus 40 (SV40), metallothionein promoters, or Ubiquitin C promoter), and regulated by any appropriate mammalian regulatory element or intron (e.g. the elongation factor 1a enhancer/promoter/intron structure). For example, if desired, enhancers
10 known to preferentially direct gene expression in specific cell types can be used to direct the expression of a nucleic acid. The enhancers used can include, without limitation, those that are characterized as tissue- or cell-specific enhancers. Alternatively, if a genomic clone is used as a therapeutic construct, regulation can be mediated by the cognate regulatory sequences or, if desired, by regulatory sequences derived from a heterologous source, including any of the
15 promoters or regulatory elements described above.

Methods for delivering the genome editing agents/systems can vary depending on the need. In certain embodiments, the components of a selected genome editing method are delivered as DNA constructs in one or more plasmids. In certain embodiments, the components are delivered via viral vectors. Common delivery methods include but is not limited to,
20 electroporation, microinjection, gene gun, impalefection, hydrostatic pressure, continuous infusion, sonication, magnetofection, adeno-associated viruses, envelope protein pseudotyping of viral vectors, replication-competent vectors cis and trans-acting elements, herpes simplex virus, and chemical vehicles (e.g., oligonucleotides, lipoplexes, polymersomes, polyplexes, dendrimers, inorganic Nanoparticles, and cell-penetrating peptides).

25 **5.9. Formulations and Administration**

The presently disclosed subject matter also provides compositions comprising the presently disclosed cells (e.g., those disclosed in Section 5.5). In certain embodiments, the composition is a pharmaceutical composition that further comprises a pharmaceutically acceptable carrier.

30 Compositions comprising the presently disclosed cells can be conveniently provided as sterile liquid preparations, e.g., isotonic aqueous solutions, suspensions, emulsions, dispersions, or viscous compositions, which may be buffered to a selected pH. Liquid preparations are normally easier to prepare than gels, other viscous compositions, and solid compositions. Additionally, liquid compositions are somewhat more convenient to administer, especially by

injection. Viscous compositions, on the other hand, can be formulated within the appropriate viscosity range to provide longer contact periods with specific tissues. Liquid or viscous compositions can comprise carriers, which can be a solvent or dispersing medium containing, for example, water, saline, phosphate buffered saline, polyol (for example, glycerol, propylene glycol, liquid polyethylene glycol, and the like) and suitable mixtures thereof.

Compositions comprising the presently disclosed cells can be provided systemically or directly to a subject for inducing and/or enhancing an immune response to an antigen and/or treating and/or preventing a neoplasm. In certain embodiments, the presently disclosed cells or compositions comprising thereof are directly injected into an organ of interest (*e.g.*, an organ affected by a neoplasm). Alternatively, the presently disclosed cells or compositions comprising thereof are provided indirectly to the organ of interest, for example, by administration into the circulatory system (*e.g.*, the tumor vasculature). Expansion and differentiation agents can be provided prior to, during or after administration of the cells or compositions to increase production of cells *in vitro* or *in vivo*.

The quantity of cells to be administered can vary for the subject being treated. In certain embodiments, between about 10^4 and about 10^{10} , between about 10^4 and about 10^7 , between about 10^5 and about 10^7 , between about 10^5 and about 10^9 , or between about 10^6 and about 10^8 of the presently disclosed cells are administered to a subject. In certain embodiments, between about 10×10^6 and about 150×10^6 of the presently disclosed cells are administered to a subject. In certain embodiments, between about 25×10^6 and about 150×10^6 of the presently disclosed cells are administered to a subject. In certain embodiments, between about 25×10^6 and about 50×10^6 of the presently disclosed cells are administered to a subject. In certain embodiments, at least about 10×10^6 , about 25×10^6 , about 50×10^6 , about 100×10^6 , or about 150×10^6 of the presently disclosed cells are administered to a subject. In certain embodiments, about 25×10^6 of the presently disclosed cells are administered to a subject. The precise determination of what would be considered an effective dose can be based on factors individual to each subject, including their size, age, sex, weight, and condition of the particular subject. Dosages can be readily ascertained by those skilled in the art from this disclosure and the knowledge in the art.

The presently disclosed cells and compositions can be administered by any method known in the art including, but not limited to, intravenous administration, subcutaneous administration, intranodal administration, intratumoral administration, intrathecal administration, intrapleural administration, intraosseous administration, intraperitoneal administration, pleural administration, and direct administration to the subject. The presently disclosed cells can be administered in any physiologically acceptable vehicle, normally

intravascularly, although they may also be introduced into bone or other convenient site where the cells may find an appropriate site for regeneration and differentiation (*e.g.*, thymus).

5.10. Methods of Treatment

The presently disclosed subject matter provides various methods of using the presently disclosed cells or compositions comprising thereof. The presently disclosed cells and compositions comprising thereof can be used in a therapy or medicament. For example, the presently disclosed subject matter provides methods for inducing and/or increasing an immune response in a subject in need thereof. The presently disclosed cells and compositions comprising thereof can be used for reducing tumor burden in a subject. The presently disclosed cells and compositions comprising thereof can reduce the number of tumor cells, reduce tumor size, and/or eradicate the tumor in the subject. The presently disclosed cells and compositions comprising thereof can be used for treating and/or preventing a tumor in a subject. The presently disclosed cells and compositions comprising thereof can be used for prolonging the survival of a subject suffering from a tumor. In certain embodiments, each of the above-noted method comprises administering the presently disclosed cells or a composition (*e.g.*, a pharmaceutical composition) comprising thereof to achieve the desired effect, *e.g.*, palliation of an existing condition or prevention of recurrence. For treatment, the amount administered is an amount effective in producing the desired effect. An effective amount can be provided in one or a series of administrations. An effective amount can be provided in a bolus or by continuous perfusion.

In certain embodiments, the tumor is associated with ADGRE2 and/or CLEC12A. In certain embodiments, the tumor cell expresses both ADGRE2 and CLEC12A. In certain embodiments, the tumor cell overexpresses both ADGRE2 and CLEC12A.

In certain embodiments, the tumor is a cancer. In certain embodiments, the tumor is blood cancer. In certain embodiments, the tumor is selected from the group consisting of multiple myeloma, leukemia, lymphomas, and myeloid malignancies. Non-limiting examples of leukemia include acute myeloid leukemia (AML), chronic myeloid leukemia (CML), acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute promyelocytic leukemia (APL), mixed-phenotype acute leukemia (MLL), hairy cell leukemia, and B cell prolymphocytic leukemia. Non-limiting examples of lymphoma include AIDS-related lymphoma, ALK- positive large B-cell lymphoma, Burkitt's lymphoma, Diffuse large B-cell lymphoma (DLBCL), Follicular lymphoma, Intravascular large B-cell lymphoma, Large B-cell lymphoma arising in HHV8- associated multicentric Castleman's disease, Lymphomatoid granulomatosis, Lymphoplasmacytic lymphoma, Mantle cell lymphoma (MCL), Marginal zone B-cell lymphoma (MZL), Mucosa-Associated Lymphatic Tissue lymphoma (MALT), Nodal

marginal zone B cell lymphoma (NMZL), Nodular lymphocyte predominant Hodgkin's lymphoma, Non-Hodgkin's lymphoma, Plasmablastic lymphoma, Primary central nervous system lymphoma, Primary effusion lymphoma, Splenic marginal zone lymphoma (SMZL), and Waldenstrom's macroglobulinemia. The lymphoma can be Hodgkin's lymphoma or non-Hodgkin's lymphoma. Non-limiting examples of myeloid malignancies include myelodysplastic syndromes (MDS), myeloproliferative neoplasms (MPN), myeloid/lymphoid neoplasms (e.g., myeloid/lymphoid neoplasms with eosinophilia and rearrangement of Platelet Derived Growth Factor Receptor Alpha (PDGFRA), Platelet Derived Growth Factor Receptor Beta (PDGFRB), or Fibroblast Growth Factor Receptor 1 (FGFR1), or with PCM1-JAK2), acute myeloid leukemia (AML), blastic plasmacytoid dendritic cell neoplasm, B-lymphoblastic leukemia/lymphoma, and T-lymphoblastic leukemia/lymphoma. In certain embodiments, the myeloid malignancies comprise myelodysplastic syndromes.

In certain embodiments, the tumor is acute myeloid leukemia (AML). In certain embodiments, the tumor is relapsed/refractory acute myeloid leukemia (R/R AML).

In certain embodiments, the subject is a human subject. The subjects can have an advanced form of disease, in which case the treatment objective can include mitigation or reversal of disease progression, and/or amelioration of side effects. The subjects can have a history of the condition, for which they have already been treated, in which case the therapeutic objective will typically include a decrease or delay in the risk of recurrence.

As a consequence of surface expression of at least one presently disclosed chimeric receptor (e.g., two presently disclosed chimeric receptors, e.g., a presently disclosed ADGRE2-targeted CAR and a presently disclosed CLEC12A-targeted CCR), adoptively transferred cells are endowed with augmented and selective cytolytic activity at the tumor site. Furthermore, subsequent to their localization to tumor and their proliferation, the cells turn the tumor site into a highly conductive environment for a wide range of cells involved in the physiological anti-tumor response.

Further modification can be introduced to the presently disclosed cells to avert or minimize the risks of immunological complications (known as "malignant T-cell transformation"), e.g., graft versus-host disease (GvHD), or when healthy tissues express the same target antigens as the tumor cells, leading to outcomes similar to GvHD. A potential solution to this problem is engineering a suicide gene into the presently disclosed cells. Suitable suicide genes include, but are not limited to, Herpes simplex virus thymidine kinase (hsv-tk), inducible Caspase 9 Suicide gene (iCasp-9), and a truncated human epidermal growth factor receptor (EGFRt) polypeptide. In certain embodiments, the suicide gene is an EGFRt

polypeptide. The EGFRt polypeptide can enable T-cell elimination by administering anti-EGFR monoclonal antibody (*e.g.*, cetuximab). EGFRt can be covalently joined to the upstream of the presently disclosed chimeric receptor(s). The suicide gene can be included within the vector comprising a nucleic acid encoding a presently disclosed chimeric receptor. In this way,
 5 administration of a prodrug designed to activate the suicide gene (*e.g.*, a prodrug (*e.g.*, AP1903 that can activate iCasp-9) during malignant T-cell transformation (*e.g.*, GVHD) triggers apoptosis in the suicide gene-activated cells expressing the presently disclosed chimeric receptor. The incorporation of a suicide gene into the a presently disclosed chimeric receptor gives an added level of safety with the ability to eliminate the majority of receptor-expressing
 10 cells within a very short time period. A presently disclosed cell incorporated with a suicide gene can be pre-emptively eliminated at a given timepoint post the cell infusion, or eradicated at the earliest signs of toxicity.

6. EXAMPLES

The practice of the present disclosure employs, unless otherwise indicated, conventional
 15 techniques of molecular biology (including recombinant techniques), microbiology, cell biology, biochemistry and immunology, which are well within the purview of the skilled artisan. Such techniques are explained fully in the literature, such as, “Molecular Cloning: A Laboratory Manual”, second edition (Sambrook, 1989); “Oligonucleotide Synthesis” (Gait, 1984); “Animal Cell Culture” (Freshney, 1987); “Methods in Enzymology” “Handbook of Experimental
 20 Immunology” (Weir, 1996); “Gene Transfer Vectors for Mammalian Cells” (Miller and Calos, 1987); “Current Protocols in Molecular Biology” (Ausubel, 1987); “PCR: The Polymerase Chain Reaction”, (Mullis, 1994); “Current Protocols in Immunology” (Coligan, 1991). These techniques are applicable to the production of the polynucleotides and polypeptides disclosed herein, and, as such, may be considered in making and practicing the presently disclosed subject
 25 matter. Particularly useful techniques for particular embodiments will be discussed in the sections that follow.

The following examples are put forth so as to provide those of ordinary skill in the art with a complete disclosure and description of how to make and use the presently disclosed cells and compositions, and are not intended to limit the scope of what the inventors regard as their
 30 invention.

Example 1 – Targeting ADGRE2 and CLEC12A

The presently disclosed subject matter evaluates a novel combinatorial CAR format for R/R AML that has the potential to provide improved safety and efficacy relative to alternative CAR therapies currently under clinical investigation.

Application of CAR therapy in AML is challenged by its intra- and interindividual phenotypic heterogeneity, and the ideal CAR target needs to be validated. To identify potential CAR targets, the available transcriptomics and proteomics datasets from malignant and normal tissues were analyzed and flow cytometric analysis of primary AML patient samples, healthy
5 bone marrow hematopoietic stem/progenitor cells (HSPCs), and healthy primary T cells were carried out (Perna et al., *Cancer Cell* 2(4):506-519.e5. (2017)). None of the targets showed a surface expression profile comparable with that of CD19, which was expressed at high levels in virtually all B cell leukemia cells, completely absent from HSPCs and T cells, and undetectable systematically outside B cell areas. However, the analysis identified the adhesion G protein-
10 coupled receptor E2 (ADGRE2), a novel potential CAR target for AML. Pair-wise analyses of the potential CAR targets suggested that, consistent with AML clonal heterogeneity, a combinatorial CAR targeting approach can be potentially efficacious in eradicating AML tumors while minimizing toxicity.

ADGRE2 (EMR2) is a member of the epidermal growth factor (EGF)-TM7 family of
15 proteins (Lin et al., *Genomics* 41.3 (1997): 301-308). Its expression is restricted to monocytes/macrophages and is not upregulated in activated T and B cells (Lin et al., *Genomics* 67.2 (2000): 188-200). Flow cytometric analyses revealed ADGRE2 positivity on >90% of AML cells in the majority of the analyzed R/R AML patient population (Figure 1). ADGRE2 was found to be positive both in the total AML bulk population and, most importantly, in the
20 therapeutically relevant fraction of leukemic stem cells (LSC). Other candidate targets such as CD33 and CD123 were also found to be positive in the majority of patients, however not as consistently as ADGRE2, especially in LSCs. Therefore, ADGRE2 was selected as the CAR target as it can offer a higher chance for achieving complete remission in R/R AML patients.

C-type lectin domain family 12 member A (CLEC12A/CD371) is a well-described
25 candidate target in AML, and it is expressed in the majority of AML patients (Perna et al., *Cancer cell* 32.4 (2017): 506-519; Haubner et al., *Leukemia* 33.1 (2019): 64-74; Bakker et al., *Cancer research* 64.22 (2004): 8443-8450). Other groups are already pursuing it as a CAR target in ongoing Phase 1 clinical trials in the US (Tashiro et al., *Molecular Therapy* 25.9 (2017): 2202-2213).

30 The presently disclosed subject matter proposes using a combinatorial CAR-CCR vector, termed ADCLEC.syn1 (Figure 2), which encodes a CAR specific for ADGRE2 and a CCR specific for CLEC12A to treat R/R AML. The CAR comprises a CD28 costimulatory domain and an attenuated CD3 ζ 1XX activation domain. It was previously demonstrated that genetic modification of the ITAM motifs of the CD3 ζ signaling domain provided an enhanced

therapeutic benefit by achieving a favorable balance of effector and memory signatures, thereby enhancing the persistence of functional CAR T cells in a pre-B acute lymphoblastic leukemia NALM6 mouse model (Feucht et al., *Nature medicine* 25.1 (2019): 82-88). The CCR provides 4-1BB co-stimulation to enhance T cell persistence and prevents antigen-low AML escape; it does not comprise a CD3 ζ domain and thus does not mediate cell killing like a CAR.

ADGRE2 expression is commonly upregulated in AML cells as compared to non-malignant cells. Considering the ADGRE2 expression in some normal cell types, including HSCs, a targeting strategy that would preferentially target AML cells was designed. In this approach, a first step was decreasing the affinity and activation potential of the ADGRE2 CAR to improve the safety of the CAR therapy, and a second step was rescuing ADGRE2 CAR engagement against LSCs by co-targeting CLEC12A (CD371), a second molecule expressed on LSCs but not HSCs, to prevent AML escape. CLEC12A was targeted through a chimeric costimulatory receptor (CCR), which provides increased avidity and co-stimulation but does not initiate cytolytic activity. Thus, the CCR assists the CAR to detect ADGRE2 in AML cells.

CAR signaling is triggered upon target engagement of the scFv portion of the CAR, which depends on CAR scFv affinity and CAR target antigen density. The ADGRE2 CAR scFv affinity were optimized so that healthy cells, which have lower ADGRE2 antigen levels than AML tumor cells, did not trigger CAR activation and were therefore spared, adding an important safety feature but at the same time increasing the risk of AML escape via downregulation of ADGRE2 antigen levels (Figure 3). To mitigate the risk of ADGRE2-low AML escape, the addition of the CLEC12A CCR increased the overall avidity to AML cells and thereby "compensated" for the lower-affinity ADGRE2 CAR, while it does not initiate the elimination of ADGRE2-negative/CLEC12a-positive cells. As the CLEC12A CCR lacks a CD3 ζ domain, it did not function as a CAR. Isolated CCR activation in the absence of simultaneous CAR activation did not trigger T cell activation or cytotoxicity (Figure 3).

The choice of targets and chimeric receptor design was made under consideration of safety features linked to the target expression in normal tissues and normal hematopoiesis. Co-expression of ADGRE2 and CLEC12A was limited to the monocyte subset, while all other major lineages had either a low or undetectable expression of ADGRE2 by flow cytometry (Figure 4A) suggesting that ADCLEC.syn1 would display diminished activity against HSCs and granulocytes (Figure 5). In comparison, the alternative targets CD33 and CD123, which were co-expressed in HSCs, led to greater CAR-mediated hematologic toxicity (Figures 4B and 5). Using commercially available antibodies for ADGRE2 and CLEC12A for IHC, the presently disclosed subject matter demonstrated that non-hematopoietic tissues had a largely non-

overlapping expression profile with the majority of the detected signal associated with tissue-resident myeloid-derived cells such as macrophages (Figure 4C). Taken together, these target expression data indicate that combinatorial targeting of ADGRE2 with a CAR and CLEC12A with a CCR via ADCLEC.syn1 vector can minimize the toxicity of the CAR-CCR T cells to normal hematopoietic and non-hematopoietic tissues relative to ADGRE2 targeting alone and provides a higher chance of sparing HSC compared to CD33 or CD123 CAR T cells.

In summary, the ADGRE2 CAR and CLEC12A CCR combined in the ADCLEC.syn1 vector mitigated the risk of ADGRE2 antigen escape and enhanced overall CAR T cell efficacy via optimized delivery of CD28 and 4-1BB costimulatory signaling in the context of fine-tuned CD3 ζ 1XX CAR signaling, but without cumulating potential on-target/off-tumor toxicity as would arise by combining two CARs. This rational combinatorial choice of target and chimeric receptor design can reduce the risk of unwanted toxicity while enhancing the targeting of R/R AML, including LSCs.

Example 2 – ADGRE2 scFv

The ADGRE2 single-chain fragment variable (scFv) in the ADCLEC.syn1 vector was selected from 24 versions of the humanized recombinant antibodies generated using the peptide sequence of the monoclonal anti-human ADGRE2 clone 2A1 antibody. The binder selection scheme is present in Figure 6. The mouse monoclonal anti-human ADGRE2 clone 2A1 is a widely used antibody to detect ADGRE2 expression in human samples (Boyden et al., *N Engl J Med.* 374(7):656-63. (2016)). Based on (1) the expression of the humanized 2A1 antibody variants, (2) the binding of the recombinant antibodies to ADGRE2-overexpressing murine lymphoma EL4 cells as measured by flow cytometry, and (3) the immunogenicity score, 18 humanized recombinant antibodies were selected from the pool of candidates. Next, VH and VL domains were identified to generate 18 scFv candidates that were subsequently integrated into the SFG based gammaretroviral CAR vectors and tested in functional CAR assays (Figures 7A-7C and 8).

ADGRE2-specific CAR T cells were produced by transducing T cells with the SFG-gammaretroviral vector expressing each of the humanized 2A1 scFv in the CAR cassette, and CAR T cell cytotoxicity was measured using the AML cell line MOLM13. Cognizant of ADGRE2 expression in some normal cell types, including HSCs, which express lower levels of ADGRE2 than AML cells, MOLM13 cell lines were genetically modified for high (WT), low, or very low levels of ADGRE2 expression, with coexpression of low (WT) or high levels of CLEC12A (see Table 17 below).

Table 17. MOLM13 cell lines for CAR studies used for identification of lead ADGRE2 and CLEC12A scFvs

Target cell line	ADGRE2 level (MFI relative to WT)	CLEC12A level (MFI relative to WT)
MOLM13-WT	high (1x)	low (1x)
MOLM13_ADGRE2-1E8	low (0.2x)	low (1x)
MOLM13_ADGRE2-9D6	very-low (0.1x)	low (1x)
MOLM13_ADGRE2-E6_CLEC12A-C6	low (0.2x)	high (25.9x)
MOLM13_ADGRE2-9D6_CLEC12A-B6	very-low (0.1x)	high (15.7x)

These modified MOLM13 cell lines allowed the identification of the humanized
 5 ADGRE2 scFv with the highest potential of efficiently depleting ADGRE2-high AML cells
 while sparing ADGRE2-low normal cells and thereby maintaining a favorable safety profile
 (Figures 7A-7C and 8). The *in vitro* CAR screening included 18 different ADGRE2 scFv
 candidates in the context of two different signal peptides (CD8a or IgHV1-4). A set of 6 scFvs
 that mediated the most suitable pattern of *in vitro* target cell lysis (maximum lysis of ADGRE2-
 10 high cells and minimum lysis of ADGRE2-very-low cells) were identified with a high similarity
 between the two tested signal peptides (Figures 7A-7C). Then, these 6 scFvs were tested in *in*
vivo model using the same AML cell line MOLM13 with high (WT), low or very low levels of
 ADGRE2. Here, the ADGRE2 scFv ADGRE2-A showed the most suitable *in vivo* response
 pattern, with maximum efficacy against target cells with high ADGRE2 levels and
 15 reduced/absent efficacy against target cells with low/very-low ADGRE2 levels, respectively.
 Therefore, ADGRE2-A was selected as ADGRE2 scFv and with the CD8a signal peptide.

Example 3 – CLEC12A scFv

The human CLEC12A scFv was selected from 74 unique human antibodies produced by
 hybridomas generated by fusing P3X63Ag8U.1 cell with lymphocytes isolated from mice
 20 immunized with recombinant human CLEC12A protein. Positive clones were selected by using
 on-cell binding to CLEC12A-expressing CHO-S cells and surface plasmon resonance assay. The
 selection scheme of the scFv selection is shown in Figure 9.

16 different human CLEC12A scFv candidates were tested in a 28z1XX TRAC-CAR
 format using *in vitro* 18h CAR cytotoxicity assays and *in vivo* xenograft models. Different from
 25 the strategy for ADGRE2 scFv identification, here the efficacious scFv were prioritized in the
 context of both high and low target antigen levels, considering that the eventual application of
 the scFv would be in a CCR, not CAR, and high target sensitivity of the CLEC12A scFv would
 therefore not be associated with increased toxicity. *In vitro* screening of 16 scFvs in the context

of U937 (CLEC12A-high) and MOLM13 (CLEC12A-low) cell lines identified 9 highly potent CLEC12A scFvs (Figures 10A and 10B). Subsequent *in vivo* screening of these 9 scFvs identified the lead CLEC12A scFv (CLEC12A-A) (Figure 11).

Example 4 – Off-target binding of ADGRE2 scFv and CLEC12A scFv

The off-target binding interactions of ADGRE2 scFv (ADGRE2-A) and CLEC12A scFv (CLEC12A-A) to human plasma membrane proteins were carried out in a 4-phase approach: (1) pre-screening to determine the optimal concentrations of purified recombinant ADGRE2 scFv-Fc and CLEC12A scFv-Fc test proteins for the screening; (2) screening for binding of the test proteins against fixed HEK293 cells overexpressing 5,474 full-length human plasma membrane proteins and cell surface tethered human secreted proteins and 371 human cell surface heterodimers, which identified library hits; (3) confirmatory/specific screens using fixed-cell and live-cell microarrays; (4) flow cytometry-based follow-on study to investigate further identified test protein-specific interactions on live cells; and (5) cell-to-cell binding assays to confirm positive hits. The table below summarizes the off-binding data for ADGRE2 scFv and CLEC12A scFv.

Table 18. Binding of ADGRE2 scFv and CLEC12A scFv to proteins identified in the fixed and live-cell screenings

Test Article	Interacting Proteins identified from the screens	Protein Name	Flow Cytometry EC50	Cell-to-Cell Binding
ADGRE2 scFv-Fc	ADGRE2	Adhesion G protein-coupled receptor E2	Not tested	Not tested
CLEC12A scFv-Fc	CLEC12A	C-type lectin domain family 12 member A	0.081 µg/mL	medium to strong
	SECTM1	Secreted and transmembrane protein 1	799.5 µg/mL	weak to very weak
	RTN4R	Reticulon-4 receptor	>300 µg/mL	Not tested

From the 5,845 plasma membrane proteins tested, the purified ADGRE2-scFv-Fc protein bound only its primary target cell surface protein, ADGRE2, both in fixed-cell and live-cell microarrays. In addition, ADGRE2-scFv-Fc did not bind to other ADGRE proteins ADGRE1, ADGRE3, and ADGRE5.

CLEC12A scFv-Fc showed a strong specific interaction with its primary target, CLEC12A. It also had a low but detectable interaction with SECTM1 in both fixed-cell and live-cell microarrays and with RTN3R in live-cell microarray only. Follow-on studies using dose titration and flow cytometry experiments using purified CLEC12A scFv-Fc demonstrated that CLEC12A scFv EC50s against SECTM1 and RTN4R were 800-fold and >3,700-fold

greater than against the primary target CLEC12A, respectively. Furthermore, although the CLEC12A CCR-expressing Jurkat cells bound CLEC12A-overexpressing HEK293 cells, CLEC12A CCR-expressing Jurkat cells had very weak to weak binding to SECTM1-overexpressing HEK293 cells. Together, these data suggest that the binding of CLEC12A scFv-Fc to SECTM1 and RTN4R may not be physiologically relevant. Any potential off-target binding of the CLEC12A CCR does not lead to cytotoxicity without simultaneous ADGRE2 CAR activation, adding another safety layer (Figure 12).

Example 5 – Validation of combinatorial CAR+CCR targeting concept of ADCLEC.syn1

As outlined in the schematics depicted in Figures 3 and 5, the presently disclosed subject matter hypothesized that the combinatorial CAR+CCR design of ADCLEC.syn1 would allow efficient elimination of AML while sparing normal cells with low CAR target levels. Importantly, the CCR alone should assist and enhance CAR-mediated cytotoxicity, however, not trigger cytotoxicity independently. This approach was validated in *in vitro* and *in vivo* models (Figure 12). First, an *in vitro* model was established with a target cell line expressing either no target (ADGRE2-/CLEC12A-), CAR target alone (ADGRE2+/CLEC12A-), CCR target alone (ADGRE2-/CLEC12A+), or both CAR and CCR targets (ADGRE2+/CLEC12A+). The CCR target alone did not trigger *in vitro* killing, however, the CAR target alone triggered killing, which was further enhanced when the CCR target was co-expressed on the target cell line (Figure 12A). Next, it was demonstrated *in vivo* that ADGRE2 CAR signaling alone was not sufficient to fully eradicate ADGRE2-low cells (modeling normal cells), however, combined ADGRE2 CAR and CLEC12A CCR signaling allowed for complete and durable AML remission (Figures 12B and 12C). Overall, these results indicate the potential of ADCLEC.syn1 to spare normal cells with low levels of CAR target while efficiently eradicating AML.

Example 6 – SFG-ADCLEC.syn1 Retroviral vector

The gammaretroviral plasmid SFG-ADCLEC.syn1 (Figure 13) was constructed and the identity of the plasmid was verified by Sanger sequencing analysis. The gammaretroviral vector SFG-ADCLEC.syn1 expresses both the ADGRE2-specific CAR and CLEC12A-specific CCR linked through a P2A element, as shown in Figure 14.

The SFG plasmid is used to transiently transfect 293Vec-RD114 cells, a HEK 293-based packaging cell line that produces retroviral vectors pseudotyped with feline RD114 envelope. The vector supernatant that is harvested from the 293Vec-RD114TM packaging cells is subsequently used to transduce the 293Vec-GalVTM, a second HEK 293-based packaging cell line pseudotyped with the gibbon ape leukemia virus envelope protein, to generate a stable producer cell population expressing the 293Vec-GalV-SFG-ADCLEC.syn1. Single clones are

isolated from the 293Vec-GalVTM SFG-ADCLEC.syn1 vector producer population, and several seed banks are generated and best titer clones are characterized. The best producer cell line, the lead clone, is used to generate the Master Cell Bank (MCB) from the seed banks. Retroviral Vector stock (VS) is manufactured from one vial of the MCB.

5 **Example 7 – Ex vivo transduction of autologous T cells with SFG-ADCLEC.syn1**

Activated, autologous patient-derived peripheral blood T cells are transduced *ex vivo* with GalV pseudotyped SFG-ADCLEC.syn1 retroviral vector stocks. CD8⁺ and CD4⁺ T cells are positively isolated using CD8 and CD4 Microbeads using the Prodigy CliniMACS plus instrument (Miltenyi Biotec) and activated with Dynabeads (ThermoFisher). The initial positive selection of CD8⁺ and CD4⁺ T cells mainly minimizes the number of B lymphocytes, plasma cells, and monocytes in the transduced T cell product. Fluorescence-activated cell sorting (FACS) assays using dye-labeled purified ADGRE2 or CLEC12A polypeptides are carried out to measure the expression of the ADGRE2 CAR and CLEC12A CCR to determine transduction efficiency. Products for patient administration have transduction efficiency greater than or equal to 4%.

Example 8 – Dosage Form, Route of Administration, And Dosing Regimen (Frequency and Duration)

ADCLEC.syn1 CAR T cells are provided in a cryopreserved bag, thawed at the facility, e.g., hospital facility, and administered as an intravenous (IV) infusion via gravity. The planned dose levels to be evaluated during dose escalation are described in Table 19 below.

Table 19. Planned ADCLEC.syn1 CAR T cells Dose Levels

Dose Level (DL)	ADCLEC.syn1 CAR T cell dose (flat)
-1	10×10^6
1	25×10^6
2	50×10^6
3	100×10^6
4	150×10^6

The starting dose for ADCLEC.syn1 CAR T cells is 25×10^6 CAR T cells. This dose is significantly lower than the approved dosing of CD19 CARs (2×10^6 CAR T cells/kg for axicabtagene and $6\text{--}60 \times 10^7$ CAR T cells for tisagenlecleucel), and also lower than the doses of BCMA CARs currently being investigated in multiple myeloma ($50\text{--}800 \times 10^6$ CAR T cells). Dose escalation follows a standard 3+3 design. Following identification of the RP2D, the RP2D dose cohort can be expanded.

Example 9 – Clinical Study

The present example is a phase 1, open-label, dose-escalation study to evaluate safety and activity of ADCLEC.syn1 CAR T cells disclosed herein in adult patients with R/R AML. A standard 3+3 dose escalation scheme is used to determine the maximum tolerated dose (MTD) or maximal administered dose (MAD) if the MTD is not reached. Once the MTD or MAD is identified, the cohort is expanded to include additional patients to further evaluate the safety and activity of ADCLEC.syn1 CAR T cells.

Cohorts of 3-6 patients are infused with escalating doses of ADCLEC.syn1 CAR T cells to establish the MTD. There are 4 planned dose levels: 25×10^6 , 50×10^6 , 100×10^6 , 150×10^6 CAR T cells. A standard 3+3 dose escalation design is implemented starting from dose 25×10^6 . 3-6 patients are treated in each cohort and dose escalation proceeds to the next cohort if less than 33% of patients in a cohort experience unanticipated dose-limiting toxicity (DLT). If unacceptable toxicity is seen in 1 of 3 patients in any given cohort, up to 6 patients are treated in that cohort using a conventional dose escalation scheme. If 2 of 6 patients in any given cohort experience unacceptable toxicity, the MTD of T cells has been exceeded, and established at the previous cohort dose level. If the first dose level exceeds the MTD, a subsequent cohort of 3-6 patients is treated at the -1 dose level of 10×10^6 ADCLEC.syn1 CAR T cells.

Conditioning or lymphodepleting chemotherapy. Patients receive conditioning chemotherapy consisting of fludarabine $25\text{mg}/\text{m}^2$ on days -4, -3, -2, and cyclophosphamide $500\text{mg}/\text{m}^2$ on days -3, -2, followed by CAR T cell infusion on day 0.

Bridging therapy. At the discretion of the treating physician, bridging therapy may be considered. Bridging therapy may be administered after leukapheresis and must be discontinued at least 1 week prior to administration of conditioning chemotherapy, with the exception of hydroxyurea which can be continued until at least 24 hours prior to the start of conditioning chemotherapy. Subjects should be restaged after the end of the bridging therapy and prior to start of conditioning chemotherapy or within 48 hours prior to administration of conditioning chemotherapy.

Disease response assessment. Bone marrow biopsy is obtained at day 28-35 of CAR T cell infusion for response assessment and is assessed by the ELN criteria.

Treatment course following D28-35 disease response assessment. Following the disease response assessment, subsequent care is guided per the suggested algorithm as shown in Figure 16.

Toxicity assessment. At each study visit, toxicities are graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version

5.0 and ASTCT consensus grading for cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS).

Pharmacokinetic assessment. Blood tests for pharmacokinetic measurements are performed prior to dosing, on day 1, 3, 5, 7, 14, 21, and 28-30. Subsequent blood samples are collected on months 2, 3, 6, 9, 12 and 24 months.

ADCLEC.syn1 CAR T cell Dose Levels. The starting dose for ADCLEC.syn1 CAR T cells is 25×10^6 CAR T cells. This dose is significantly lower than the approved dosing of CD19 CARs (2×10^6 CAR T cells/kg for axicabtagene and $6-60 \times 10^7$ CAR T cells for tisagenlecleucel), and also lower than the doses of BCMA CARs currently being investigated in multiple myeloma ($50 - 800 \times 10^6$ CAR T cells). Assuming a body weight of 70kg, the proposed starting dose translates to 2×10^5 CAR T cells/kg and is comparable (or slightly lower) compared to other autologous AML CAR starting doses.

Dose Limiting Toxicity (DLT). A DLT is defined as any of the following adverse event (AE) that occurs within 28 days of the ADCLEC.syn1 CAR T cell infusion, based on Common Terminology Criteria for Adverse Events (CTCAE) v5.0, or the ASTCT Consensus Grading guidelines for Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity Syndrome (ICANS): (a) any Grade ≥ 3 non-hematologic AE to vital organs (excluding CRS and ICANS) which fail to resolve to grade 2 or below within 7 days; (b) Grade 4 neutropenia or thrombocytopenia and day 28 bone marrow cellularity of $<5\%$ in the absence of persistent AML. Persistent cytopenias that were present at baseline (pre-conditioning chemotherapy and T cell infusion) that persist until day 30 in the absence of active disease is not considered a DLT; (c) $\geq$ Grade 3 infusion reaction; (d) Grade 3 or 4 ICANS of any duration; (e) Grade 4 CRS of any duration; (f) Grade 4 tumor lysis syndrome; (g) Grade 4 capillary leak syndrome; and (h) any Grade 5 event related to ADCLEC.syn1 CAR T cells.

Dose Escalation. The objective of Dose Escalation is to determine the MTD/MAD of ADCLEC.syn1 CAR T cells. Dose escalation follows 3+3 dose escalation rules as follows: (a) subjects are enrolled in cohorts of three subjects per dose level with a minimum of 10 days between ADCLEC.syn1 CAR T cells dosing of the first and the second subject within a cohort; (b) if no DLT is reported in the initial cohort of three subjects, dose escalation can proceed to the next higher dose level; (c) if one subject has a DLT, the cohort is expanded up to six subjects. If no additional DLTs are observed, that dose level is considered tolerable and dose escalation can proceed to the next higher dose level; (d) a subject who discontinues study treatment or withdraws from the study prior to the end of the DLT observation period for reasons other than DLT is considered unevaluable for DLT and is replaced; (e) if more than one subject out of six

enrolled subjects enrolled at the same dose level cohort has a DLT, the MTD has been exceeded. Further enrollment in that dose cohort stops; six subjects at a lower dose level are enrolled to determine the MTD per 3+3 dose escalation rules; (f) if the dose level that exceeded the MTD is ≥ 2 times higher than the previously highest tolerable dose level, another dose level approximately midway between these two levels can be enrolled to determine the MTD per 3+3 dose escalation rules; (g) the MTD is the highest dose level cohort with at most one DLT in six evaluable subjects.

Dose Expansion. The objectives of Dose Expansion are to further assess safety and tolerability and to identify activity signals to guide and support future development. The dose of ADCLEC.syn1 CAR T cells in the Dose Expansion is the MTD/MAD that was established during Dose Escalation. During the Dose Expansion phase, subjects with R/R AML are treated in the same manner as in the Dose Escalation phase and includes up to approximal 12 subjects.

Investigational Medicinal Product. ADCLEC.syn1 CAR T cells are provided as a cryopreserved bag, thawed at the facility, and administered as an intravenous (IV) infusion via gravity. The planned dose levels is evaluated during dose escalation described herein. ADCLEC.syn1 CAR T cells are administered on Day 0.

Non-Investigational Medicinal Products. Conditioning chemotherapy includes (a) cyclophosphamide (CY), 500 mg/m² IV on Days -3 and -2 of each treatment cycle; and (b) fludarabine (FLU), 25 mg/m² IV on Days -4, -3 and -2 of each treatment cycle. The dose and schedule of CY and FLU may be modified based on cytopenia and medical comorbidities.

Study Endpoints. Primary endpoints include the incidence and nature of DLTs when ADCLEC.syn1 CAR T cells are administered in patients with R/R AML. Secondary endpoints include (a) incidence, nature and severity of adverse events of ADCLEC.syn1 CAR T cells; (b) investigator-assessed objective-response rate (ORR), defined as the proportion of subjects who achieve a Complete Response (CR), CR with incomplete hematologic recovery (CRi), morphologic leukemia free state (MLFS) and partial response (PR), as per the ELN response criteria; (c) progression-free survival (PFS), defined as the duration from first dose of ADCLEC.syn1 CAR T cells (Day 0) to progressive disease (PD), or to the day of death for any reason, whichever occurs earlier; (d) one-year overall survival (OS), defined as the percentage of subjects who are alive at one year from initiation of study treatment; and (e) cellular kinetics of ADCLEC.syn1 CAR T cell, peak expansion and persistence defined as duration from Day 1 to the last assessment of detectable levels of ADCLEC.syn1 CAR T cells, as assessed by PCR and flow cytometry. Exploratory endpoints include (a) association of ORR and/or PFS with expansion and duration of ADCLEC.syn1 CAR T cells, with ADGRE2 and CLEC12A antigen

- expression, and CAR T cell phenotypes ; (b) MRD assessment in those patients who achieve CR or CRi as assessed by multiparameter flow cytometry and/or NGS; (c) analysis of serum cytokines following CAR T cell infusion; (d) analysis for immunogenicity towards the CAR-CCR construct; and (e) association of relapse with ADGRE2 and CLEC12A expression levels,
- 5 ADCLEC.syn1 CAR T cell persistence and phenotype and changes in tumor microenvironment.

- Tumor Response Assessment Criteria. Antitumor responses is assessed according to the ELN response criteria in AML. Eligibility/Inclusion criteria include (a) being ≥ 18 years of age at the time of signing the ICF; (b) have been refractory or relapsed AML who have exhausted or are not eligible or intolerant to, standard therapeutic options (the following disease status is
- 10 eligible for the study: (1) primary refractory disease after two courses of induction chemotherapy or after one course of hypomethylating agent or low dose cytarabine in combination with venetoclax that has not achieved CR/CRi or MLFS by the ELN criteria; or (2) recurrent AML at any time after achieving a response (CR or CRi) during or after the course of treatment, including HSCT); (c) any degree of detectable disease is eligible; (d) ECOG
- 15 performance status 0 or 1; (e) having a suitable stem cell donor identified who may donate cells in the event that the subject needs to undergo an allogeneic HSCT for rescue from prolonged marrow aplasia (donor can be from related or unrelated matched source, haplo or cord, and must be found to be suitable according to standard criteria); and (f) having adequate organ function defined as serum creatinine < 2.0 mg/100ml, direct bilirubin < 2.0 mg/100ml, AST and/or ALT
- 20 $\leq 5 \times$ ULN, unless considered due to leukemic organ involvement. Exclusion Criteria include (a) diagnosis of acute promyelocytic leukemia; (b) radiologically-detected or symptomatic CNS disease or CNS 3 disease, i.e., presence of ≥ 5 /ul WBCs in CSF (subjects with adequately treated CNS leukemia are eligible); (c) oxygen saturation $< 90\%$ on room air; (d) prior allogeneic HSCT within 3 months of signing ICF or with ongoing requirement for systemic graft-versus-host
- 25 therapy; (e) clinically significant cardiovascular disease, including stroke or myocardial infarction within 6 months prior to first study medication; or the presence of unstable angina or congestive heart failure of New York Heart Association grade 2 or higher, or cardiac ejection fraction $< 40\%$; (f) uncontrolled clinically significant infections; (g) positive serologic test results for HIV; (h) acute or chronic HBV or HCV infection as assessed by serologic (HBVsAg or HCV ab) or PCR results; and (i) active second malignancy that requires systemic treatments,
- 30 with the exception of malignancy treated with curative intent and without evidence of disease for > 2 years before screening. Stopping Rules include (a) for Dose Escalation, the stopping rules are as per the dose escalation rules; (b) for Dose Expansion, a temporary halt to enrollment in the study occurs when any patient death deemed probably or possibly related to

ADCLEC.syn1 CAR T cells, or $\geq 30\%$ subjects in an expansion cohort, where at least 6 subjects have been enrolled, experience an ADCLEC.syn1 CAR T cell treatment-related toxicity at any time on study that would have otherwise qualified as a DLT.

Statistical Methods. In general, clinical data are summarized by cohort, separately by each regimen, using descriptive statistics (n, mean, standard deviation, standard error, median, first quartile (Q1), third quartile (Q3), minimum, and maximum for continuous variables, and frequencies and percentages for categorical variables). When categorical data are presented, the percentages are suppressed when the frequency count is zero. Non-zero percentages are rounded to one decimal place, except 100% is displayed without any decimal places. For selected assessments, confidence intervals (CIs) is displayed. Time-to-event variables are summarized using Kaplan-Meier methods.

Example 10 – Identification and characterization of anti-ADGRE2 antibodies and scFvs

The present example demonstrates derivation and characterization of binding affinities of anti-ADGRE2 antibodies and scFvs. Antibodies were developed using hybridoma technology, comprising 24 humanized sequences of the mouse Reference 1 Clone. Antibodies were selected based on expression as recombinant protein variants, binding to ADGRE2-overexpressing murine lymphoma EL4 cells as measured by FACS, and immunogenicity score, 18 humanized recombinant antibodies were selected representing a range of ADGRE2 binding affinities. The amino acid sequence of the Reference 1 anti-ADGRE2 antibody was determined by endoprotease digestion and subsequent analysis of peptide pools by LC-MS/MS. Briefly, the heavy and light chains of the antibody were separated by SDS-PAGE under reducing conditions. After staining with Coomassie Blue, respective bands were cut from the gel and digested with Asp N, chymotrypsin, trypsin and elastase endopeptidases. In addition, antibody was digested in solution by pepsin. The pool of peptides generated from digestion was analyzed on an Orbitrap analyzer (LC-MS/MS Q-Exactive, ThermoFisher). LC-MS/MS data was processed using the PEAKS AB antibody sequencing software. The Reference 1 anti-ADGRE2 VH and VL coding sequences were derived from the respective antibody chain sequences, and cloned with an IgG2 constant region. Recombinant Reference 1 antibody was expressed in HEK293 cells, and purified antibody was compared with commercially available Reference 1 antibody by surface plasmon resonance (SPR) K_D analysis using a recombinantly produced protein comprising the extracellular domain of ADGRE2 as well as EC50 determination was carried out for binding to cells expressing ADGRE2. For subsequent antibody screening work, purified recombinant Reference 1 antibody was used as a reference antibody.

Example 11 – On-cell binding of anti-ADGRE2 scFvs

This example illustrates the on-cell binding for the anti-ADGRE2 scFvs as measured by flow cytometry. The on-cell binding for the anti-ADGRE2 scFvs was assessed by flow cytometry on the E4 cells overexpressing ADGRE2. Each of the scFvs were tested for binding to ADGRE2 and compared to the Reference 1 mAb. Briefly, 100,000 cells per well, were plated in 96 well V bottom plate, scFvs were diluted to 200 nMscFv then 1:4 serially down to 0.01nM. A dose dependent titration of the scFvs validated recombinant scFvs folding and binding to ADGRE2. EC₅₀ affinities were compared in order to better interpret any differences seen in-vivo that might be caused by variations in affinities resulting from the humanization process. Data was analyzed using Prism software, using a four parameter regression. The approximate EC₅₀ values were determined using equation: $Y = \text{Bottom} + (\text{Top} - \text{Bottom}) / (1 + 10^{((\text{LogEC}_{50} - X) * \text{HillSlope}))}$ where the fitted parameters are defined as follows: Bottom, the lower plateau describing minimum binding achievable; Top, the upper plateau describing the maximum binding achievable; LogEC₅₀, the inflection point of the dose response curve also known as the concentration producing a half-maximal response; and Hill-Slope, the slope of the dose response curve.

Table 20. Binding Affinity of anti-ADGRE2 scFv

scFv	Affinity (EC ₅₀ nm)
ADGRE2-D	16.4
ADGRE2-B	55.3
ADGRE2-E	10.6
ADGRE2-A	93.8
ADGRE2-F	16.4
ADGRE2-C	53.2
Reference 1	10.1

As shown in Table 20, the EC₅₀ values calculated from the curves show that each of the antibodies binds cells at affinities from 10.2 to 93.8. Overall, the results showed that the tested humanized scFvs had EC₅₀ values comparable to the Reference 1 standard.

Example 12 – In silico immunogenicity analysis of anti-ADGRE2 scFv

This example illustrates *in silico* immunogenicity analysis. Briefly, mouse Reference 1 scFv sequences was analyzed with the humanized scFvs by a human MHCI and MHCII presentation prediction software, based on various prediction databases IEDB, SMN-Align, NN-Align.

Table 21. Immunogenicity of anti-ADGRE2 scFvs

scFv	Immunogenicity		
	MHC I	MHC II	MHC I + MHC II
ADGRE2-D	533	645	1178
ADGRE2-B	686	876	1562
ADGRE2-E	500	685	1185
ADGRE2-A	647	995	1642
ADGRE2-F	628	844	1472
ADGRE2-C	643	941	1584
Reference 1	886	1183	2069

As shown in Table 21, the immunogenicity of the antibody was characterized based on MHC I or MHC II binding or binding to both MHC I and MHC II. Overall, the data predict low immunogenicity for all tested humanized antibodies.

5 **Example 13 – Off-target Screening Panel Assay of anti-ADGRE2 scFv**

This example illustrates the specificity of anti-ADGRE2 scFvs in an off-target binding assay. Briefly, humanized scFv variants were tested for off-target binding. Three exemplary ADGRE2 scFv clones were run in the “Cut-down Assay” to screen for binding of to over 3000 human receptors. In the cut-down assay, the higher the binding, the higher the likelihood of the interaction being real. Generally, hits labelled “V. weak” are unlikely to be real interactions. The results showed that all the clones tested did not show any off-target binding. Thus, these clones were found to be highly specific for ADGRE2.

Example 14 – Characterization of Clec12A binding of anti-CLEC12A scFv

The present example demonstrates derivation and characterization of binding affinities of anti-CLEC12A antibodies. In order to select and screen for Clec12A antibodies, hybridoma technology was used. Selections were carried out on Clec12A overexpressing CHO-S cells. Antibodies were selected for a diversity of sequences. 16 antibodies were selected out of 74 antibodies for a range of soluble and on-cell Clec12A binding affinities. The binding affinities of Clec12A antibodies were determined by Biacore analysis.

Further, the present example evaluates non-specific binding of the anti-CLEC12A antibodies. To assess the potential for the anti-CLEC12A antibodies to bind non-specific membrane proteins, scFvs derived from the 4 lead antibodies were evaluated in a surface membrane protein (SMP) assay (Figure 17A). The SMP assay used was an ELISA based assay with human HEK-293 or insect SF9 cell membranes coated on the plate to test for non-specific binding to these membranes by the test antibodies. Internal control high and low non-specific

binding antibodies were included. The high non-specific binding control, sc209, used was an antibody that has off target tox in clinic while the low non-specific binding control, 5f9, has not demonstrated off target tox in clinic (Figure 17B).

Overall, the results showed low non-specific binding by anti-CLEC12A antibodies
5 CLEC12-C, CLEC12-D, and CLEC12A (Figure 17B)

Example 15 – Off-target Screening Panel Assay of anti-CLEC12A scFvs

This example illustrates the specificity of anti-CLEC12A scFvs in an off-target binding assay. Briefly, to test anti-CLEC12A scFvs for specificity to Clec12A as well as other membrane proteins, an off-target binding assay was conducted. Two selected Clec12A scFv
10 clones were run in a “cut-down assay” to screen for binding of over 3000 human receptors. In the cut-down assay, the higher the binding, the higher the likelihood of the interaction being real. Generally, hits labelled “V. weak” are unlikely to be real interactions. scFvCLEC12A-A did not show any non-specific interactions to any receptor other than Clec12A or the receptors which come up as artifacts in this assay. The cut-down assay was used to screen clones for off-
15 target assays. Selected scFv-Fc clones are being tested more comprehensively in additional screening and confirmation assays.

Example 16 – Preclinical Study

CAR T cell therapy provides a potent therapeutic option in various B cell-related hematologic malignancies. One of the major efficacy challenges is escape of tumor cells with
20 low antigen density, which has been clinically observed in several malignancies treated with CAR therapy. Novel concepts of CAR design are needed to address phenotypic heterogeneity including clonal variability of target antigen expression. Figure 18A illustrates previously reported combinatorial CAR concepts including Boolean-logic OR- and AND-gate concepts as well as IF-THEN-gated CAR expression.

25 The inventors developed a combinatorial CAR concept that can overcome AML resistance due to target heterogeneity and antigen-low escape. Antigen-low relapse can be prevented via a novel chimeric receptor design with combinatorial signaling that is synergistic and adjusted to the respective target choice.

Flow cytometric antigen expression profiling in AML versus normal hematopoiesis was
30 performed for several previously discovered CAR target candidates in AML. To provide a platform for identification of the ideal combinatorial CAR design, *in-vitro* and *in-vivo* models based on human AML cell lines with up-or down-regulated antigen levels of ADGRE2 and CLEC12A were established to mimic AML target heterogeneity and antigen-low escape. Using

a bicistronic γ -retroviral vector, different combinatorial CAR formats targeting ADGRE2 and CLEC12A were screened.

ADGRE2 was selected as a CAR target due to its high rate of positivity on AML bulk and leukemic stem cells (LSC) in a molecularly heterogeneous AML patient population (Figures 1A and 1B). The affinity of an ADGRE2-targeted CAR comprising an extracellular antigen-binding domain comprising the ADGRE2-A scFv was measured and CD3zeta signaling was fine-tuned to achieve an ideal killing threshold that would allow for sparing of ADGRE2-low normal cells. Next, the inventors investigated the potential of co-targeting of a second AML-related antigen to mitigate potential CAR target antigen-low AML escape. CLEC12A was identified as a suitable co-target due to its non-overlapping expression profiles in normal hematopoiesis and other vital tissues (Figures 4A-4C).

ADCLEC.syn1, a novel combinatorial CAR construct including an ADGRE2-targeted 28z1XX-CAR that comprises an extracellular antigen-binding domain comprising the ADGRE2-A scFv and a CLEC12A-targeted chimeric costimulatory receptor (CCR) that comprises an extracellular antigen-binding domain comprising the CLEC12A-A scFv was developed. In addition, a construct including an ADGRE2-targeted 28z1XX-CAR that comprises an extracellular antigen-binding domain comprising the ADGRE2-A scFv and a CLEC12A-targeted BBz-CAR that comprises an extracellular antigen-binding domain comprising the CLEC12A-A scFv was also developed.

ADCLEC.syn1 operates based on a gating strategy described as “IF-BETTER” (Figure 18B): high CAR target expression alone triggers killing, whereas low CAR target expression does not, unless a CCR target is present. Additional CCR interaction lowers the threshold for CAR-mediated killing through increased avidity and co-stimulation, allowing for higher CAR sensitivity that is purposefully limited to target cells expressing both antigens.

In the context of ADCLEC.syn1, ADGRE2-positive/CLEC12A-negative and ADGRE2-positive/CLEC12A-positive cells triggered cell lysis while ADGRE2-negative/CLEC12A-positive cells and ADGRE2-negative/CLEC12A-negative cells were spared. Importantly, ADCLEC.syn1 mediated more efficient killing of ADGRE2-positive/CLEC12A-positive cells as compared to ADGRE2-positive/CLEC12A-negative cells (Figure 19A).

Using AML cell lines with varying levels of ADGRE2 to model antigen escape, ADCLEC.syn1 had superior killing capacity against ADGRE2-low/CLEC12A-low and ADGRE2-very-low/CLEC12A-low AML target cells as compared to ADGRE2-CAR (Figure 19B).

Using NSG *in-vivo* xenograft models of engineered MOLM13 AML cell line variants with low levels of ADGRE2 to model antigen escape, it was found that ADCLEC.syn1 outperformed an ADGRE2-targeted CAR comprising an extracellular antigen-binding domain comprising the ADGRE2-A scFv alone without a CLEC12A-targeted CCR lacking assistance via CLEC12A-CCR. Importantly, ADCLEC.syn1 also outperformed an otherwise identical alternative dual-CAR version (OR-gated ADGRE2-CAR+CLEC12A-CAR) in the setting of ADGRE2-low MOLM13, further underlining the importance of fine-tuned overall signaling (Figure 20). High *in-vivo* potency was also confirmed against diverse AML cell lines with a wide range of ADGRE2 and CLEC12A levels reflecting population-wide AML heterogeneity (Figure 20).

At clinically relevant CAR T cell doses, ADCLEC.syn1 induced complete and durable remissions in xenograft models of MOLM13 (ADGRE2-high/CLEC12A-low) and U937 (ADGRE2-low/CLEC12A-high). Specifically, in NSG xenograft models using a MOLM13 AML cell line variant with ADGRE2-high(WT) and CLEC12A-high antigen levels, ADCLEC.syn1 CAR T cells were titrated to low doses, establishing 1×10^5 ADCLEC.syn1 T cells as minimum efficacious dose to induce complete and durable remission (Figure 20). ADCLEC.syn1 CAR T cells were found to be functionally persistent for >70 days, with a single CAR T cell dose potentially averting relapse modeled via AML re-challenges (Figure 21).

In summary, these data provide pre-clinical evidence that an “IF-BETTER”-gated CAR+CCR T cell (ADCLEC.syn1) can outperform a single-CAR T cell (ADGRE2-CAR) and a dual-CAR T cell (ADGRE2-CAR+CLEC12A-CAR). ADCLEC.syn1 enhanced antileukemic efficacy and prevented antigen-low AML escape via detection of a rationally selected combinatorial target antigen signature that is commonly found in AML but limited in vital normal cells. Using phenotypically representative AML xenograft models and clinically relevant T cell doses, it was demonstrated the high therapeutic potential of ADCLEC.syn1 CAR T cells, further supporting clinical translation of an “IF-BETTER”-gated CAR concept into a phase 1 trial.

Although the presently disclosed subject matter and certain of its advantages have been described in detail, it should be understood that various changes, substitutions and alterations can be made herein without departing from the spirit and scope of the disclosure. Moreover, the scope of the present application is not intended to be limited to the particular embodiments of the process, machine, manufacture, and composition of matter, and methods described in the specification. As one of ordinary skill in the art will readily appreciate from the disclosure of

the presently disclosed subject matter, processes, machines, manufacture, compositions of matter, or methods, presently existing or later to be developed that perform substantially the same function or achieve substantially the same result as the corresponding embodiments described herein may be utilized according to the presently disclosed subject matter.

- 5 Accordingly, the appended claims are intended to include within their scope such processes, machines, manufacture, compositions of matter, or methods.

Various patents, patent applications, publications, product descriptions, protocols, and sequence accession numbers are cited throughout this application, the disclosure of which are incorporated herein by reference in their entireties for all purposes.

10

WHAT IS CLAIMED IS:

1. A chimeric receptor, comprising an extracellular antigen-binding domain that binds to ADGRE2, a transmembrane domain, and an intracellular domain, wherein the extracellular antigen-binding domain comprises:
 - a) a heavy chain variable region comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 33 or a conservative modification thereof, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 34 or a conservative modification thereof, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 35 or a conservative modification thereof; and/or
 - b) a light chain variable region comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 36 or a conservative modification thereof, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 37 or a conservative modification thereof, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 38 or a conservative modification thereof.
2. The chimeric receptor of claim 1, wherein the extracellular antigen-binding domain comprises a single-chain variable fragment (scFv), a Fab, or a F(ab)₂.
3. The chimeric receptor of claim 2, wherein the extracellular antigen-binding domain comprises a single chain variable fragment (scFv).
4. The chimeric receptor of claim 3, wherein the scFv is a humanized scFv.
5. The chimeric receptor of any one of claims 1-4, wherein the heavy chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 33, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 34, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 35.
6. The chimeric receptor of any one of claims 1-5, wherein the light chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 36, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 37, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 38.
7. The chimeric receptor of any one of claims 1-6, wherein the heavy chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 33, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 34, and a CDR3 comprising the

amino acid sequence set forth in SEQ ID NO: 35; and the light chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 36, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 37, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 38.

8. The chimeric receptor of any one of claims 1-7, wherein the heavy chain variable region comprises an amino acid sequence that is at least about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98% or about 99% identical or homologous to the amino acid sequence set forth in SEQ ID NO: 39, SEQ ID NO:43, SEQ ID NO:46, SEQ ID NO:49, SEQ ID NO: 52, SEQ ID NO: 55, or SEQ ID NO: 146.

9. The chimeric receptor of any one of claims 1-8, wherein the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 39, SEQ ID NO:43, SEQ ID NO:46, or SEQ ID NO:49.

10. The chimeric receptor of any one of claims 1-9, wherein the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 39.

11. The chimeric receptor of any one of claims 1-10, wherein the light chain variable region comprises an amino acid sequence that is at least about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98% or about 99% identical or homologous to the amino acid sequence set forth in SEQ ID NO: 40, SEQ ID NO: 44, SEQ ID NO: 47, SEQ ID NO: 50, SEQ ID NO: 53, SEQ ID NO: 56, or SEQ ID NO: 147.

12. The chimeric receptor of any one of claims 1-11, wherein the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 40, SEQ ID NO: 44, SEQ ID NO: 47, or SEQ ID NO: 50.

13. The chimeric receptor of any one of claims 1-12, wherein the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 40.

14. The chimeric receptor of any one of claims 1-13, wherein the heavy chain variable region comprises an amino acid sequence that is at least about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%

or about 99% identical or homologous to the amino acid sequence set forth in SEQ ID NO: 39, SEQ ID NO:43, SEQ ID NO:46, SEQ ID NO:49, SEQ ID NO: 52, SEQ ID NO: 55, or SEQ ID NO: 146; and the light chain variable region comprises an amino acid sequence that is at least about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98% or about 99% identical or homologous to the amino acid sequence set forth in SEQ ID NO: 40, SEQ ID NO: 44, SEQ ID NO: 47, SEQ ID NO: 50, SEQ ID NO: 53, SEQ ID NO: 56, or SEQ ID NO: 147.

15. The chimeric receptor of any one of claims 1-14, wherein the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 39, SEQ ID NO:43, SEQ ID NO:46, or SEQ ID NO:49; and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 40, SEQ ID NO: 44, SEQ ID NO: 47, or SEQ ID NO: 50.

16. The chimeric receptor of any one of claims 1-15, wherein:

- a) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 39; and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 40;
- b) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 43; and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 44;
- c) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 46; and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 47;
- d) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 49; and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 50;
- e) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 52; and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 53;
- f) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 55; and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 56; or

- g) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 146; and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 147.
17. The chimeric receptor of any one of claims 1-16, wherein:
- a) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 39; and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 40;
 - b) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 43; and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 44;
 - c) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 46; and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 47; or
 - d) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 49; and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 50;
18. The chimeric receptor of any one of claims 1-17, wherein the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 39; and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 40.
19. The chimeric receptor of any one of claims 1-18, wherein the extracellular antigen-binding domain comprises a linker between the heavy chain variable region and the light chain variable region.
20. The chimeric receptor of claim 19, wherein the linker consists of the amino acid sequence set forth in SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, or SEQ ID NO: 149.
21. The chimeric receptor of any one of claims 1-20, wherein the heavy chain variable region and the light chain variable region are positioned from the N- to the C-terminus: V_H-V_L.
22. The chimeric receptor of any one of claims 1-21, wherein the extracellular antigen-binding domain comprises or is an scFv, which comprises or consists of the amino acid sequence set forth in SEQ ID NO: 41, SEQ ID NO: 45, SEQ ID NO: 48, SEQ ID NO: 51, SEQ ID NO: 54, SEQ ID NO: 57, or SEQ ID NO: 148.

23. The chimeric receptor of any one of claims 1-22, wherein the extracellular antigen-binding domain comprises or is an scFv, which comprises or consists of the amino acid sequence set forth in SEQ ID NO: 41, SEQ ID NO: 45, SEQ ID NO: 48, or SEQ ID NO: 51.
24. The chimeric receptor of any one of claims 1-23, wherein the extracellular antigen-binding domain comprises or is an scFv, which comprises or consists of the amino acid sequence set forth in SEQ ID NO: 41.
25. The chimeric receptor of any one of claims 1-24, wherein the extracellular antigen-binding domain binds to ADGRE2 with a disassociation constant (K_D) of than less than about 10^{-8} M, less than about 10^{-9} M, less than about 10^{-10} M, less than about 10^{-11} M, less than about 10^{-12} M, or less than about 10^{-13} M.
26. The chimeric receptor of any one of claims 1-25, wherein the extracellular antigen-binding domain binds to ADGRE2 with an EC50 of between about 1 nM and about 100 nM.
27. The chimeric receptor of claim 26, wherein the EC50 is between about 10 nM and about 95 nM.
28. The chimeric receptor of claim 26, wherein the EC50 is between about 25 nM and about 75 nM.
29. The chimeric receptor of any one of claims 1-28, wherein the transmembrane domain comprises a CD8 polypeptide, a CD28 polypeptide, a CD3 ζ polypeptide, a CD4 polypeptide, a 4-1BB polypeptide, an OX40 polypeptide, an ICOS polypeptide, a CTLA-4 polypeptide, a PD-1 polypeptide, a LAG-3 polypeptide, a 2B4 polypeptide, or a BTLA polypeptide.
30. The chimeric receptor of claim 29, wherein the transmembrane domain comprises a CD28 polypeptide.
31. The chimeric receptor of any one of claims 1-30, wherein the intracellular domain comprises a CD3 ζ polypeptide.
32. The chimeric receptor of claim 31, wherein the CD3 ζ polypeptide is a modified CD3 ζ polypeptide.

33. The chimeric receptor of claim 32, wherein the modified CD3 ζ polypeptide comprises a native ITAM1, an ITAM2 variant consisting of two loss-of-function mutations, and an ITAM3 variant consisting of two loss-of-function mutations.
34. The chimeric receptor of claim 33, wherein the native ITAM1 consists of the amino acid sequence set forth in SEQ ID NO: 15.
35. The chimeric receptor of claim 33 or 34, wherein the ITAM2 variant consists of the amino acid sequence set forth in SEQ ID NO: 21.
36. The chimeric receptor of any one of claims 33-35, wherein the ITAM3 variant consists of the amino acid sequence set forth in SEQ ID NO: 25.
37. The chimeric receptor of any one of claims 32-36, wherein the modified CD3 ζ polypeptide comprises or consists of the amino acid sequence set forth in SEQ ID NO: 27.
38. The chimeric receptor of any one of claims 31-37, wherein the intracellular domain further comprises at least one co-stimulatory signaling region.
39. The chimeric receptor of claim 38, wherein the at least one co-stimulatory signaling region comprises a CD28 polypeptide, a 4-1BB polypeptide, an OX40 polypeptide, an ICOS polypeptide, a DAP-10 polypeptide, or a combination thereof.
40. The chimeric receptor of claim 39, wherein the at least one co-stimulatory signaling region comprises a CD28 polypeptide.
41. The chimeric receptor of any one of claims 1-40, wherein the chimeric receptor is a chimeric antigen receptor (CAR), a chimeric co-stimulating receptor (CCR), or a TCR like fusion molecule.
42. The chimeric receptor of claim 41, wherein the chimeric receptor is a CAR.
43. A chimeric receptor, comprising an extracellular antigen-binding domain that binds to CLEC12A, a transmembrane domain, and an intracellular domain, wherein the extracellular antigen-binding domain comprises:
- a) a heavy chain variable region comprising:
 - i) a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 69 or a conservative modification thereof, a CDR2 comprising the amino acid

- sequence set forth in SEQ ID NO: 70 or a conservative modification thereof, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 71 or a conservative modification thereof;
- ii) a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 81 or a conservative modification thereof, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 82 or a conservative modification thereof, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 83 or a conservative modification thereof;
- iii) a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 89 or a conservative modification thereof, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 90 or a conservative modification thereof, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 91 or a conservative modification thereof;
- iv) a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 89 or a conservative modification thereof, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 90 or a conservative modification thereof, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 98 or a conservative modification thereof;
- v) a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 81 or a conservative modification thereof, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 103 or a conservative modification thereof, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 83 or a conservative modification thereof;
- vi) a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 109 or a conservative modification thereof, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 103 or a conservative modification thereof, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 83 or a conservative modification thereof;
- vii) a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 89 or a conservative modification thereof, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 90 or a conservative modification thereof, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 114 or a conservative modification thereof;

- viii) a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 120 or a conservative modification thereof, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 121 or a conservative modification thereof, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 122 or a conservative modification thereof; or
- ix) a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 129 or a conservative modification thereof, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 130 or a conservative modification thereof, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 131 or a conservative modification thereof; and/or
- b) a light chain variable region comprising:
 - i) a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 72 or a conservative modification thereof, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 73 or a conservative modification thereof, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 74 or a conservative modification thereof;
 - ii) a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 84 or a conservative modification thereof, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 73 or a conservative modification thereof, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 85 or a conservative modification thereof;
 - iii) a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 92 or a conservative modification thereof, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 93 or a conservative modification thereof, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 94 or a conservative modification thereof;
 - iv) a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 99 or a conservative modification thereof, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 93 or a conservative modification thereof, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 151 or a conservative modification thereof;
 - v) a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 104 or a conservative modification thereof, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 73 or a conservative modification thereof,

and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 105 or a conservative modification thereof;

- vi) a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 110 or a conservative modification thereof, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 73 or a conservative modification thereof, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 85 or a conservative modification thereof;
- vii) a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 115 or a conservative modification thereof, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 93 or a conservative modification thereof, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 116 or a conservative modification thereof;
- viii) a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 123 or a conservative modification thereof, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 124 or a conservative modification thereof, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 125 or a conservative modification thereof; or
- ix) a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 132 or a conservative modification thereof, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 133 or a conservative modification thereof, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 134 or a conservative modification thereof.

44. The chimeric receptor of claim 43, wherein the extracellular antigen-binding domain comprises a single-chain variable fragment (scFv), a Fab, or a F(ab)₂.

45. The chimeric receptor of claim 44, wherein the extracellular antigen-binding domain comprises a single chain variable fragment (scFv).

46. The chimeric receptor of claim 45, wherein the scFv is a human scFv.

47. The chimeric receptor of any one of claims 43-46, wherein the heavy chain variable region comprises:

- a) a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 69, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 70, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 71;

- b) a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 81, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 82, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 83;
- c) a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 89, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 90, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 91;
- d) a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 89, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 90, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 98;
- e) a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 81, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 103, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 83;
- f) a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 109, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 103, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 83;
- g) a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 89, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 90, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 114;
- h) a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 120, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 121, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 122; or
- i) a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 129, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 130, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 131.

48. The chimeric receptor of any one of claims 43-47, wherein the heavy chain variable region comprises:

- a) a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 69, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 70, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 71;
- b) a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 81, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 82, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 83;

- c) a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 89, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 90, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 91; or
- d) a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 89, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 90, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 98.

49. The chimeric receptor of any one of claims 43-48, wherein the heavy chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 69, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 70, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 71.

50. The chimeric receptor of any one of claims 43-49, wherein the light chain variable region comprises:

- a) a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 72, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 73, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 74;
- b) a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 84, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 73, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 85;
- c) a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 92, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 93, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 94;
- d) a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 99, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 93, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 151;
- e) a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 104, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 73, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 105;
- f) a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 110, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 73, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 85;
- g) a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 115, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 93, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 116;

- h) a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 123, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 124, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 125; or
- i) a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 132, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 133, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 134.

51. The chimeric receptor of any one of claims 43-50, wherein the light chain variable region comprises:

- a) a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 72, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 73, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 74;
- b) a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 84, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 73, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 85;
- c) a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 92, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 93, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 94; or
- d) a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 99, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 93, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 151.

52. The chimeric receptor of any one of claims 43-51, wherein the light chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 72, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 73, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 74.

53. The chimeric receptor of any one of claims 43-52, wherein:

- a) the heavy chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 69, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 70, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 71; and the light chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 72, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 73, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 74;

- b) the heavy chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 81, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 82, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 83; and the light chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 84, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 73, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 85;
- c) the heavy chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 89, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 90, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 91; and the light chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 92, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 93, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 94;
- d) the heavy chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 89, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 90, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 98; and the light chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 99, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 93, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 151;
- e) the heavy chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 81, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 103, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 83; and the light chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 104, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 73, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 105;
- f) the heavy chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 109, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 103, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 83; and the light chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 110, a CDR2

- comprising the amino acid sequence set forth in SEQ ID NO: 73, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 85;
- g) the heavy chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 89, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 90, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 114; and the light chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 115, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 93, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 116;
- h) the heavy chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 120, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 121, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 122; and the light chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 123, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 124, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 125; or
- i) the heavy chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 129, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 130, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 131; and the light chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 132, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 133, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 134.

54. The chimeric receptor of any one of claims 43-53, wherein:

- a) the heavy chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 69, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 70, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 71; and the light chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 72, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 73, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 74;
- b) the heavy chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 81, a CDR2 comprising the amino acid sequence

- set forth in SEQ ID NO: 82, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 83; and the light chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 84, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 73, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 85;
- c) the heavy chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 89, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 90, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 91; and the light chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 92, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 93, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 94; or
- d) the heavy chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 89, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 90, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 98; and the light chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 99, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 93, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 151.

55. The chimeric receptor of any one of claims 43-54, wherein the heavy chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 69, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 70, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 71; and the light chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 72, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 73, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 74.

56. The chimeric receptor of any one of claims 43-55, wherein the heavy chain variable region comprises an amino acid sequence that is at least about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98% or about 99% identical or homologous to the amino acid sequence set forth in SEQ ID NO: 75, SEQ ID NO: 86, SEQ ID NO: 95, SEQ ID NO: 100, SEQ ID NO: 106, SEQ ID NO: 111, SEQ ID NO: 117, SEQ ID NO: 126, or SEQ ID NO: 135.

57. The chimeric receptor of any one of claims 43-56, wherein the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 75, SEQ ID NO: 86, SEQ ID NO: 95, SEQ ID NO: 100, SEQ ID NO: 106, SEQ ID NO: 111, SEQ ID NO: 117, SEQ ID NO: 126, or SEQ ID NO: 135.
58. The chimeric receptor of any one of claims 43-57, wherein the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 75, SEQ ID NO: 86, SEQ ID NO: 95, or SEQ ID NO: 100.
59. The chimeric receptor of any one of claims 43-58, wherein the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 75.
60. The chimeric receptor of any one of claims 43-59, wherein the light chain variable region comprises an amino acid sequence that is at least about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98% or about 99% identical or homologous to the amino acid sequence set forth in SEQ ID NO: 76, SEQ ID NO: 87, SEQ ID NO: 96, SEQ ID NO: 101, SEQ ID NO: 107, SEQ ID NO: 112, SEQ ID NO: 118, SEQ ID NO: 127, or SEQ ID NO: 136.
61. The chimeric receptor of any one of claims 43-60, wherein the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 76, SEQ ID NO: 87, SEQ ID NO: 96, SEQ ID NO: 101, SEQ ID NO: 107, SEQ ID NO: 112, SEQ ID NO: 118, SEQ ID NO: 127, or SEQ ID NO: 136.
62. The chimeric receptor of any one of claims 43-61, wherein the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 76, SEQ ID NO: 87, SEQ ID NO: 96, or SEQ ID NO: 101.
63. The chimeric receptor of any one of claims 63-62, wherein the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 76.
64. The chimeric receptor of any one of claims 43-63, wherein:
- a) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 75; and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 76;

- b) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 86; and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 87;
- c) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 95; and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 96;
- d) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 100; and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 101;
- e) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 106; and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 107;
- f) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 111; and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 112;
- g) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 117; and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 118;
- h) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 126; and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 127; or
- i) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 135; and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 136.

65. The chimeric receptor of any one of claims 43-64, wherein:

- a) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 75; and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 76;
- b) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 86; and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 87;

- c) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 95; and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 96; or
- d) the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 100; and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 101.

66. The chimeric receptor of any one of claims 43-65, wherein the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 75; and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 76.

67. The chimeric receptor of any one of claims 43-66, wherein the extracellular antigen-binding domain comprises a linker between the heavy chain variable region and the light chain variable region.

68. The chimeric receptor of claim 67, wherein the linker consists of the amino acid sequence set forth in SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, or SEQ ID NO: 149.

69. The chimeric receptor of any one of claims 43-68, wherein the heavy chain variable region and the light chain variable region are positioned from the N- to the C-terminus: V_H-V_L.

70. The chimeric receptor of any one of claims 43-69, wherein the extracellular antigen-binding domain comprises or is an scFv, which comprises or consists of the amino acid sequence set forth in SEQ ID NO: 79, SEQ ID NO: 88, SEQ ID NO: 97, SEQ ID NO: 102, SEQ ID NO: 108, SEQ ID NO: 113, SEQ ID NO: 119, SEQ ID NO: 128, or SEQ ID NO: 137.

71. The chimeric receptor of any one of claims 43-70, wherein the extracellular antigen-binding domain comprises or is an scFv, which comprises or consists of the amino acid sequence set forth in SEQ ID NO: 79, SEQ ID NO: 88, SEQ ID NO: 97, or SEQ ID NO: 102.

72. The chimeric receptor of any one of claims 43-71, wherein the extracellular antigen-binding domain comprises or is an scFv, which comprises or consists of the amino acid sequence set forth in SEQ ID NO: 79.

73. The chimeric receptor of any one of claims 43-72, wherein the extracellular antigen-binding domain comprises or is an scFv binding to CLEC12A with a disassociation constant

(K_D) of less than about 10⁻⁸ M, less than about 10⁻⁹ M, less than about 10⁻¹⁰ M, less than about 10⁻¹¹ M, less than about 10⁻¹² M, or less than about 10⁻¹³ M.

74. The chimeric receptor of claim 73, wherein the K_D is about 0.1 pM or below.

75. The chimeric receptor of claim 73, wherein the K_D is between about 0.05 pM and about 0.5 pM.

76. The chimeric receptor of claim 73, wherein the K_D is between about 0.1 nM and about 5.0 nM.

77. The chimeric receptor of claim 76, wherein the K_D is between about 0.3 nM and about 3.5 nM.

78. The chimeric receptor of any one of claims 43-77, wherein the extracellular antigen-binding domain comprises or is an scFv binding to CLEC12A with an EC50 is between about 1 nM and about 100 nM.

79. The chimeric receptor of any one of claims 43-78, wherein the transmembrane domain comprises a CD8 polypeptide, a CD28 polypeptide, a CD3ζ polypeptide, a CD4 polypeptide, a 4-1BB polypeptide, an OX40 polypeptide, an ICOS polypeptide, a CTLA-4 polypeptide, a PD-1 polypeptide, a LAG-3 polypeptide, a 2B4 polypeptide, or a BTLA polypeptide.

80. The chimeric receptor of claim 79, wherein the transmembrane domain comprises a CD8 polypeptide.

81. The chimeric receptor of any one of claims 43-80, wherein the chimeric receptor is a chimeric antigen receptor (CAR), a chimeric co-stimulating receptor (CCR), or a TCR like fusion molecule.

82. The chimeric receptor of claim 81, wherein the chimeric receptor is a chimeric co-stimulating receptor (CCR).

83. The chimeric receptor of any one of claims 43-82, wherein the intracellular domain does not comprise a CD3ζ polypeptide.

84. The chimeric receptor of any one of claims 43-83, wherein the intracellular domain comprises at least one co-stimulatory signaling region.

85. The chimeric receptor of claim 84, wherein the at least one co-stimulatory signaling region comprises a CD28 polypeptide, a 4-1BB polypeptide, an OX40 polypeptide, an ICOS polypeptide, a DAP-10 polypeptide, or a combination thereof.
86. The chimeric of claim 85, wherein the at least one co-stimulatory signaling region comprises a 4-1BB polypeptide.
87. The chimeric receptor of any one of claims 1-86, wherein the chimeric receptor is expressed from a vector.
88. The chimeric receptor of claim 87, wherein the vector is a viral vector.
89. The chimeric receptor of claim 88, wherein the viral vector is a retroviral vector.
90. A cell comprising the chimeric receptor of any one of claims 1-89.
91. A cell comprising a) a first chimeric receptor that is the chimeric receptor of any one of claims 1-42 and 87-89, and b) a second chimeric receptor that is the chimeric receptor of any one of claims 43-89.
92. The cell of claim 91, wherein the first chimeric receptor is a chimeric antigen receptor (CAR), and b) the second chimeric receptor is a chimeric co-stimulatory receptor (CCR).
93. The cell of claim 92, wherein the CAR comprises an extracellular antigen-binding domain that binds to ADGRE2 and comprises:
- a) a heavy chain variable region comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 33 or a conservative modification thereof, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 34 or a conservative modification thereof, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 35 or a conservative modification thereof; and/or
 - b) a light chain variable region comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 36 or a conservative modification thereof, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 37 or a conservative modification thereof, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 38 or a conservative modification thereof.
94. The cell of claim 93, wherein the heavy chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 33, a CDR2 comprising the amino

acid sequence set forth in SEQ ID NO: 34, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 35; and the light chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 36, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 37, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 38.

95. The cell of claim 93 or 94, wherein

- a) the heavy chain variable region comprises an amino acid sequence that is at least about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98% or about 99% identical or homologous to the amino acid sequence set forth in SEQ ID NO: 39; and/or
- b) the light chain variable region comprises an amino acid sequence that is at least about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98% or about 99% identical or homologous to the amino acid sequence set forth in SEQ ID NO: 40.

96. The cell of claim 95, wherein the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 39; and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 40.

97. The cell of any one of claims 92-96, wherein the CCR comprises an extracellular antigen-binding domain that binds to CLEC12A and comprises:

- a) a heavy chain variable region comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 69 or a conservative modification thereof, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 70 or a conservative modification thereof, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 71 or a conservative modification thereof; and/or
- b) a light chain variable region comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 72 or a conservative modification thereof, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 73 or a conservative modification thereof, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 74 or a conservative modification thereof.

98. The cell of claim 97, wherein the heavy chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 69, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 70, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 71; and the light chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 72, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 73, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 74.
99. The cell of claim 97 or 98, wherein
- a) the heavy chain variable region comprises an amino acid sequence that is at least about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98% or about 99% identical or homologous to the amino acid sequence set forth in SEQ ID NO: 75; and/or
 - b) the light chain variable region comprises an amino acid sequence that is at least about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98% or about 99% identical or homologous to the amino acid sequence set forth in SEQ ID NO: 76.
100. The cell of claim 95, wherein the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 75; and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 76.
101. The cell of any one of claims 90-100, wherein the cell is transduced with the chimeric receptor.
102. The cell of any one of claims 90-101, wherein the chimeric receptor is constitutively expressed on the surface of the cell.
103. The cell of any one of claims 90-102, wherein the cell is an immunoresponsive cell.
104. The cell of any one of claims 90-103, wherein the cell is a cell of the lymphoid lineage or a cell of the myeloid lineage.

105. The cell of any one of claims 90-104, wherein the cell is selected from the group consisting of a T cell, a Natural Killer (NK) cell, a stem cell from which a lymphoid cell may be differentiated, and a stem cell from which a myeloid cell may be differentiated.

106. The cell of any one of claims 90-105, wherein the cell is a T cell.

107. The cell of claim 105 or claim 106, wherein the T cell is selected from the group consisting of helper T cells, cytotoxic T cells, memory T cells, regulatory T cells, tumor-infiltrating lymphocyte (TIL), Natural Killer T cells, mucosal associated invariant T cells, and $\gamma\delta$ T cells.

108. The cell of any one of claims 90-105, wherein the cell is a Natural Killer (NK) cell.

109. The cell of claim 108, wherein the NK cell is derived from a stem cell.

110. The cell of claim 105 or 109, wherein the stem cell is a pluripotent stem cell.

111. The cell of claim 110, wherein the pluripotent stem cell is an embryoid stem cell or an induced pluripotent stem cell.

112. A nucleic acid molecule encoding the chimeric receptor of any one of claims 1-89.

113. A nucleic acid molecule encoding the chimeric receptor of any one of claims 1-42 and 87-89.

114. A nucleic acid molecule encoding the chimeric receptor of any one of claims 43-89.

115. The nucleic acid molecule of any one of claims 112-114, further comprising a promoter that is operably linked to the chimeric receptor.

116. The nucleic acid molecule of claim 115, wherein the promoter is endogenous or exogenous.

117. The nucleic acid molecule of claim 116, wherein the exogenous promoter is selected from the group consisting of an elongation factor (EF)-1 promoter, a cytomegalovirus immediate-early promoter (CMV) promoter, a simian virus 40 early promoter (SV40) promoter, a phosphoglycerate kinase (PGK) promoter, a metallothionein promoter, and Ubiquitin C promoter.

118. The nucleic acid molecule of claim 117, wherein the promoter is an inducible promoter.
119. The nucleic acid molecule of claim 118, wherein the inducible promoter is selected from the group consisting of a NFAT transcriptional response element (TRE) promoter, a CD69 promoter, a CD25 promoter, an IL-2 promoter, a 4-1BB promoter, a PD1 promoter, and a LAG3 promoter.
120. The nucleic acid molecule of claim 116, wherein the promoter is an endogenous promoter.
121. The nucleic acid molecule of claim 120, wherein the endogenous promoter is selected from a TCR alpha promoter, a TCR beta promoter, and a beta 2-microglobulin promoter.
122. A nucleic acid composition comprising a first nucleic acid molecule that is the nucleic acid molecule of any one of claims 113 and 114-121, and a second nucleic acid molecule that is the nucleic acid molecule of any one of claims 114-121.
123. A vector comprising the nucleic acid molecule of any one of claims 112-121.
124. A vector comprising the nucleic acid composition of claim 122.
125. The vector of claim 123 or 124, wherein the vector is a viral vector.
126. The vector of claim 125, wherein the viral vector is as retroviral vector.
127. A cell comprising the nucleic acid molecule of any one of claims 112-121.
128. A cell comprising the nucleic acid composition of claim 122.
129. A cell comprising the vector of any one of claims 123-126.
130. The cell of any one of claims 127-129, wherein the cell is a T cell.
131. The cell of any one of claims 127-129, wherein the cell is a Natural Killer (NK) cell.
132. The cell of claim 131, wherein the NK cell is derived from a stem cell.
133. A composition comprising the cell of any one of claims 90-111, and 127-132.
134. The composition of claim 133, which is a pharmaceutical composition further comprising a pharmaceutically acceptable carrier.

135. The composition of claim 133 or claim 134, comprising between about 25×10^6 and about 150×10^6 cells.
136. The composition of any one of claims 133-135, comprising between about 25×10^6 and about 50×10^6 cells.
137. The composition of any one of claims 133-136, comprising about 2.5×10^6 cells.
138. A method of reducing tumor burden in a subject, comprising administering to the subject the cell of any one of claims 90-111, and 127-132 or the composition of any one of claims 133-137.
139. The method of claim 138, wherein the method reduces the number of tumor cells, reduces tumor size, and/or eradicates the tumor in the subject.
140. A method of increasing or lengthening survival of a subject having a tumor, comprising administering to the subject the cell of any one of claims 90-111, and 127-132 or the composition of any one of claims 133-137.
141. A method of treating and/or preventing a tumor in a subject, comprising administering to the subject the cell of any one of claims 90-111, and 127-132 or the composition of any one of claims 133-137.
142. The method of any one of claims 138-141, wherein the tumor expresses ADGRE2 and/or CLEC12A.
143. The method of any one of claims 138-142, wherein the tumor is cancer.
144. The method of any one of claims 138-143, wherein the tumor is blood cancer.
145. The method of claim 144, wherein the tumor is selected from the group consisting of multiple myeloma, leukemia, lymphomas, and myeloid malignancies.
146. The method of claim 145, wherein the leukemia is selected from the group consisting of acute myeloid leukemia (AML), chronic myeloid leukemia (CML), acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute promyelocytic leukemia (APL), mixed-phenotype acute leukemia (MLL), hairy cell leukemia, and B cell prolymphocytic leukemia.
147. The method of claim 146, wherein the leukemia is acute myeloid leukemia (AML).

148. The method of claim 147, wherein the AML is relapsed/refractory acute myeloid leukemia (R/R AML).
149. The method of claim 145, wherein the myeloid malignancies are selected from the group consisting of myelodysplastic syndromes (MDS), myeloproliferative neoplasms (MPN), myeloid/lymphoid neoplasms (e.g., myeloid/lymphoid neoplasms with eosinophilia and rearrangement of Platelet Derived Growth Factor Receptor Alpha (PDGFRA), Platelet Derived Growth Factor Receptor Beta (PDGFRB), or Fibroblast Growth Factor Receptor 1 (FGFR1), or with PCM1-JAK2), acute myeloid leukemia (AML), blastic plasmacytoid dendritic cell neoplasm, B-lymphoblastic leukemia/lymphoma, and T-lymphoblastic leukemia/lymphoma.
150. The of claim 149, wherein the myeloid malignancies comprise myelodysplastic syndromes (MDS).
151. The method of any one of claims 138-150, wherein the subject is a human subject.
152. A method for producing a cell comprising the chimeric receptor of any one of claims 1-90, comprising introducing into the cell a nucleic acid molecule that encodes the chimeric receptor of any one of claims 1-90.
153. A method for producing a cell comprising the chimeric receptor of any one of claims 1-42 and 87-89 and the chimeric receptor of any one of claims 43-89, comprising introducing into the cell a nucleic acid molecule that encodes the chimeric receptor of any one of claims 1-42 and 87-89 and the chimeric receptor of any one of claims 43-89.